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SUMMARY OF THESIS 
Left ventricular hypertrophy (LVH) is highly prevalent in patients with coronary artery 
disease (CAD) irrespective, of blood pressure (BP) and is associated with an 
increased risk of all-cause mortality and cardiovascular events including myocardial 
infarction, heart failure, stroke and arrhythmias. Previous studies of mainly 
antihypertensive therapies have shown LVH to be a reversible risk factor. However, 
controlling BP is only partially effective as LVH persists in 20% of hypertensive patients 
who attain target BP. Therefore, novel ways of regressing LVH, independent of BP, in 
patients with CAD could reduce cardiovascular events and mortality in this patient 
group.  
Apart from uncontrolled BP, insulin resistance (IR) and central obesity are implicated 
in the development of LVH. Metformin - an anti-diabetic drug, has been shown to 
reduce body weight and to improve insulin sensitivity, thus reducing IR. These 
properties of metformin may have the potential of regressing LVH. Additionally, 
metformin has complex multiple modes of actions involving both AMP-activated 
protein kinase (AMPK)-dependent and AMPK-independent mechanisms that is 
implicated in cardiac hypertrophy. Indeed, metformin has been shown to reduce 
cardiac hypertrophy in different animal models of hypertrophy. However, there has 
never been a clinical study to show that metformin is capable of regressing LVH.  
In my PhD, I tested the hypothesis that metformin may regress LVH in patients who 
have CAD with insulin resistance and/or pre-diabetes.  
The MET-REMODEL trial was a randomized, double-blinded, placebo controlled study 
of 68 patients without diabetes who had well controlled blood pressure and have CAD, 
LVH and IR and/or prediabetes. Study subjects were assigned to receive either 
metformin (2000mg/day) or placebo therapy, over a 12 month follow up period. LV 
mass was measured at baseline and 12 months using cardiac magnetic resonance 
imaging (CMR). Primary endpoint of this study was change in left ventricular mass 
indexed (LVMI) to height1.7 (LVMI); other endpoints were changes in left ventricular 
mass (LVM), changes in body weight, abdominal obesity (measured by MRI), 
endothelial function, BP and biomarkers of cardiac wall stress and fibrosis, 
inflammation and oxidative stress. 
20 
 
In this study, we demonstrated 2000 mg daily of metformin therapy over a 12-month 
treatment period significantly reduced LVMI, LVM, office systolic blood pressure 
(SBP), body weight and oxidative stress. In the modified intention-to-treat (mITT) 
analysis (n=63), metformin treatment significantly reduced LVMI (metformin -2.71 ± 
2.31 g/m1.7 vs. placebo -1.34 ± 2.65 g/m1.7; P=0.033) and LVM (metformin -6.53 ± 
5.59g vs. placebo -3.23 ± 6.32g; P=0.032). Metformin also significantly reduced other 
secondary study end points such as: body weight (P=0.001), sub-cutaneous adipose 
tissue (P=0.024), SBP (P=0.022) and concentration of thiobarbituric acid reactive 
substances (TBARs), a biomarker for oxidative stress (P=0.04). The per protocol 
analysis (n=56) also produced findings consistent with findings to mITT, but a more 
significant reduction of LVMI (P=0.005). The glycated haemoglobin A1C concentration 
and fasting insulin resistance index did not differ between study groups at the end of 
the study.  
These results may suggest a potentially novel cardio-protective effect of metformin 
and raise the possibility of using metformin in patients without diabetes with CAD. 
Although LVH is a good surrogate marker of cardiovascular outcome, definitive 
evidence for the cardio-protective role of metformin in non-diabetic cardiovascular 
disease will have to be provided by large randomized cardiovascular outcome clinical 
trials. 
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CHAPTER 1: Introduction 
1.1. Global and UK Burden of Cardiovascular Diseases  
Cardiovascular diseases (CVDs) are the leading cause of global mortality and a key 
impediment to sustainable human development (1). CVDs are now formally 
recognized as a major concern for global health by the United Nations who have now 
set out measures to dramatically reduce the burden of CVDs in all regions (2). 
Importantly, 80% of CV mortality occurs in low and middle income countries (LMICs), 
with nearly 52% of deaths in LMICs occurring among those under 60 years old (3,4) . 
As per the Global Burden of Disease 2015 study (GBD 2015), the total number of CVD 
cases worldwide is 422.7 million (95% uncertainty interval: 415.53 to 427.87 million 
cases) and 17.92 million CVD deaths (95% uncertainty interval: 17.59 to 18.28 million 
CVD deaths) (5). The GBD 2016 study reported 17·6 million CVD deaths [95% 
uncertainty interval: 17·3 million to 18·1 million] (6). Additionally, the GBD 2016 study 
reported elevated global CVD mortality rates between 2006 and 2016: a 14.5% 
increase (95% uncertainty interval: 12·1–17·1), however, the age-standardised CVD 
mortality rates decreased by 14·5% (12·5–16·2) over this time period. Ischemic heart 
disease (IHD) and cerebrovascular disease (stroke) combined accounted for 85·1% 
of all CVD mortality in 2016. However, mortality rates from IHD increased by 19% 
(95% CI 16.2-22.1) in 2016: 7·96 million IHD deaths in 2006 to 9·48 million deaths in 
2016 (6). It is noteworthy that the decline in age-standardised CVD mortality observed 
were mainly due to the decline in cerebrovascular disease mortality rates: decrease 
of 21% between 2006 and 2016, from an age-standardised death rate of 110 deaths 
per 100000 (106–113) in 2006 to 86·5 deaths (83·3–89·9) per 100000 in 2016 (6). 
In 2014, CVD accounts for the second main cause of death in the United Kingdom 
(UK) (7). The GBD 2015 study have reported a decline (53%) in the burden of CVD 
mortality rates between 1990 and 2013: 60% reduction in coronary heart disease 
(CHD) mortality, and stroke by 46% (5). Another study linking morbidity and mortality 
data from England reported a 50% decline in age-standardised mortality from 
myocardial infarction (MI), primarily due to reduced incidence and case fatality (8). 
Although the total burden of CVD declined notably between 1979 and 2013 in UK, the 
absolute rates of reduction were not uniform between its four constituent countries, or 
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between men and women (7). During these periods, the total CVD mortality was 
decreased by 70% in England, 69% in Wales and Scotland and 75% in Northern 
Ireland. For CHD mortality rates, there was a 72% reduction in England, 70% in Wales, 
71% in Scotland and 76% in Northern Ireland.  Despite decreasing CHD mortality rates 
in UK since the 1970s, CHD is still the most common cause of death before the age 
of 75 in the UK (9). Additionally, CVD is a leading public health problem in the UK in 
terms of economic burden from disease. The total annual cost of all CVD related 
burden has been estimated to £19 million, of which £6.7 billion is due to CHD burden 
(10).  
In conclusion, there are large disparities in the total burden of CVD between different 
regions of the world, with substantial and disproportionate growing burden of CVD in 
LMICs compared to high income countries (HIC). Therefore, it is vital to address this 
health and associated economic burden of CVD by developing effective screening and 
preventative measures, with potential universal applicability to tackle this disease.  
1.2. Coronary Artery Disease 
1.2.1. Definition 
 
Of the various diseases that account for CVD, CAD accounts for a major proportion of 
the CVD burden. CAD, IHD and coronary heart disease (CHD) are terms that are often 
used interchangeably. In this thesis, CAD will be used to imply atherosclerosis of the 
coronary arteries.  
Atherosclerosis is a progressive multifactorial disease in which arteries are hardened 
due to the accumulation of plaques. A plaque is made up of components such as: (i) 
a fat component - accumulation of fat, cholesterol, calcium, and other substances 
found in the blood; (ii) cellular components - inflammatory cells, smooth muscle cells; 
and (iii) a fibrous component of – connective tissue. The underlying pathogenesis of 
atherosclerosis is due to a dysregulated lipid metabolism and a maladaptive immune 
response, resulting in chronic inflammation of the arterial wall (11).  
The vascular endothelial cells line the whole circulatory system and are involved in 
atherosclerosis. The primary role of endothelial cells is to maintain a regulatory 
function including regulation of vascular tone, formation of vasodilatory molecules 
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(such as nitric oxide, prostacyclins), formation of vasoconstrictor molecules (such as 
endothelin and angiotensin-II), maintenance of the composition of subendothelial 
matrix, proliferation of smooth muscle cells, coagulation, fibrinolysis, permeability of 
lipoproteins and plasma proteins, and adhesion and migration of blood cells (12).  
Over the past 150 years, there has been intense research to better understand the 
plausible mechanisms leading to the development of atherosclerosis. Three main 
hypotheses have been proposed as plausible mechanisms for the accumulation of 
lipids in the initiation of atherosclerosis: (i) response-to-injury theory, and (ii) response 
to–retention theory, and (iii) oxidative modification hypothesis.  
According to the “Response to Injury Theory” proposed by Ross et al (1977) (13) , 
an insult to the endothelial cell layer of arteries, either by subtle physical or chemical 
insults or in combination can result in atherosclerosis.  
Such triggers include: 
• “ Physical injury or stress as a result of direct trauma or hypertension 
• Turbulent blood flow, for example, where arteries branch 
• Circulation of reactive oxygen species (free radicals), e.g., from smoking or air 
pollutants 
• Hyperlipidaemia (high blood concentrations of very low density lipoprotein 
(VLDL) 
• Chronically elevated blood glucose levels 
• Homocystaeinemia, which results from an inherited metabolic defect that leads 
to very high levels of the homocysteine, a metabolite of methionine; high 
concentrations are toxic to the endothelium ”  (14). 
Under normal conditions, the blood leukocytes do not adhere to the endothelium of 
blood vessels. However, insults to endothelial cells trigger (Figure 1) an inflammatory 
response by: (i) by secreting chemokines, (ii) produce cell surface adhesion molecules 
(vascular cell adhesion molecule – VCAM-1), (iii) causing monocytes and T 
lymphocytes (cell-mediated immunity) to adhere to the endothelium and then migrate 
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beneath it. Circulating monocytes and T-lymphocytes are then attracted to injury sites 
by chemokines (15).  
 
Figure 1: Inflammatory response following injury to endothelial cells (15) 
Consequently, the structure of endothelial cells are altered leading to increased 
endothelial permeability and deposition of both leucocyte and LDL into the sub-
endothelial space. The recruited leucocytes release cytokines and vasoconstrictory 
agents and growth factors that further enhance a proinflammatory response and 
recruitment of macrophages into the arterial wall.   
The lipoprotein particles, particularly LDL, enter the arterial wall and are oxidised by 
the nitric oxide, macrophages, resulting in the oxidation of LDL. The macrophages 
subsequently pick up the oxidised LDL that migrates to the intima, and become more 
lipid laden to form “foam cells” which are considered to be the hall mark of early 
atherosclerotic lesions.  Although these foam cells eventually undergoes apoptosis, 
the lipids will still accumulate in the intima (15). 
However, the “response-to-injury” hypothesis was challenged and superseded by 
the “response-to-retention” hypothesis, proposed by William et al in 1995 as there 
was no conclusive evidence that endothelial injury is either necessary or sufficient for 
lesion formation (16).  According to this theory, the retention of lipoprotein is the 
triggering event for atherosclerosis. When the levels of lipoproteins such as low 
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density lipoprotein cholesterol (LDL-C) are high, more amounts of LDL-C are retained 
within the arterial wall. The retention of lipoproteins within the arterial wall however, 
appears tightly linked to components of the extracellular matrix such as apolipoprotein 
B and arterial proteoglycans. The lipoproteins are bound to proteoglycans by 
apolipoprotein B (16). Additionally, the aggregated LDL is ingested by the 
macrophages and smooth muscle cells resulting in foam cell formation. Therefore, 
many features implicated in the development of atherosclerosis can be attributed to 
enhanced retention of LDL within the arterial wall and its association with 
proteoglycans. It is proposed that lipoprotein retention is enhanced by lipoprotein 
lipase produced by the endothelial cells (16). 
Another hypothesis implicated on the development of atherosclerosis is the “oxidative 
modification hypothesis” (17). As per this theory, LDL in its natural state is not 
atherogenic rather, chemically modified LDL is readily internalized by macrophages 
by the “scavenger receptor” pathway. The chemical modification refers to redox 
modifications of polyunsaturated fatty acids, including LDL. Exposure to vascular cells 
in medium that contains transition metals also results in oxidative modification of LDL 
such that it serves as a ligand for the scavenger receptor pathway. This hypothesis 
asserts that oxidation of LDL result in proatherogenic events including the activation 
of macrophages, leading to the formation of “foam cells”. Additionally, oxidized LDL is 
associated with the production of smooth muscle cells and is also immunogenic. 
Furthermore, the formation of immune complexes enables macrophages to internalize 
LDL. This forms the basis of “oxidative modification hypothesis” in the development 
of atherosclerosis. The oxidative modification hypothesis is ubiquitous in the fact that 
it emphasizes oxidative events and redox reactions as a prominent atherogenic 
element. 
As discussed above, each hypothesis is distinct, importantly in their initiating events. 
However, it’s worth noting that each hypothesis is linked to inflammation. Recently, 
the CANTOS study suggested, and at least in part proved the “inflammatory 
hypothesis” of atherosclerosis (18). There are now several lines of evidence 
suggesting atherosclerosis as a chronic inflammatory disorder and not just a disorder 
of sub-intimal deposition of lipoprotein particles in the arterial walls (18). However, it 
is yet to be conclusively elucidated whether inflammation is a cause or result of 
vascular disorders in atherosclerosis. A recent review on this aspect concluded that 
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the initial inflammatory response is to be considered as a defence/protective 
mechanism but, its further amplification may enhance the atherosclerotic process (18).  
The first sign of atherosclerosis are fatty streaks, consisting of lipid-containing foam 
cells in the arterial wall just beneath the endothelium, which are visible without 
magnification (Figure 2).  These lesions occur in the aorta and coronary arteries of 
most people by age 20 and eventually these lesions can develop into atherosclerotic 
plaques or remain stable or even regress (15) 
 
Figure 2 : Image of inside of artery: the two denoted are the yellowish fatty streaks 
beneath the thin endothelial lining of the artery (15) 
As the lipids accumulate in the foam cells, the slowly growing plaques expand 
gradually and tend to stabilize however, they are not prone to rupture. These plaques 
can build up and harden causing narrowing of the blood vessels resulting in reduced 
blood flow to the heart. This can cause symptomatic or asymptomatic ischemia 
(angina). In contrast, other plaques grow more aggressively resulting in rapid lipid 
accumulation. These plaques have thin fibrin caps and are prone to rupture resulting 
in acute thrombosis (clot) by activating platelets and the clotting cascade. These blood 
clots can cause partial or complete blockage (Figure 3). This results in an acute 
coronary syndrome (ACS) (19). 
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Figure 3: Illustration of evolution of stable and unstable plaques (15): There are 
two possible forms of evolution. Slowly growing plaques expand gradually and are 
generally not prone to rupture. The other form of plaque are the ones that grow more 
rapidly and are vulnerable to plaque rupture. Plaque rupture leads to acute coronary 
syndrome (ACS).  
ACS is a continuum of events which include: - 
• STEMI (ST elevation MI) – The ST segment is seen elevated on the 
electrocardiogram (ECG) and is often referred to as an acute myocardial 
infarction (AMI) or heart attack and usually encompasses complete blockage of 
the artery. Cardiac enzymes will be raised.  
• NSTEMI (Non-ST elevation MI) – is when there is an AMI but ST elevation does 
not occur on the ECG. This is usually associated with partial rather than 
complete blockage of the culprit artery. Cardiac enzyme blood tests are also 
raised in NSTEMI (although often not as high as in STEMI), indicating that 
damage is occurring to heart muscle. 
• Unstable angina – this is when there is partial blockage of the artery but the 
severity is insufficient to cause release of cardiac enzymes. However, this is 
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also thought to be caused by coronary artery spasm where there may be partial 
and temporary blockage of arteries. 
 
Figure 4: Coronary Artery Disease Morphology (20)  
Stable CAD is characterised by events of reversible ischemia or hypoxia (transient 
imbalance between blood oxygen supply and myocardial demand) usually triggered 
by exercise, emotions or other stressors, although it can occur suddenly. 
Conventionally, the underlying mechanisms are thought to be plaque related 
obstruction of coronary arteries. However, more recently focal or diffuse spasms of 
normal or plaque diseased arteries, microvascular dysfunction and left ventricular 
dysfunction have been shown to also cause symptoms of CAD (21). These 
mechanisms are thought to be able to act singly or in combination. Although, stable 
CAD lesions rarely show erosion or rupture of the endothelial layer, stable CAD and 
ACS are considered as part of a continuum and not distinct entities (21). The 
morphology of CAD is shown in Figure 4.  
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1.2.2. Epidemiology of Coronary Artery Disease 
As per the World Health Organization (WHO) estimate (2016) > 80% global mortalities 
are due to CAD and stroke with higher cardiovascular (CV) mortality rates attributed 
to LMICs (22).The  WHO statistics are often the most comprehensive and comparable 
data available on a global scale, although the quality of the data collected varies 
substantially across countries. Many HIC have advanced health surveillance and 
death certification record systems whereas in many countries—particularly in LMICs, 
health statistics are often based on surveillance that does not cover all areas of the 
country therefore, may be incomplete in the areas it does cover, or is collected by 
undertrained staff who may not accurately report the pertinent data. 
Mortality rates for CAD have been declining in the UK since the early 1970s; although 
this has fallen more in younger age groups, with CAD being the leading cause of 
premature mortality. This declining mortality rates was attributable to reductions in 
major CVD risk factors – principally smoking, advances in treatment modalities (such 
as improved management of AMI resulting in a reduced case fatality rate), and to 
secondary prevention (23).  
Although, the halving of UK CAD mortality rates since the 1970s, represents a major 
public health achievement, available mortality data within UK suggests that CAD 
mortality rates are highest in Scotland and the North of England and lowest in South 
of England. The figures for premature CAD mortality rate for Scottish men is 65% 
higher than the South West of England and 112% higher for women (24,25). In 
Scotland, geographical variations have been attributed to mortality rates. For example, 
mortality rates were higher or decline as slower in the most deprived areas of Scotland 
than elsewhere, suggesting that relative health inequality gap has increased slightly 
over the long-term while the absolute inequality gap has narrowed (26).  
The recent Scottish estimates for acute myocardial infarction (AMI) (based on hospital 
and death certification) suggest a decline in the incidence of AMI ;  25% decrease from 
2002 to 2010, although the number of people who have had AMI increased since 
1960’s (25). This is primarily due to the fact that incidence of AMI increases with age 
and Scotland has an increasingly ageing population; one in five people (19%) in 
Scotland were aged 65 (>58% over 65 years) and over as per the 2017 National 
Records of Scotland estimates (27). The age-sex standardised incidence rates for AMI 
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decreased by 22.3% between 2003/04 and 2007/08 but increased by 12.9% between 
2007/08 and 2010/11. This increase may be because of the introduction of more 
sensitive tests for diagnosis (such as cardiac enzymes), resulting in more accurate 
diagnosis of AMI.  
Incidence of CAD has declined over the past 15 years, with the standardised incidence 
rate falling by 27.3% from 361.7 per 100,000 per person years in 2003/04 to 262.8 in 
2012/13. Between 1994 and 2003, incidence fell by 14% in men (from 585 to 501 per 
100,000 person years) and by 19% in women (449 to 366 per 100,000 person years) 
(25). There were regional and socioeconomic variations in incidence rates of CHD. 
The age-sex standardised rates were 238.0 per 100,000 per person years in 2012/13 
in the NHS Lothian Health Board area compared with 286.9 per 100,000 per person 
years in the more deprived Greater Glasgow and Clyde Health Board area (25). 
Although the premature death rate has fallen across all social groups for both men 
and women in the UK, the decline has been greater in people in higher socio-economic 
groups (28). The incidence of CAD increases sharply with age. In Scotland, the 
standardised incidence rate for the under 75 age group in 2012/13 was 197.5 per 
100,000 compared with 1,829.2 in the 75 and over group. 
Data on prevalence of CAD in Scotland can be tracked using the Scottish Health 
Survey, and Information services division (ISD - which uses inpatient hospital 
discharge and day case procedure data). The self-reported prevalence of CAD was 
7.3% (8.2% of men and 5.7% of women) in the 2012 Scottish Health Survey, which 
showed little change since the 2003 survey. But this increased to 30.7% in men and 
21.2% of women, for those aged 75 years and over. As per the ISD (2017) estimate, 
15% of adults had any CVD, 6% had doctor diagnosed diabetes, 19% had any CVD or 
diabetes, 5% had IHD, 3% had stroke and 7% had stroke or IHD, with no significant 
change since 2016 (29). 
1.3. Coronary Artery Disease and Left Ventricular Hypertrophy 
(LVH). 
Left ventricular hypertrophy (LVH) is a common finding in patients with CAD and is an 
independent predictor of mortality in patients with CAD. The prevalence of LVH is 
higher in patients with CAD than those without CAD. In a study by Ghali et al (1992), 
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the prevalence of LVH was 51% in patients with CAD compared to 40% in those 
without CAD (30) . It is noteworthy that in this study, majority of the study population 
were black and had hypertension. However, in another study by Ang et al (2007) 
assessed the prevalence of LVH in Caucasian patients with IHD. This study reported 
a prevalence of 50-75%, according to different cut-off values of LVH, with up to 62% 
of LVH in patients with normotensive BP (31). Importantly, presence of LVH is 
associated with worse clinical outcome, irrespective of presence of CAD. In an 
echocardiography study of LVH, the relative risk of all-cause mortality was higher 
among patients with LVH than those without LVH: 4.14 (CI, 1.77 to 9.71) among those 
with CAD and 2.14 (95% CI, 1.24 to 3.68) among those without CAD (30). This finding 
was further corroborated by other studies that reported LVH as one of the most 
powerful prognostic factors in CAD, after age and coronary disease severity with a 
prognostic importance equivalent to that of left ventricular ejection fraction (32,33).  In 
a recent study (N=3,754) that assessed association between LVMI, all-cause 
mortality, and need for revascularization in patients undergoing coronary angiography, 
the authors reported that higher LVMI is an independent predictor of all-cause mortality 
and need for revascularization: each 10 g/m2increase in LV mass index was 
associated with a 6% greater risk of mortality (hazard ratio: 1.06; 95% confidence 
interval [CI]: 1.01 to 1.11; p = 0.02) and a 10% greater need for revascularization 
(hazard ratio: 1.10; 95% CI: 1.04 to 1.17; p < 0.01). Additionally, this study also 
reported a 7-fold risk of mortality (95% CI: 1.2 to 2.3) and 1.8-fold need for 
revascularization (95% CI: 1.18 to 2.67) in those with moderate to severe hypertrophy 
(34). Furthermore, a recent study has shown that presence of LVH is independently 
associated with larger infarct size, less myocardial salvage, higher incidence of 
microvascular obstruction, lower left ventricular ejection fraction (LVEF), higher risk of 
all-cause mortality and incidence of heart failure for STEMI patients treated with 
primary PCI(35). 
Therefore, regressing LVH may have important prognostic benefits. In this context, 
several studies have reported that regressing LVH is associated with lower risk of 
future events. Literature around LVH regression will be discussed in detail later in this 
thesis.  
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1.4. Coronary Artery Disease and Dysglycemia 
It is well known that patients with type 2 diabetes mellitus (T2DM) have an increased 
risk of mortality from CVD. However, there is now mounting evidence suggesting that 
nondiabetic levels of glucose metabolism, defined as impaired fasting glucose (IFG), 
and impaired glucose tolerance (IGT) who are at higher risk for T2DM are also 
associated with higher risk of CV events and worse prognosis (36). Additionally, 
nondiabetic hyperglycemia is common in patients with CAD (37). Importantly, degree 
of coronary atherosclerosis and plaque vulnerability were reported to be more 
advanced in prediabetic than in nondiabetic patients and is equivalent between 
prediabetic and diabetic patients” (36).  Furthermore, studies have also shown that 
nondiabetic dysglycemia is a strong predictor for CVD and CAD, and is associated 
with higher mortality rates due to CAD, even in patients without diabetes (37).  In the 
Whitehall study encompassing 18,403 subjects, the age –adjusted CAD mortality rates 
after 7.5 years, were related to blood glucose levels after a 2-hour oral glucose 
tolerance test  (OGTT) and also associated with a two-fold increased risk of CAD 
morality in nondiabetic subjects (38).  An increased insulin response to OGTT is a 
common clinical finding in subjects with atherosclerosis of the peripheral, cerebral and 
coronary arteries (39,40).  Furthermore, two large studies, the Helsinki Policeman 
study and the Paris Civil Servant study have reported higher CAD mortality rates and 
incidence of MI in subjects with hyperinsulinemia in men aged 30-59 years, even in 
nondiabetic subjects (41,42).  As hyperinsulinemia is considered as a consequence of 
insulin resistance (IR), these evidences corroborate that IR is associated with 
development of CAD and also associated with worse clinical outcome, including 
nondiabetic subjects.  Additionally, there are studies that demonstrated that CAD is 
truly an IR state, even after adjusting for potential confounding influences (43-45). 
Bressler et al (1996), in a study of normal weight, normotensive subjects with 
angiographically documented CAD reported that the magnitude of IR was positively 
correlated with the severity of CAD (r=0.480, P<0.05) and that CAD patients were 
characterised by moderate-severe IR and hyperinsulinemia (46). In a recent multi-
vessel angioscopic study of CAD patients aimed to determine if prediabetes (ADA 
defined) was associated with atherosclerosis of coronary arteries reported that 
coronary atherosclerosis and plaque vulnerability were more advanced in prediabetic 
than in nondiabetic patients and comparable between prediabetic and diabetic 
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patients (36).  All these evidences support the notion that prediabetes is a strong risk 
factor for adverse CV events in nondiabetic subjects with CAD and therefore, may be 
a potential target for therapy.   
In this trial, we had selected CAD patients with LVH and dysglycemic states identified 
as those with prediabetes and/or IR. As discussed in the earlier paragraph, both 
prediabetes and IR have been associated with poor prognosis in patients with CAD, 
Additionally, LVH is very common in patients with CAD and studies have shown that 
IR is associated with the development of LVH (47,48). Therefore, nondiabetic CAD 
patients with LVH and prediabetes and/or IR will be the therapeutic focus of the MET-
REMODEL trial. The association between dysglycemia and LVH will be critically 
reviewed later in this thesis.  
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CHAPTER 2: Literature Review 1 – LVH and Dysglycemia 
 
As discussed in Chapter 1, LVH and dysglycemia are very common in CAD patients 
and are associated with worse prognosis. Hence it is imperative to focus on therapies 
targeted at these two conditions to reduce the risk of future events. This chapter will 
review the existing literature around the pathophysiology of LVH, pathophysiology of 
CVDs and abnormal glucose metabolism, particularly review the role of dysglycemic 
states such as IR, in the development of LVH and potential treatment strategies to 
improve IR in CVD.  
2.1. Left Ventricular Hypertrophy (LVH) 
2.1.1. Definition of LVH 
LVH is the abnormal thickening of the walls of the left ventricle due to non-specific 
physiological or maladaptive cardiac response to a large array of stimuli mediated by 
increased workload and numerous cardiac and neurohormonal factors. LVH often 
represents a pathophysiologic condition, and can develop intrinsic stimuli (obstructive 
cardiomyopathy), or secondary to extrinsic stimuli, such as pressure overload (such 
as hypertension and valvar disease) or volume overloaded conditions (such as aortic 
regurgitation and interatrial shunts) (Figure 5). Myocardial hypertrophy is also part of 
the remodelling process, particularly following an acute myocardial infarction (AMI), 
which is a common finding in patients with systolic or diastolic congestive heart failure 
(CHF). At a molecular level, the cardiomyocytes increase in size and has enhanced 
protein synthesis. According to the LaPlace’s Law, the load on any region of 
myocardium is given as follows: (pressure x radius)/ (2 x wall thickness). Although 
initially beneficial to compensate for hemodynamic overload, chronic hypertrophy may 
be deleterious as it predisposes to future risk of CHF development and sudden cardiac 
deaths (49,50). The precise mechanisms of LVH development and diagnosis will be 
discussed later in this thesis.  
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Figure 5: Left Ventricular Hypertrophy, a condition with diverse background (50) 
 
2.1.2. Types of LVH 
Hypertrophy does not have a uniform appearance. Depending on the underlying 
pathomechanism, it has different morphological and functional features. Generally, 
four types of geometric LV patterns have been described based on relative wall 
thickness (RWT) and left ventricular mass (LVM). They are: normal geometry (normal 
RWT and LVM), concentric remodelling (Normal LVM and increased RWT), concentric 
hypertrophy (increased RWT and LVM), and eccentric hypertrophy (normal RWT and 
increased LVM) (Figure 6) (51). Eccentric LVH, occurring as a result of volume 
overload, is a result of sarcomeres added in series to lengthening of cardiomyocytes, 
whereas concentric LVH tends to occur as a response to pressure overload as a result 
of sarcomeres added in parallel leading to increased cardiomyocytes thickening 
(52,53). Patients with concentric remodelling may equally have increased adverse  CV 
risk as those with concentric hypertrophy(54).                              
Left Ventricular Hypertrophy 
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Figure 6: Pathological Heart Remodelling: Differentiation between eccentric and 
concentric hypertrophy (53,55). 
2.1.3. Prevalence of LVH 
The prevalence of echocardiographic LVH in general population ranges from 10-20% 
in young and middle-aged subjects to 30-50% in elderly subjects (56-58), and is highly 
prevalent in the settings of obesity, hypertension or CAD, peripheral arterial disease 
(PVD) and valvular disease (58-60). Another study reported a high prevalence of LVH 
in subjects with CAD, as high as 62% in subjects with normotensive BP (31). It is 
noteworthy that the prevalence of LVH reported in the literature varies depending on 
the population group studied and the different diagnostic criteria applied to define LVH.  
In the Framingham study, LVH was reported in 16% of men and 19% women using 
echocardiography and the prevalence increased with age, as 33% of men and 49% of 
women aged 70 or older had LVH in their cohort (58). In the Tromoso study (N=3287), 
the prevalence of LVH was reported to be 14.9% in men and 9.1% in women, when 
diagnosed using echocardiography (61). Studies in the past have shown that LVH is 
a common finding in high risk cardiac patients, diabetics, peripheral arterial disease 
(PAD) and patients with chronic kidney disease (CKD). Ang et al (2007) reported a 
high prevalence of LVH in a study of stable angina patients; 73% (when LVM indexed 
to BSA) and it increased to 75% (when indexed to height2.7 (31). In an observational 
study of 500 patients with T2DM, the prevalence of LVH was reported to be 71% (when 
LVM indexed to height) and 43% when LVM was indexed to body surface area (BSA) 
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(62).  Other studies have also reported a high prevalence of LVH in other population 
groups: 50% in patients with PAD and 74% in patients with CKD (60,63,64).  
It is now becoming increasingly recognised that abnormal glucose tolerance (diabetes 
and/or non-diabetic hyperglycaemia) is an independent predictor of LVH. As described 
above, LVH is highly prevalent in patients with T2DM. In a small study of 40 
normotensive, non-diabetic, otherwise healthy, obese subjects, Sasson et al 
demonstrated that IR was strongly associated with LVH and that this association was 
independent of BP and body mass index (BMI) (65). Nakamura et al in 1994 reported, 
albeit in small population that LVMI in hypertensive patients with glucose intolerance 
(mean LVM = 115.6 ± 28.2 g/m2) was significantly higher than that in hypertensive 
patients without glucose intolerance (mean LVM= 102.1 ± 22.1 g/m2) (66). In a recent 
cross-sectional sub study of the ASTRONOMER (Aortic Stenosis Progression 
Observation: Measuring Effects of Rosuvastatin) trial, which enrolled patients with mild 
to moderate aortic stenosis, the authors reported that metabolic syndrome (MetS) was 
independently associated with a higher prevalence of concentric LVH and in another 
sub study they reported that IR is a power independent predictor of progression to 
LVH in patients with aortic stenosis (AS) (67,68). All these findings support the notion 
that IR may be a potential target for treatment for LVH.  
2.1.4. Aetiology of LVH 
LVH is considered as a structural adaptation of the heart, at least in part, as a 
compensatory mechanism for chronic neurohormonal activation and an abnormal 
hemodynamic load (i.e. increased preload or afterload). Figure 7 depicts the different 
determinants of LVH. When the heart is challenged with hemodynamic burden, i.e. a 
higher afterload, such as an aortic valve stenosis or an increased peripheral arterial 
resistance with arterial hypertension, the left ventricle is believed to respond with 
thickening of the ventricular walls and, ultimately, concentric LVH. However, if the 
heart is challenged with a higher preload, as in the case of a larger circulating blood 
volume in obesity or a regurgitating valve, the left ventricle is believed to respond with 
dilatation and, which in turn causes, eccentric LVH. Although, all these mechanisms 
(thickening and dilatation) may initially serve as compensatory mechanisms due to 
increased hemodynamic stress and to improve cardiac function, this may 
consequentially result in an increase in the weight of the heart.  This increased mass 
is due to cardiomyocyte hypertrophy, rather than hyperplasia, because 
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cardiomyocytes are perhaps terminally differentiated shortly after birth (49). The 
myocyte hypertrophy is accompanied by non-myocyte proliferation and fibrosis, 
eventually leading to the alteration of structure of myocardium (69). Taken together, 
these mechanisms will no longer be considered compensatory or physiologic, but 
pathologic, thereby increasing the subsequent risk of CHF and premature deaths (70). 
However, the repertoire of stimuli that may cause LVH stretches far beyond 
hemodynamic ones, and is yet largely unknown. 
 
 
 
Figure 7. Determinants of Left Ventricular Hypertrophy 
 
Several cross-sectional LVH studies in the past have shown that factors such as age, 
BP, obesity, valvular diseases, alcohol use, genetics, blood viscosity and CAD to be 
related to LVH or LVM (58,59,71-74). LVH is a common finding in patients with 
hypertension due to the increased cardiac afterload. The Framingham Heart Study 
has shown that the increase in LVM associated with average systolic BP reflected 
changes in left ventricular wall thickness at follow-up (58).  LVH is highly prevalent in 
patients with hypertension and therefore, hypertension is considered as the worst 
culprit indicated by large clinical trials showing that antihypertensive therapy can 
reduce LVM and RWT (75-77). However, the association between magnitude of BP 
lowering and magnitude of LVH reduction in previous studies is not always exciting 
(75), and the variation in 24-hour BP explains only 25-30% of the variation in LVM 
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(78), albeit with inconsistent findings (79). These findings highlight the importance of 
other factors in the aetiology of LVH. In this context, oxidative stress has been 
identified as one of the key contributing factors of LVH (80). Clinical trials in the past 
have shown that reducing oxidative stress can regress LVH (81-83). Another important 
determinant of LVM is obesity, as reported in the Framingham Heart Study (84). 
Obesity is often associated with numerous structural imbalances of the heart and has 
a positive correlation with LVM. Obesity can cause volume overload in the heart (due 
to elevated blood volume and cardiac output), with consequent left ventricular 
dilatation and hypertrophy. Obesity is also associated with other predictors of LVH 
such as arterial hypertension, oxidative stress and IR (85). Figure 8 depicts the various 
mechanisms by which obesity can cause LVH 
 
Figure 8: Mechanisms by which obesity can cause LVH (85). 
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It is therefore common to index LVM for a measurement of obesity, such as body 
surface area (BSA), height or height2.7 / height1.7, to obtain LVMI (86-88). Weight loss 
has been shown to reduce LVM and RWT (85) and LVMI in overweight hypertensive 
patients suggesting that control of obesity is important, not only for the treatment of 
hypertension but also for the prevention of left ventricular hypertrophy (89).  
Additionally, evidences from lifestyle intervention studies have also reported that 
lifestyle modifications such as reducing weight, dietary salt intake, alcohol intake and 
increasing physical activity in sedentary subjects is as effective in decreasing LVM by 
itself as in combination with antihypertensive medication, which may in part account 
for development of unexplained LVH (90). Another factor that has been implicated in 
the development of LVH is IR.  Abnormal glucose metabolism is linked to IR and 
several lines of evidence suggest that there is a significant relationship between LVH 
and IR. The larger studies are mostly positive including the Framingham, the Whitehall 
study, the Strong Heart study, and the Women's Health Initiative study, while 
HyperGEN is the one large negative study (47,91-94). The association of IR with LVH 
will be detailed later in this thesis.  
2.1.5. Methods of diagnosing LVH 
Primarily, there are four ways to clinically diagnose LVH: 
(i) Electrocardiographic (ECG) Detection 
(ii) Echocardiographic (ECHO) Detection 
(iii) Cardiac Magnetic Resonance Imaging (CMR) and  
(iv) Computed Tomography 
 
(i) Electrocardiographic (ECG) Detection: 
ECG is a commonly employed and traditional method to identify LVH. However, the 
limitations of the ECG relate to its moderate specificity or sensitivity depending upon 
the diagnostic criteria applied (95). The Framingham study reported a low sensitivity 
(6.9%) for the ECG-LVH criteria (96).  Ang et al also reported a low sensitivity for ECG 
in detecting LVH in CAD patients(31).  Despite many different ECG-LVH criteria that 
have been developed over the years to detect LVH, their sensitivity still remains under 
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60% (97-99). It is noteworthy that the sensitivity and specificity of the various ECG-
LVH criteria’s depends upon the study population being studied.  
Increased QRS amplitude and duration, left axis deviation, prolonged intrinsicoid 
deflection and ST-T changes are the typical ECG changes found to be associated with 
the presence of LVH. The most widely used ECG criteria for LVH include the Sokolow-
Lyon (SLV) and the Cornell voltage criteria. SLV criteria is defined as the sum of the 
S wave in V1 and the R wave from the highest of either V5 or V6 and Cornell voltage 
criteria is defined as the sum of S wave in V3 and R wave in aVL. However, it is now 
acknowledged that these two criteria’s have poor sensitivity in detecting LVH 
compared to echocardiographic based assessment of LVH (100,101). The LIFE study 
has reported the low performance of ECG criteria in detecting LVH in diabetic patients 
(102).  
(ii) Echocardiographic (ECHO) Detection: 
Echocardiography, introduced in 1950s has become the cornerstone of non-invasive 
imaging of the heart. This technique is based on ultrasound waves directed to the 
heart, which are reflected and translated into several modalities that can be employed 
in the assessment of LVH. The different modalities that are used to assess LVH are: 
(i) M-mode echo; (ii) two dimensional echocardiography (2DE) and (iii) three-
dimensional echocardiography (3DE) images (103,104) and is eight times more 
sensitive than ECG in detecting LVH and has been validated in necropsy studies 
(96,105). The most often employed modality in assessing presence of LVH is the 2D 
M-mode measurement. However, geometric assumptions represent a major limitation 
in LVM assessment in M-mode and 2DE, but this can be overcome by the use of 3DE 
(but less widely available): 3DE measurements correlate better with the gold standard, 
CMR measurements compared to 2DE. Additionally, echo is operator and patient 
dependent, which could result in an increased inter-observer variability (106). M-mode 
measurement is widely used to assess the presence of LVH. LVM calculations can be 
calculated using a formula (such as Penn or Devereux modified cubed formula), as 
validated by studies for good accuracy (correlation coefficient >0.9) (105).  
Penn formula: LV mass = 1.04 [(LVIDD+LVPW+IVSd)3 – (LVIDd)3]-13.6  
Devereux modified cubed formula:  
LV mass = 0.8 [1.04 [(LVIDD+LVPW+IVSd)3 - (LVIDd)3]] + 0.6  
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Echocardiographic measurements of LVH are generally defined using the American 
Society of Echocardiography (ASE) recommendations (86). Measurements are taken 
at end diastole at the onset of the QRS complex to calculate LVM. LVM is indexed to 
body surface area (BSA) and presence of LVH is defined as greater than 95g/m2 for 
women and 115g/m2 for men. LVM can also be indexed to height to avoid 
underestimating the prevalence of LVH in overweight patients, which has been 
prognostically validated (86). In this study we indexed LVM to height1.7. This method 
has been shown to be more sensitive than LVM/BSA and was most consistently 
associated with cardiovascular events and all-cause death (88).  
(iii) Cardiac Magnetic Resonance Imaging (CMR): 
CMR uses nuclear magnetic resonance of hydrogen to identify specific tissues (107) 
and was introduced in the beginning of 1980. (108). CMR is considered as the gold 
standard for assessment of most cardiac parameters including LVM. It does not 
depend on acoustic windows and measurements are less operator dependent with an 
overall good image resolution (109,110). However, due to its relatively expensive costs 
and less availability, it is not widely utilized. Additionally, this technique is 
contraindicated in patients with mechanical devices (e.g., pacemakers, prosthetic 
valves, metallic implants etc.), and has relatively low spatial resolution (compared to 
CT), and prolonged examination time (109,110).  
However, there is a significant poor correlation in LVM measurements obtained using 
CMR and M-mode echo, as M-mode echo tends to overestimate LVM assessments 
(111-113). A study by Tse HF et al reported that echo based assessment of LVM was 
higher compared to CMR (LVM values 27.6g higher at baseline and 37.1g at 1 year 
compared to CMR) (114). This echo based over estimation of LVH is a consistent 
finding: Simpson et al (2010) reported higher mean LVMI in echo assessed data than 
the CMR derived mean LVMI (115); another study also reported that echo significantly 
overestimates LVM relative to MRI, and this overestimation was attributed to the 
assumptions by which LVM was calculated (112). As CMR only takes fewer geometric 
assumptions (calculated from three-dimensional data) and the myocardial borders are 
easily identified due to the much better spatial resolution, this technique is considered 
to be more accurate than echo. This assumption has been validated in a study of 
human post-mortem hearts imaged ex-vivo (116,117) and furthermore, another study 
has shown the accuracy of CMR in assessing deformed (post MI) and hypertrophied 
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ventricles (118,119).  Another aspect of CMR is its reproducibility in quantifying LVM 
compared to M-mode and 3D echo (117,120-122).  
However, there are limitations and challenges in MRI acquisition. Firstly, CMR is not 
a widely available imaging technique and also needs specialized training in performing 
the scan and interpreting images.  Secondly, we cannot exclude the possibility of inter-
observer variability when deciding basal and apical slices to include due to the 
following reasons: (i) each slice may have large cross sectional area which can have 
a greater impact on mass/volume assessments; (ii) practical difficulties in defining 
most basal slice adjacent to the mitral value plane due to partial volume effects (123). 
Furthermore, it is difficult to obtain images without artefacts in patients with 
arrhythmias and also by the artefacts generated by the blood flow itself that generates 
its own magnetic field in homogeneity – a problem exacerbated by the requirement to 
use fast gradient echo sequences in order to capture the heart in motion. Another 
limitation is use of MRI in patients with claustrophobia and contraindications such as 
pacemakers, defibrillators and certain metal implants.  
There are two methods that are used for cine sequence acquisition for LV dimension 
assessment: (i) FLASH (Fast Low Angle Shot MRI / Fast Gradient Echo Cine 
Sequence. (ii) SSFP (Steady-State Free Precession or True FISP). SSFP has 
advantages over FLASH and is used in current clinical practice. SSFP allows faster 
imaging and more accurate endocardial and epicardial border definition with less blood 
flow dependence compared to FLASH, enabling a more accurate measurement of 
LVM and LV function (124).  
Majority of data from CMR studies were derived from 1.5T machines and recently a 
much higher field strength 3T machines are used. In this study, we used the 3T 
machine for CMR assessments. It is noteworthy that sequences derived from both 
1.5T and 3T machines have shown no difference in quantification of LVM and 
volumes, hence the normal LVM range should be transferable to both types of MRI 
machines (125).  
(iv) Computed Tomography (CT) 
In CT technique, X-ray radiations are passed through the body and are absorbed at 
different intensities depending on the tissues. Tissue differentiation is captured using 
the remaining X-ray radiation that are captured by the detectors on the other side of 
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body (126). However, a recent methodological review by Alkema et al (2016) have 
highlighted the paucity of data regarding the reference values for parameters such as 
wall thickness in mid-diastole (126). Cardiac CT is widely used in identifying the 
presence of CAD in patients with intermediate risk (127). Additionally, in patients with 
contraindications to MRI, CT is used which is an excellent alternative that can offer 
better spatial resolution and unrestricted field of view.  However, cardiac CT is the 
least preferred technique among the other three LV assessments due to the low 
temporal resolution and radiation exposure (109,110). Table 1 summarises the key 
technically and clinically important characteristics of echo, CMR and CT. 
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Table 1: Comparison of imaging modalities used for LVH severity grading   (106).
Characteristics M-mode Echo 2S Echo 3D Echo CMR CT 
Spatial Resolution ++++ ++++ ++ +++ ++++ 
Temporal Resolution ++++ +++ +++ ++ + 
Radiation - - - - + 
Renal Failure - - - + + 
Mechanical Implants - - - + - 
Operator Dependent ++ ++ ++ + + 
Low Availability - - - ++ + 
Cost & Resources + + + +++ ++ 
Tissue Characterization - - - +++ ++ 
Geometric Assumptions ++ ++ - - - 
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2.1.6. Mechanisms whereby LVH increases CVD risk 
 
2.1.6.1. Myocardial Ischemia 
LVH is highly prevalent in patients with IHD, even in the absence of hypertension (31) 
and is a strong independent predictor of CV mortality and morbidity (128,129). There 
are many plausible mechanisms by which LVH can cause myocardial ischemia: (i) risk 
factors of LVH such as age, BP and T2DM can cause atherosclerosis, and eventually 
predisposing the patients for future CV events; (ii) white blood cell (WBC) count, 
fibrinogen levels and blood viscosity associated with LVH leading to myocardial 
ischemia (74,130); (iii) LVH also causes reduced coronary flow reserve (due to 
imbalance between myocardial oxygen supply and demand) (131). As LVM increases, 
there will be increased myocardial oxygen demand and cardiomyocytes hypertrophy 
to compensate this extra demand.  When the corresponding oxygen level  fails to 
compensate this increasing demand, perfusion is unable to compensate accordingly 
resulting in reduced coronary flow reserve (ratio of hyperemic to baseline myocardial 
blood flow) and an increase in coronary vascular resistance (132). This phenomenon, 
known as coronary microvascular dysfunction is clinically relevant when the 
myocardium is placed under stress (not at rest), as de-compensation occurs during 
stress (e.g., exercise, pharmacologic agents etc.). This explains the high prevalence 
of myocardial ischemia in hypertensive patients with non-obstructive CAD (133) and 
subsequent worsened clinical outcome (134). This impaired sub-endocardial blood 
flow may contribute to diastolic dysfunction and predispose to the risk or severity of 
heart failure (135).  
 
2.1.6.2. Heart Failure 
LVH is an independent predictor for the development of heart failure (HF), both in 
general population and also in high-risk patients (136-138). Khouri et al (2010) 
proposed a four subgroup classification of LVH based on LV geometry for risk 
stratification of CVD; (i) eccentric non-dilated (or intermediate hypertrophy); (ii) 
eccentric dilated; (iii) concentric non-dilated LVH and (iv) concentric dilated LVH (139). 
This classification was prognostically validated in hypertensive patients (N=939) from 
the LIFE study (mean follow-up of 4 years), which identified a low-risk subset with 
eccentric non-dilated LVH and 3 subsets of LVH at high risk of developing LV 
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dysfunction and HF (140). This finding was further validated in another CMR study 
(N=2458) of LVH, where the authors reported an elevated risk of HF and CV deaths 
in patients with either dilated hypertrophy or both thick and dilated hypertrophy (141). 
Diastolic LV dysfunction, a functional determinant predisposing to heart failure with 
preserved ejection fraction (HFpEF), is a common finding in patients with concentric 
dilated LVH whereas systolic dysfunction is associated with eccentric dilated LVH and 
is a determinant of heart failure with reduced ejection fraction (HFrEF) (142). 
Additionally, the impaired coronary physiology as a result of myocardial ischemia 
(even in the absence of demonstrable CAD) predicts development of LV dysfunction 
in patients with LVH (143). Furthermore, increased baseline LVM on ECHO or ECG 
was an independent predictor of depressed LV ejection fraction (137). In the HOPE 
trial, over a mean follow-up period of 4.5 years, 6.1% of those with ECG-LVH 
developed HF compared to 2.9% without ECG-LVH (138). All these evidences 
suggest that mechanisms such as coronary myocardial dysfunction, myocardial 
ischemia, neurohormonal activation and reduced LV compliance (resulting in diastolic 
dysfunction) play a major role in the progressive decompensation of the hypertrophied 
LV and has an important pathogenic role in contributing to the remodelling towards LV 
dysfunction and HF.  
2.1.6.3. Arrhythmia 
It is now widely accepted that sudden cardiac death is either ischemic, arrhythmic or 
thrombotic, representing a complex interaction due to reduced coronary flow reserve, 
increased myocardial oxygen demand, lethal arrhythmias and sub endocardial 
ischemia. Therefore, it is likely that the arrhythmic propensity in LVH is multifactorial 
in origin (135,144).  
Evidences from experimental studies suggest that myocardium with pathological 
hypertrophy facilitate the development and propagation of ventricular arrhythmia. 
Biopsy studies have conclusively shown the presence of greater degree of myocardial 
fibrosis in patients with ventricular tachycardia (VT) and normal LV function. 
Myocardial fibrosis inhibits the propagation of electrical impulses through the 
myocardium and enables re-entrant arrhythmias (135).  
Several lines of evidences suggest that LVH is strongly associated with non-sustained 
ventricular tachycardia (VT) and ventricular ectopics. Increased ventricular ectopic 
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activity and VT were a common finding in patients with LVH (144-146). Additionally, 
another study has shown that LVH is associated with ventricular arrhythmias, even in 
the absence of CAD, and have also showed that every one millimetre increase in 
thickness of inter-ventricular septum or posterior wall is associated with a 2-3 fold 
increase in the occurrence and complexity of ventricular arrhythmias (147). The 
Framingham study also reported an elevated mortality rate in patients with 
asymptomatic ventricular tachycardia and LVH and a 3-4 times increased risk of AF 
after adjusting for potential confounders. Furthermore, they also reported that every 
increase in 4mm in LV wall thickness was associated with 28% increased risk of non-
rheumatic AF (148). In another study of subjects with essential hypertension 
(N=2482), the authors reported that every one standard deviation increase in LVM, 
there was a 1.2 fold increased risk of AF, indicating that risk of AF increases with LVM 
(149).  
Although not completely elucidated, there are numerous plausible mechanisms to 
explain the arrhythmogenicity of LVH. Firstly, the anatomical changes such as fibrosis 
and collagen deposits inhibit the smooth propagation of electrical impulses through 
the myocardium. Secondly, electrophysiological changes of the hypertrophied 
myocardial cells such as prolongation of the action potential duration (150), reduced 
membrane repolarisation (i.e. increased QT interval enabling re-entrant arrhythmias) 
(151), repolarisation heterogeneity (resulting in increased incidence of T wave 
alternans) (152), early or delayed depolarisation (153) and expression of If channels 
(increasing automaticity) (154).  
2.1.7. Prognostic Implications of LVH 
Although, starting as an adaptive response of the heart for increased cardiac workload, 
when pathogenic, LVH per se is associated with a higher risk of CV mortality, sudden 
death, CAD, HF and stroke through its effects on coronary circulation, ventricular 
function and arrhythmogenic property (155). The Framingham study reported a 
prevalence (age dependant) of LVH, increasing from 6% in subjects under age 30 
years to 43% in those who are over 69 years old (58). However, the prevalence of 
LVH varies according to the population group studied and the different diagnostic 
criteria applied to define LVH; 20% in patients with mild hypertension; ≥50% in patients 
with severe hypertension (156,157); 50% in patients with PAD and 74% in patients 
with CKD (60,63,64); 62% in normotensive patients with CAD (31) and between 43% 
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and 71% in patients with T2DM(62). Several studies have highlighted the clinical 
relevance of LVH in causing elevated risk of mortality and morbidity thereby, 
supporting the notion that regressing LVH can have a positive outcome on prognosis 
(158). In this context, the LIFE study provided conclusive evidence that LVH per se 
reduces future CV events irrespective of BP (159).  
Vakili et al (2001), in a comprehensive review on prognostic implications of LVH 
reported that LVH consistently predicted poor prognosis, independently of 
confounding influence, with no clear difference in relation to race, presence of absence 
of hypertension or CAD, or between clinical and epidemiological samples (160). From 
a total of 20 studies (N=48,545) examined, the prevalence of baseline LVH was higher 
in echocardiographic studies than in ECG studies (16% -7.4% vs 1%- 44%, 
respectively).  The adjusted risk of future CV morbidity associated with baseline LVH 
ranged from 1.5 to 3.5, with a weighted mean risk ratio of 2.3; adjusted risk for all-
cause mortality ranged from 1.5 to 8.0 with a weighted mean risk ratio of 2.5 for all 
studies examined in this review. Women had the worst outcome compared to men, 
irrespective of the ethnic group studied. (160). In another meta-analysis by Verdecchia 
et al, the regression of LVH was associated with 59% reduced risk of CV events 
compared to those with persistent or new LVH on echo (161) 
Thus, available data from various studies support the notion that the presence of 
baseline LVH is strongly associated with subsequent CV events and regressing LVH, 
per se, can improve prognosis in subjects with LVH. Therefore, clinical trials and 
treatment strategies that can prevent or regress LVH in specific study population can 
be proven beneficial.  
2.1.8 LVH regression 
It is now widely recognized that LVH is a clinically important intermediate end point 
because it predates many different CV events. LVH is arrhythmogenic and causes 
sudden death, it impedes LV filling and leads to diastolic heart failure (HF), it reduces 
coronary perfusion reserve, and it causes left atrial enlargement, atrial fibrillation, and 
cardio embolic strokes(33). Therefore, regressing LVH can reduce the risk of future 
CV events. Controlling BP and using drugs that block the renin-angiotensin system 
are the standard approaches to the management of LV, because systolic BP is the 
primary stimulus for LVH development. Studies have shown that reducing BP 
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produces some degree of LVH regression, however, this relationship is weak, 
emphasising the contribution of non-hemodynamic factors (162). Studies have also 
shown that directly acting vasodilators such as hydralazine and minoxidil do not cause 
LVH regression, both in experimental animals and man despite a reduction in BP 
(163). This observation highlights that both can trigger sympathetic activation, 
demonstrating the importance of neurohormonal stimuli.  
Numerous studies have shown some beneficial effect of antihypertensive drugs on 
LVH regression (Figure 9) (164). A meta-analysis by Dahlof et al, involving 109 
published studies reported that the magnitude of LVH regression measured by echo 
ranged from 7.7% with diuretics to 16.3% with ACE inhibitors, the most effective class 
of drug studied (165). Another meta-analysis by Klingbeil et al showed that this was a 
consistent finding with most clinical studies and extensive animal data (166). All 
available evidences from multiple studies suggest that angiotensin-converting enzyme 
inhibitors, AT1 receptor blockers, and calcium antagonists were found to be more 
potent than beta-blockers; the efficiency of diuretics was intermediate. However, the 
results from these meta-analysis should be interpreted with caution as many studies 
included in this meta-analysis were small size, of short duration, used non-blinded 
reading of echocardiograms and also limited by the fact that they do not represent 
drug-by-drug comparisons.  
Although, there is no general consensus on the best pharmacologic intervention to 
regress LVH, majority of the evidences from clinical trials support the drugs that target 
the renin angiotensin aldosterone system (RAAS). Pre-clinical evidences have 
demonstrated that activation of RAAS system can result in hypertrophy of 
cardiomyocytes, much analogous to load-induced hypertrophy and fibrosis, both of 
which are modulated by angiotensin II via angiotension-1 (AT-1) receptor. 
Furthermore, modulation of the RAAS system has been shown to regress LVH and 
consequent clinical outcome benefits(167). Additionally, numerous clinical trials have 
also shown that angiotensin receptor blockers (ARB) seem to have beneficial effects 
on LVH regression, independent of BP control. 
The Losartan Intervention for Endpoint reduction in hypertension (LIFE study) was the 
first trial that compared the effects of specific drugs on both LVM regression and 
clinical end point. In the echocardiographic sub study (N=941) of LIFE study to 
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determine the prognostic significance of LVM reduction, reduction in LVM was found 
to be significantly greater in losartan group (mean reduction 21.7g/m2 vs 17.7 g/m2: 
P=0.21) and also showed that lower LVM during antihypertensive therapy was 
associated with lower rates of clinical endpoints, independent of BP, treatment 
assignment, other risk factors, and comorbidities (168). This study reported that a 
reduction in LVMI by 1 SD (25.3 g/m2) was associated with a calculated 22% reduction 
in the primary end point and a 28% reduction in total mortality additional to that 
predicted by BP reduction alone 
                                  
Figure 9: LVH regression with antihypertensive treatment (164). LVH, left 
ventricular hypertrophy; ARB angiotensin-receptor blocker, CCB calcium channel 
blocker; ACEI angiotensin converting enzyme inhibitor,; BB beta-blocker (160) 
Furthermore, this finding was corroborated in another three-dimensional 
echocardiographic and MRI study. which showed a reduction in LV mass among the 
hypertensive patients treated with telmisartan as compared with carvedilol (169). In 
the Heart Outcome Prevention (HOPE) Study, the ace inhibitor Ramipril reduced the 
development and regression of ECG-LVH independent of BP reduction, and these 
changes are associated with reduced risk of death, myocardial infarction, stroke, and 
congestive heart failure in a cohort of patients who are at high risk for CAD (170).  In 
another double-blind RCT on LVH regression (LIVE study, indapamide versus 
enalapril), indapamide significantly reduced the LV mass index from the baseline (–
8.4 ± 30.5 g/m2 from baseline; P < 0.001); whereas enalapril did not (−1.9 ± 28.3 g/m2) 
even though both the drugs significantly reduced BP. Additionally, in this study, the 
change in LVMI did not correlate with BP and indapamide progressively reduced wall 
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thickness throughout the study period (171). Similarly, in the Prospective Randomised 
Enalapril Study Evaluating Reversal of Ventricular Enlargement (PRESERVE) study 
that evaluated whether antihypertensive treatment with enalapril induces greater LVH 
regression than nifedipine by > 10 g/m2 despite equivalent BP reduction have reported 
no difference between the treatment groups in terms of LVH regression from the 
baseline after a one year follow up (172).  
Therefore, it is not yet clear whether dual blockage of RAAS with different 
pharmacological interventions will gain incremental benefit in BP control and LVM 
reduction. In the 4E-Left Ventricular trial that studied LVH regression among groups 
treated with eplerenone, enalapril and eplerenone/enalapril, the reduction of LVM from 
baseline was statistically significant in all three groups. Greater absolute reduction of 
LVM was observed in the eplerenone/enalapril arm. Additionally, there was no 
correlation between antihypertensive effect of the drug and LVM reduction (173). 
Similarly, few other studies reported no additional benefit with dual RAAS blockage. 
In patients at high vascular risk, the combination of ramipril and telmisartan had a 
similar effect on LVH to that of ramipril alone (174). A similar result was reported from 
the Aliskiren in Left Ventricular Hypertrophy (ALLAY) study. In this study, the authors 
reported that Aliskiren, a direct renin inhibitor was as effective as losartan in causing 
LVM regression and that regression in LVM with the combination of aliskiren plus 
losartan was not significantly different from that with losartan monotherapy, 
independent of BP lowering (175). 
2.1.9. Need for Alternative Strategies for Regressing LVH 
Controlling BP using an angiotensin converting enzyme inhibitor (ACEi) or angiotensin 
receptor blocker (ARB) is only partially effective at regressing LVH, as LVH persists in 
20% of hypertensive patients who attain target BP (176). Importantly, BP only 
contributes 25% to the variability in LVM seen in a population (177). Studies have also 
shown that despite a  “normal” BP, LVH is just as risky as is LVH in patients with 
hypertension (178). Nevertheless, it is well established that regressing LVH 
irrespective of BP changes is an effective way to reduce the incidence of all major CV 
events including specifically sudden deaths, heart failure hospitalisations, new onset 
AF and strokes.(158,161,179-184). Therefore, additional ways (non-BP targets) of 
regressing LVH are required to regress LVH in patients who are normotensive.  
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Recently, additional targets such as oxidative stress, IR, downstream pathways have 
been proposed in the pathogenesis of LVH.  In this context, oxidative stress has 
emerged as a potential target for LVH regression and previous studies have shown 
that allopurinol can reduce oxidative stress and also cause LVH regression. 
Szwejkowski et al (2013) and Rekraj et al (2013) have shown in randomised, double-
blind, placebo-controlled studies that, allopurinol regress LVH in high risk patients 
(185,186). The non-pharmacological intervention and lifestyle changes aimed at LVH 
regression involve weight loss, aerobic exercise and low-salt diet (164). The other 
major therapeutic target whose manipulation might regress LVH is IR, which is the 
therapeutic focus of this study. As discussed in chapter 1, non-diabetic hyperglycemia 
is highly prevalent in patients with CAD (187) and is associated with cardiovascular 
mortality(188). Hyperglycemia is linked to insulin resistance (IR) and prediabetes and 
the literature is awash with observational studies linking insulin resistance to LVH.  
Majority of the larger studies are positive which includes the Framingham, 
WHITEHALL study, the STRONG HEART study and the Women’s Health Initiative 
study, while HyperGEN is the one large negative study.(47,91-94). The association 
between IR and LVH will be discussed in detail, later in this thesis (174). 
Literature around the pathogenesis of IR in the development of LVH will be discussed 
in detailed, later in this thesis.  
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2.2. Cardiovascular Diseases and Abnormal Glucose 
Metabolism 
2.2.1. Incidence and Burden of Type II Diabetes Mellitus in Cardiovascular 
Diseases 
As per the latest Diabetes UK report (2016), almost 4.5 million people in UK have been 
diagnosed with diabetes including 1 million people with undiagnosed Type 2 
diabetes(189).  It is estimated that one third of mortalities in diabetic patients are due 
to CVD, making CVD a major independent predictor of worse outcome in people with 
diabetes compared to people without diabetes mellitus (DM) (190). The term CVD 
includes an array of diseases that affect the heart and circulatory system and the major 
types of CVD that affect people with DM are CAD, diabetic cardiomyopathy, peripheral 
arterial disease, stroke and heart failure (191). Additionally, the deleterious 
complications of DM can lead to body organ dysfunction and culminate in DM related 
morbidity and mortality. There are two types of DM; type 1 DM (T1DM) and type 2 DM 
(T2DM). T1DM is immune mediated and results from autoimmune destruction of 
pancreatic β-cell whereas, T2DM encompasses defects in insulin secretion and IR, 
and is the most common form of DM comprising almost 90% of all cases (192). T2DM 
patients are also at an increased risk of developing CV risk factors such as 
hypertension, endothelial dysfunction, abnormal lipid profiles and prothrombotic 
factors (193,194). Now, T2DM per se is considered as a major CV risk factor (195). 
Available data from previous studies suggest that 40% of patients with ACS have DM 
with higher mortality rates compared with non-diabetic patients (196-198). 
Furthermore, ACS patients with undiagnosed diabetes and prediabetes have 
increased 30-day mortality compared to non-diabetic patients (199). Despite CV 
mortality falling over the last 3 decades, there has not been a decline in CV mortality 
in patients with DM (193). Therefore, one third of mortalities in DM patients are due to 
CVD, making DM equivalent to CAD (190).  
2.2.2. Pathophysiology of Type II Diabetes Mellitus in Cardiovascular 
Diseases 
The pathophysiology of the link between T2DM and CVD is complex and multifactorial 
and understanding the underlying mechanisms of disease can help clinicians identify 
and treat CVD patients who are at risk of developing T2DM. T2DM is a prime risk 
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factor for CVD and the most common risk factor for mortality in patients with T2DM 
(200). T2DM also affects the heart muscle, resulting in both systolic and diastolic heart 
failure. Although, the aetiology of this excess CV morbidity and mortality on T2DM is 
not completely elucidated, several lines of evidences suggest the role of 
hyperglycemia, the hall mark of diabetes, as one of the key factors in contributing to 
myocardial damage after ischemic events (201).  
Prediabetes or intermediate hyperglycemia is a heterogeneous phenomenon, based 
on glycemic indices above normal but below diabetes thresholds, is a high risk state 
for diabetes with an annualized conversion rate of 5%-10% in general population, 
although conversion rate varies by population characteristics and the definition of 
prediabetes (202,203). IR is a major pathophysiological mechanism leading to 
elevated fasting or postprandial glucose in prediabetic subjects. Although mechanisms 
linking CVD and prediabetes remain poorly understood, both these conditions share 
IR in several tissues, resulting in an elevated risk of development of frank diabetes. 
Hyperglycemia is highly prevalent in patients with CAD and is associated with higher 
rates of CV mortality (204,205). Available evidence suggests that CHF is an IR state, 
where both share a   bi-directional relationship, with a high prevalence rate (61%) and 
also associated with decreased exercise capacity in non-diabetic CHF patients (206). 
Additionally, the recent Candesartan in Heart failure: Assessment of Reduction in 
Mortality and morbidity (CHARM) programme, which included patients with heart 
failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection 
fraction (HFpEF) reported a prediabetes (defined as HbA1c 6%-6.4%) prevalence rate 
of 20% in patients with HFpEF and 22% in patients with HFrEF (207). They also 
reported that non diabetic CHF patients with CHF had higher rates of their primary 
composite outcome such as death from CV causes or a hospitalization for HF, as well 
as all-cause mortality compared to normoglycemic CHF patients (Figure 3) (207). 
Furthermore, there are mounting evidences from studies reporting that non diabetic 
CHF patients with hyperglycemia or hyperinsulinemia have worse NYHA functional 
classification and was associated with worse prognosis (208-210).  
This increased understanding of the relationship between non-diabetic hyperglycemia 
and CV diseases that they are an intricate pair that forms a viscous cycle that worsens 
each other, at both tissue and cellular levels, provides a clear rationale in targeting IR 
or non-diabetic hyperglycemia as a target for treatment in high risk CVD patients. This 
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will help clinicians in either delaying the development of T2DM or in prevention of 
future CV events. 
2.2.2.1. Multistage Model of Development of Type II Diabetes Mellitus 
Several observational studies and clinical trials have supported the understanding that 
T2DM is a preventable disease in subjects who are at high risk in the development or 
T2DM (211-214). Weir et al (2004) coined a multistage model of diabetes development 
(215). The initial stage in development of diabetes is a long compensatory period 
where IR is present with higher rates of insulin secretion (216) and higher  cell mass 
(217). In the next stage (stable adaptation period),  cells no longer compensate for 
increased IR, resulting in an impaired fasting / or post load glucose values. This stable 
adaptation phase is initiated when fasting and post load glucose levels fall in the 
normal range (218) and is usually accompanied by a reduction in acute insulin 
secretion that is present at fasting plasma glucose levels around 5.6mmol/L (217). 
Both these stages occur before the prediabetic phase. In the next stage, the  cell 
becomes unable to compensate for the degree of IR resulting in glucose levels to 
increase rapidly (215,217) as evidenced by other longitudinal studies and Whitehall II 
study (219,220). This stage is termed as the unstable early decompensation phase 
and probably extends from prediabetes to frank diabetes of stage 4, which is 
characterised as stable decompensation phase with more severe beta cell 
dedifferentiation. Finally, in the 5th stage, i.e. severe decompensation phase, there will 
be a profound reduction in beta cell mass with progression to ketosis (215).  
2.2.2.2. Prediabetes: a high-risk state for development of Type II Diabetes Mellitus 
In the general population, the estimated annualized conversion rate of prediabetes to 
diabetes is around 5-10% depending upon the population studied and the criteria used 
(202,203). Gerstein et al (2007), in a meta-analysis of prospective studies published 
up to 2004, looked at the annual incidence and relative risk of diabetes in various 
categories of dysglycemia. He reported that the annualized incidence rates of diabetes 
for isolated impaired glucose tolerance (4-6%) and isolated impaired fasting glucose 
(6-9%) were lower than those for IFG and IGT combined (15-19%) (221). This 
progression estimates were a similar finding in other major studies: 11% in the 
diabetes prevention program (DPP) outcomes study (222); 6% in participants with IFG 
in the Multi-Ethnic Study of Atherosclerosis (MESA) (223); 9% (IFG) and 7% (HbA1c 
5.7-6.4%) in the TOPICS3 study, a Japanese population based study (224). 
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Additionally, studies have also confirmed that the risk of T2DM development on the 
basis of FPG and 2-hour post load glucose is broadly similar to that posed by HbA1c 
test (221,225). The American Diabetes Association (ADA) expert panel have 
estimated that 70% of individuals with prediabetes will eventually develop T2DM (203). 
In the China Da Qing Diabetes Prevention study, the 20-year cumulative incidence of 
diabetes was even higher (>90%) among controls with an IGT defined with repeated 
OGTTs (226). The study also looked at the CVD incidence and mortality, and all-cause 
mortality in this cohort, but there was no statistically significant difference between the 
intervention and control groups in the rate of first CVD events (HR 0·98; 95% CI 0·71–
1·37), CVD mortality (0·83; 0·48–1·40), and all-cause mortality (0·96; 0·65–1·41). It is 
noteworthy that this study was not powered to detect differences for these outcomes 
(226).  
As discussed earlier, dysglycemia is very common in non-diabetic patients with CVD 
and it is reasonable to postulate that in many individuals with established CVD, 
prediabetes and/or IR can lead to frank diabetes and associated CV complications. 
Furthermore, diabetes and CVD share the same traditional risk factors such as 
obesity, hypertension and dyslipidaemia, placing them at higher risk of diabetes and 
elevated rates of cardiac events. Therefore, targeting these risk factors, importantly 
prediabetes and/or IR in patients with established CVD is critical to minimise the risk 
of development of T2DM and long term CV complications.  
2.2.2.3. Insulin Resistance and Cardiovascular Diseases in Nondiabetic Individuals 
Insulin acts via multiple physiological processes and the main responsibility of insulin 
is to provide a cohesive set of signals to facilitate the precise balance between nutrient 
supply and demand (227). In a state of IR, the target cells fail to respond to normal 
circulating insulin levels, and to compensate this, increased concentration of insulin 
are released by the beta cells of the pancreas for normal response from cells (228). 
Therefore, the state of IR is defined as the state of diminished glucose uptake by 
muscle cells and consequent increased gluconeogenesis by liver resulting in 
hyperglycemia, both in fasting and postprandial states (229).  
It is now widely acknowledged that the key CV risk factors such as hypertension, IGT, 
hyperinsulinemia, dyslipidaemia and metabolic syndrome, often occur together in 
same individuals. The existence of a syndrome involving some of these disorders was 
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proposed nearly 95 years ago by a Swedish physician, Eskil Kylin, where he noted 
that overweight subjects often have elevated blood glucose levels, elevated BP and 
hyperuricemia (230). IR assessed by hyperinsulinemic euglycemic clamp method was 
been proposed in 1979 (231)  and IR was suggested  to be of pathogenic importance 
by several others  (232-234).  
Several lines of evidences from large population based studies have shown that IR 
predicts incident CAD (42,235,236). Although the initial understanding was that the 
risk associated with IR was primarily due to lipid abnormalities that was prevalent in 
people with higher insulin concentrations. The findings from these studies support the 
notion that hyperinsulinemia per se can cause alterations in the metabolic processes 
other than dyslipidaemia and could potentially increase the risk of CAD (236). 
Additionally, the United Kingdom Prospective Diabetes Study (UKPDS) have reported 
that loss of beta-cell function initiates 10-12 years before T2DM is diagnosed (237).  
The major pathophysiological mechanism leading to elevated fasting or postprandial 
glucose in prediabetes is IR in combination with impaired insulin secretion, 
predominantly seen in tissues, such as skeletal muscle, adipose tissue, endothelium 
and the liver (238). Compensatory hyperinsulinemia in prediabetes occurs when 
pancreas compensates for IR in peripheral insulin sensitive tissues. Laakso in 2010 
as the first show that IR in normoglycemic subjects, per se is directly associated with 
atherosclerosis and provided evidence that primary events responsible for 
atherothombosis could be related to IR per se (238,239).  
CVD risk factors such as IR, obesity (particularly abdominal obesity), high BP, 
elevated total triglycerides and low HDL cholesterol are often seen in subjects with 
prediabetes. Therefore, it is unclear whether dysglycemia per se in the nondiabetic 
range is casually associated with the elevated risk of CVD. However, we do know that 
T2DM patients are at least insulin resistant as prediabetic subjects and this could, at 
least partially explain the elevated atherothombosis in these conditions (Figure 10) 
(238). Furthermore, in prediabetic subjects, the potential metabolic changes observed 
are subclinical inflammation, endothelial dysfunction, dyslipidaemia, changes in 
adipokines, elevated levels of free fatty acids (FFAs) and changes in thrombosis and 
fibrinolysis (240). This realization that IR subjects were both hypercoagulable and had 
impaired fibrinolysis provided the pathologic basis for the elevated risk for acute CAD 
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events. Studies have also shown that higher proinflammatory state in prediabetic 
subjects are predominantly insulin resistant, providing additional evidence that 
prediabetic subjects may be at high risk of developing CVD (241). Additionally, 
population based studies have reported that 30% of subjects with hypertension were 
insulin resistant (242). The cellular mechanisms for these metabolic changes will be 
discussed later in this thesis, in detail.  
 
Figure 10: Relative risk of CVD in Normoglycemia, Prediabetes and T2DM (238) 
Gast et al (2012) in a meta-analysis of 65 studies (N=516,325) reported that IR was a 
good predictor of CVD; higher relative risk for CVD for an increase in one standard 
deviation in HOMA-IR compared to an increase in one standard deviation in fasting 
glucose or fasting insulin concentration (243). Furthermore, in another study by Eddy 
et al (2009) using a mathematical approach (Archimedes model) in a population 
representative of young nondiabetic adults aged 20-30 years, the authors reported 
that IR is most likely the most important cause of CAD and preventing IR would prevent 
42% of MI (244).  
The final outcome of many forms of heart disease is congestive cardiac failure (CCF), 
a condition in which the heart is unable to pump enough blood as per the body’s 
requirement. Data from several population based studies and CHF clinical trials have 
reported a high prevalence (between 12% and 49%) of T2DM in CCF patients 
(207,245), and this coexistence of T2DM and CCF may impact each other in terms of 
causation and outcome. Additionally, this coexistence can be a lethal combination 
since T2DM has been consistently shown as a strong independent predictor of worse 
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clinical outcome in patients with CCF (246) with a median survival of 4 years (247). It 
is now widely acknowledged that CCF is an insulin resistant state with a high 
prevalence rate (61%) among non-diabetic CCF subjects and is associated with 
disease severity and outcome (248). Pathophysiological processes linking IR and CCF 
also remain to be elucidated.  
2.2.2.4. Insulin Resistance and Hypertension. 
IR and hypertension often coexist (249) and data from clinical studies have shown that 
50% of hypertensive subjects have hyperinsulinemia or IGT, whereas in patients with 
T2DM, it goes up to 80% (249,250). Besides the metabolic effects, insulin has complex 
vascular effects that could appear as vasoprotective or vasodeleterious (251). Insulin 
exerts its vasoprotective effect by inducing vasorelaxation, mediating the release of 
nitric oxide (NO) in endothelium, thereby playing a key role in the regulation of arterial 
pressure during physiologic hyperinsulinemia (252) and regulates sodium 
homeostasis by enhancing sodium reabsorption in the kidney (253,254), thus 
regulating BP. Insulin exerts its vasodeleterious effect via the mitogen-activated 
protein kinase (MAPK) pathway, thereby inducing vasoconstriction, vascular smooth 
muscle cell (VSMC) proliferation and proinflammatory activity (251). Additionally, 
insulin also promotes sodium reabsorption in the kidney and promotes sympathetic 
nerve activity (254). The over activity of sympathetic nervous system can promote 
myocyte hypertrophy, interstitial fibrosis and reduced contractile function, 
complemented by increased myocyte apoptosis (255). Furthermore, insulin can be 
both inflammatory and anti-inflammatory (251,256). Insulin can exert its vasodilator 
effect and anti-inflammatory effect by inducing endothelial NO production and 
whereas, in the state of IR, this insulin induced NO pathway is selective and the 
resulting compensatory hyperinsulinemia may activate the MAPK pathway, resulting 
in vasoconstriction, systemic inflammation, increased sodium and water retention and 
higher BP (256,257). All these evidences support the notion that agents that reduce 
IR may have a rationale in treating IR subjects with hypertension. 
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2.2.2.6. Insulin Resistance and Coronary Artery Disease in Non-Diabetic Subjects 
Studies have shown that hyperglycaemia is a strong predictor for CVD and CAD and 
is associated with higher mortality rates due to CAD, even in patients without diabetes 
(37).  In the Whitehall study encompassing 18,403 subjects, the age –adjusted CAD 
mortality rates after 7.5 years, were related to blood glucose levels after a 2-hour 
OGTT and also a twofold increased risk of CAD mortality in non-diabetic subjects (38).  
An increased insulin response to OGTT is a common clinical finding in subjects with 
atherosclerosis of the peripheral, cerebral and coronary arteries (39,40).  Furthermore, 
two large studies, the Helsinki Policeman study and the Paris Civil Servant study have 
reported higher CAD mortality rates and incidence of MI in subjects with 
hyperinsulinemia (men aged 30-59), and, in nondiabetic subjects (41,42).  As 
hyperinsulinemia is considered as a consequence of IR, these evidences corroborate 
that IR is associated with development of CAD and also associated with worse clinical 
outcome, including non-diabetic subjects.  Additionally, there are studies that 
demonstrated that CAD is truly an IR state, even after adjusting for potential 
confounding influences (43-45). Bressler et al (1996), in a study of normal weight, 
normotensive subjects with angiographically documented CAD, reported that the 
magnitude of IR was positively correlated with the severity of CAD (r=0.480, P<0.05) 
and that CAD patients were characterised by moderate-severe IR and 
hyperinsulinemia (46).  
This association between IR and CAD in non-diabetic subjects dates back to early 
1960’s. Reaven et al (1963) reported that that nondiabetic individuals, who are 
clinically stable many months after a myocardial infarction, were somewhat 
hyperglycemic and hypertriglyceridemic as compared with a matched control group 
(258). There are potential links between IR and CAD.  There are multiple abnormalities 
that are associated with IR which may contribute to the development of CAD (Table 
2) (259). This cluster of abnormalities associated are also called metabolic syndrome 
or syndrome X and Figure 11 depicts the link between IR and CAD via either T2DM 
or metabolic syndrome(259).  
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Table 2: Abnormalities Associated with IR that may contribute to the 
development of CAD (259).  
Abnormalities Associated with IR that may contribute to the development of 
CAD 
• Hyperglycemia 
• Glucose Intolerance 
• Obesity 
• Dyslipidaemia 
• Higher Blood Pressure 
• Procoagulant State 
• Inflammation 
• Endothelial Dysfunction 
• Hyperuricemia 
• Enhanced Sympathetic Nervous System Activity 
• Increased Renal Tubular Sodium Reabsorption 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Illustration of link between IR and CAD via either T2DM or other 
cluster of abnormalities (metabolic syndrome) associated with IR: The majority 
of subjects with IR never develop T2DM, but the dotted line indicates the degree of 
compensatory hyperinsulinemia in some proportion of individuals with other cluster of 
abnormalities will decline and will develop T2DM (259).  
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2.2.2.7. Insulin Resistance and Endothelial Dysfunction 
Insulin is thought to play a key role in vascular homeostasis: insulin can act as a 
vasodilator by enhancing the production of NO, a crucial vasodilator but also can act 
as a vasoconstrictor by mediating the release of endothelin ET-1 or angiotensin II 
(260,261). At cellular level, this dual action of insulin is mediated via two main 
signalling pathways: (i) a vasoprotective phosphoinositide-3-kinase (PI3-K)/Akt 
pathway responsible for the expression and activation of endothelial nitric oxide 
synthase (262) and (ii) in the state of IR, the balance is shifted towards the mitogen-
activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), which 
mediates inflammation, vasoconstriction, and vascular smooth muscle cell 
proliferation (263).  
Endothelium is a multifunctional paracrine, autocrine, and endocrine organ 
responsible for vascular homeostasis and is mediated by molecules of vasodilatory 
action and vasoconstricting features (261). NO plays a protective role for endothelium 
and is considered to be the most potent endogenous vasodilator in the body and the 
reduction in NO bioavailability results in endothelial dysfunction. Endothelial 
dysfunction can contribute to T2DM and CVD, including high BP, atherosclerosis and 
CAD, which are also caused by IR (264). At cellular level, inflammatory reaction 
generated by glucotoxicity and lipotoxicity can contribute to the vascular damage and 
potentially link IR with endothelial dysfunction through different mechanisms (265).  
The glucotoxicity is exerted by the hexosamine biosynthesis pathway is activated by 
the hyperglycemia, resulting in modifications of proteins involved in insulin and NO 
signalling by the O-Glc-N-acylation of IRS-1. This derails the activation of PI3-K and 
reduces glucose uptake resulting in hyperinsulinemia (266)  and O-Glc-N-acylation of 
endothelial nitric oxide synthase (eNOS) at the Akt phosphorylation residues, leading 
to its inactivation (267). The PAI-1 gene expression is induced by the O-Glc-N-
acylation and alters tumour growth factor β(TGFβ) level, which is involved in the  
pathogenesis of vascular diabetic damage (265). The over activation of hexosamine 
biosynthesis pathway results in formation of advanced glycation end products (AGEs), 
which in turn stimulate over activation of reactive oxygen species (ROS) production 
and consequent oxidative stress (265). This increased oxidative stress can cause IR 
by impairing Akt and eNOS activation and limiting NO availability (268). Additionally 
this over activation of ROS can also enhance IKKβ kinase, which activates NF-κB and 
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overexpression of proinflammatory markers (265). AGEs can impair vascular elasticity 
and promote atherosclerosis (269).  The pathophysiological processes responsible for 
IR and/or hyperinsulinemia-induced vascular disease are not fully understood but 
might include hemodynamic factors such as hypertension, activation of the renin-
angiotensin-aldosterone system, metabolic factors such as insulin and advanced 
glycation end products, and other factors such as adipokines, inflammation, or 
oxidative stress (265).  
Lipotoxicity impedes the PI3-K/Akt signalling and triggers the MAPK/ERK pathway by 
inducing oxidative stress and inflammation through free fatty acids (FFA) (270). FFA 
trigger phosphokinase C damaging Akt function due to IRS 1/2 inactivation and 
enhance NADPH oxidase to ROS production. PAI-1, interleukin-6 (IL-6), and 
chemokine (C-C motif) ligand 2 (CCL-2) production are enhanced by NADPH oxidase, 
which stimulates the proinflammatory state and inhibits NO production by decreasing 
eNOS expression. Moreover, ROS after FFA stimulation activate NF-κB, which 
increases ET-1 expression and adhesion molecules ICAM-1 and VCAM-1 and 
increase CV risk even in healthy subjects (270). 
In clinical studies, several studies have examined the relationship between IR and 
endothelial function and have conflicting findings. Muniyappa et al (2014), in a meta-
analysis of 12 studies (N=3190), evaluated the association of IR and endothelial 
dysfunction, reporting a weak correlation between IR and endothelial function. Figure 
12 depicts the pooled correlation coefficient of these studies. Given the heterogeneity 
of studies included  (test of heterogeneity P<0.05), potentially due to different methods 
used to assess IR and endothelial function, and the limited studies reviewed, it is 
possible that this weak association could be an underestimate (271). However, it is 
noteworthy that in many studies that examined this relationship between IR and 
endothelial dysfunction, IR was not a significant predictor of endothelial dysfunction, 
even after adjusting for potential confounding influences of endothelial function (272-
275).  
These studies support the notion that IR may only partially explain endothelial 
dysfunction. However, we cannot exclude the fact that other manifestations of IR such 
as dysglycemia, dyslipidaemia, inflammation, and obesity may be intermediary 
mediators that act in concert with IR to mediate endothelial dysfunction. Therefore,  
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the synergistic antidiabetic, antihypertensive, and hypolipemizing treatment, targeted 
at multiple metabolic pathways to improve both insulin sensitivity and endothelial 
function may be considered at early stages of disturbances, before clinical progression 
of diseases, with fully developed vascular complications. 
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Figure 12: Correlation Meta-analysis: Univariate correlation coefficients between insulin sensitivity and endothelial function and 
corresponding 95% confidence intervals (271). 
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2.2.3. Pathogenesis of Cardiovascular Diseases in Type II Diabetes 
Mellitus. 
 
2.2.3.1. Cardiovascular Risk Factors in Diabetes 
T2DM has long been considered as a “cardiovascular risk equivalent” (276) and it is 
now widely acknowledged that patients with T2DM have a higher risk of CV mortality 
and morbidity and is an established risk factor for heart disease and stroke; a two to 
four fold increase in risk of incident coronary heart disease, ischemic stroke and a 1.5 
to 3.6-fold increase in mortality (277). A wealth of epidemiological evidences have 
demonstrated that T2DM is also a strong independent predictor of incident heart failure 
(278), macrovascular (coronary, cerebrovascular and peripheral vascular) and 
microvascular complications (renal, ophthalmologic and neurologic) and is associated 
with worse clinical outcome (279). Additionally, T2DM is an independent predictor of 
higher coronary death rates conferring the patient a worse clinical outcome after 
having the first CAD event (280). 
The CV risk factors in T2DM are a combination of traditional and non-traditional risk 
factors (Table 3) (281-283). Table 4 depicts the list of main traditional and non-
traditional CV risk factors in T2DM. The initial understanding was that the elevated risk 
of CV events is primarily due to the traditional risk factors such as hypertension, 
dyslipidaemia etc., which was further corroborated by conclusive evidences that 
reduction of these traditional risk factors was associated with a consequent reduction 
in CVD risk (284,285). However, the improved CV burden in T2DM patients cannot be 
attributed solely to the higher prevalence of traditional risk factors as many of the 
therapies that are currently used in the management of T2DM such as insulin-
sensitizers and statins have pleotropic effects on many of these non-traditional risk 
factors (286-288). The relative magnitude of many of these non-traditional risk factors 
has been widely reviewed in literature (282,283,289-291). To summarise, CVD burden 
is elevated in T2DM due to a complex amalgamation of numerous traditional and non-
traditional risk factors that play a pivotal role in the beginning and the evolution of 
atherosclerosis to clinical prognosis (292).  
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Table 3: Cardiovascular risk factors in diabetes mellitus (283) 
However, recent evidences indicate that CHD risk in patients with T2DM is 
heterogeneous as its effect vary by age, sex or levels of conventional risk factors that 
are uncertain (293,294). Bulugahapitiya et al (2009) in a systematic review and meta-
analysis of 13 epidemiological studies (N=45,108), in patients with and without 
diabetes reported that, in T2DM with no previous CHD, the CHD risk was 43% lower 
than when compared to individuals without diabetes with a prior myocardial infarction 
(295). In another large population based cohort study (N= 1,586,061 adults, aged 30-
90 years, 10 years follow-up) the risk of CHD was much lower among T2DM without 
CHD compared to non-diabetic patients with CHD [HR: 1.70 (95% CI 1.66–1.74) vs. 
2.80 (95% CI 2.70–2.85)] (296). In another meta-analysis of observational studies with 
T2DM patients, evaluating CV risk through coronary artery calcium score (CAC), 
Kramer et al (2013), reported a 28.5% prevalence of patient with zero CAC scores 
(297) indicating a similar 5-year survival rate as in patients without diabetes (298). 
Therefore, all these evidences support the notion that it is highly likely that a subgroup 
with lower CAD risk exists in T2DM, particularly in patients under 40 years old with 
shorter disease duration. In this context, another study reported that men younger than 
Traditional Non-traditional 
Dyslipidaemia Insulin resistance and Hyperinsulinemia 
Hypertension Postprandial Hyperglycaemia 
Obesity Glucose Variability 
Abdominal Obesity Microalbuminuria 
Physical Exercise Haematological Factors 
Cigarette Smoking Thrombogenic Factors 
 Inflammation 
 Homocysteine and vitamins 
 Erectile Dysfunction 
 Genetics & Epigenetics 
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35 years, women younger than 45 years, patients with diabetes duration of less than 
10 years without other risk factors, are at lower risk compared to patients with 
traditional CV risk factors, and subclinical or established CAD.(279). The recent 
European Society of Cardiology (ESC) guidelines recommends that the risk of CHD is 
elevated if patients have more than 10 years of disease duration or when in the 
presence of renal dysfunction or microalbuminuria (299). Additionally, patients 
younger than 40 years with a shorter duration of diabetes are currently placed in lower 
risk category. Such categorization of T2DM patients into different CV risk classification 
will allow the clinicians to identify the group of T2DM patients that might get greater 
net benefit from more intensive CV prevention.  
2.2.3.2. Types of Cardiovascular Diseases in Diabetes 
Microvascular (involving small vessels, such as capillaries) and macrovascular 
(involving large vessels, such as arteries and veins) diseases can occur concomitantly 
in diabetic patients sharing similar aetiological characteristics. Chronic hyperglycemia 
plays a key role in the instigation of diabetic vascular complications via many metabolic 
and structural derangements, including the production of advanced glycation end 
products (AGE), abnormal activation of signalling cascades (such as protein kinase C 
[PKC]), elevated production of reactive oxygen species (ROS, oxygen-containing 
molecules that can interact with other biomolecules and result in damage), and 
abnormal stimulation of hemodynamic regulation systems (such as the renin-
angiotensin system [RAS]) (300). This section will briefly describe the comorbidities, 
risk factors associated and the pathogenesis of microvascular and macrovascular 
complications in diabetes. Figure 13 summarizes the risk factors for diabetes 
associated with microvascular and macrovascular complications.  The term diabetes 
in this section (only) includes both type 1 and type 2 diabetes mellitus, as both have 
almost similar vascular pathology and aetiology.  
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Figure 13: Risk factors for diabetes associated microvascular and 
macrovascular complications. 
2.2.3.2.1. Microvascular Diseases 
Microvascular diseases associated with diabetes include retinopathy, nephropathy 
and neuropathy. However, it also affects small vessels throughout the body including 
the brain, heart and peripheral vasculature. These small vessel injuries are 
characteristically not associated to atherosclerosis and are not predicted by lipid 
levels. Diabetic patients with microvascular complications are at greater risk of 
aggressive atherosclerosis which eventually culminates in cerebrovascular and CV 
events and premature death (301). Microvessels are the basic functional unit of the 
CV system encompassing arterioles, capillaries and venules (302) and differ from 
macrovessels in architecture and cellular components. Microvessels are pivotal in 
maintaining BP and proper nutrient delivery (302). Microcirculation also has regulatory 
mechanisms controlling vascular permeability and myogenic responses that can 
regulate blood flow according to local metabolic requirements. Changes to 
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microvascular function are observed even before overt hyperglycemia and 
manifestation of vascular pathologic changes. Hyperglycemia can induce 
pathognomonic changes (such as thickness) in the microvasculature, affecting the 
arterioles, glomeruli, retina, myocardium, skin, and muscle, with consequent 
development of diabetic microangiopathy. This thickening eventually causes 
alterations in vascular structure and function, which can contribute to the development 
of hypertension, delayed wound healing and tissue hypoxia and thereby promoting 
atherosclerosis (302).  
One of the main microvascular complications in diabetic patients is diabetic 
retinopathy (DR). DR affect the peripheral retina, the macula or both and is the leading 
cause of visual disability and blindness in diabetic patients (300). The duration of 
diabetes is one of the strongest predictor of DR:  the prevalence of DR is positively 
correlated with the duration of diabetes (303) and poor glycemic control is a key factor 
in the progression of DR (300). The hyperglycemia in diabetes can result in diminishing 
retinal blood flow, elevated inflammatory cell adhesion to retinal blood vessels, and 
capillary blockage resulting in hypoxia and damage to the retina (300). 
Another important microvascular complication in diabetic patients is neuropathy. 
Diabetic neuropathy (DN) affects almost half of diabetic population and is a life 
threatening disorder that involves both peripheral and autonomic nerves (304). The 
magnitude and duration of hyperglycemia is one of the strongest independent 
predictor for the development of DR (305). Although the exact nature of the injury to 
peripheral nerves from dysglycemia is not completely understood, several 
mechanisms have been implicated in its pathogenesis. Hyperglycemia can promote 
vascular complications by multiple mechanisms such as hyperglycemia-induced 
polyol pathway, formation of AGEs and injury from AGEs, and increased oxidative 
stress. Injury to peripheral nerves may be mediated by effects on nerve tissue or by 
endothelial injury or vascular dysfunction (302).  Depending on the site, peripheral 
neuropathy can appear in several forms in patients with diabetes. It can manifest as 
sensory, focal/multifocal, and autonomic neuropathies. Studies have reported worse 
outcome in patients with DN: 80% amputations after foot ulceration or injury (305). 
Additionally, diabetic patients with peripheral neuropathy have significantly higher 
rates of CV events and peripheral vascular disease (PVD) compared to diabetic 
patients without neuropathy and is also associated with higher rates of stroke (305).  
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Nephropathy is another diabetes associated microvascular complication and is the 
leading cause of renal failure in patients with diabetes. In the setting of diabetes, 
diabetic nephropathy is defined by proteinuria > 500 mg in 24 hours, but this is 
preceded by lower degrees of proteinuria, or microalbuminuria (albumin excretion of 
30-299 mg/24 hours). In both, type 1 and 2 diabetes, if not clinically intervened, 
microalbuminuria can progress to proteinuria and overt diabetic nephropathy. 
Proteinuria occurs in 15–40% of patients with type 1 diabetes while it ranges from 5 to 
20% in patients with T2DM (305). Studies have shown that hyperglycemia being the 
strongest and modifiable risk factor for diabetic nephropathy (305). The 
pathophysiological alterations to the kidney include greater glomerular basement 
membrane thickness, microaneurysm formation, mesangial nodule formation 
(Kimmelsteil-Wilson bodies), and other changes. The underlying mechanism of injury 
may also involve some or all of the same mechanisms as diabetic retinopathy. The 
underlying pathogenic mechanism in diabetic nephropathy involve generation of 
reactive oxygen species (ROS), accumulation of AGEs, and activation of intracellular 
signalling molecules such as protein kinase C (PKC) (305). 
2.2.3.2.2. Macrovascular Diseases 
Atherosclerosis is proposed to be the central pathophysiological mechanism in 
diabetes associated macrovascular disease. IR, hyperglycemia, chronic inflammation, 
and damage to the arterial wall in the peripheral or coronary vascular system may 
result in consequent atherosclerosis. Although the pathogenesis of macrovascular 
disease is multifactorial, the common recipient of injury is vascular endothelium 
(Figure 14).  As a result of endothelial injury and inflammation, oxidized lipids from 
LDL particles amass in the endothelial wall of arteries, which are further oxidized by 
angiotensin II. Consequently monocytes infiltrate the arterial wall and differentiate into 
macrophages, resulting in accumulation of oxidized lipids to form foam cells, which 
will stimulate macrophage proliferation and attraction of T-lymphocytes. T-
lymphocytes, in turn, induce smooth muscle proliferation in the arterial walls and 
collagen accumulation resulting in the formation of a lipid-rich atherosclerotic lesion 
with a fibrous cap. Rupture of this lesion leads to acute vascular infarction (306). In 
addition, platelet adhesion and hypercoagulability in T2DM can further increase the 
risk of vascular occlusion and CV events in T2DM (307). CAD is the one of the most 
common macrovascular complication that has been associated with T2DM, supported 
74 
 
by numerous studies beginning with the Framingham study (308). Additionally, T2DM 
is a strong independent predictor of risk of stroke and cerebrovascular disease, in 
middle aged subjects (309). T2DM patients have an increased risk of 150-400% of 
having a stroke, stroke-related dementia and reoccurrence and stroke-related 
mortality (307). Another macrovascular complication associated with diabetes is PAD. 
PAD is characterised by occlusion of the lower-extremity arteries, resulting in 
intermittent claudication and pain, particularly upon exercise and activity, causing 
functional impairments and disability eventually resulting in foot ulceration and lower-
extremity amputation (300). Lower-extremity amputation is very common in diabetic 
patients with PAD than in non-diabetic subjects with PAD (310). Peripheral artery 
disease is also related to the duration and magnitude of diabetes. Hyperglycemia, 
specifically, glycation haemoglobin, has been shown to be an independent risk factor 
for PAD (300). Additionally, T2DM patients frequently have many conventional risk 
factors for CVD, including central obesity, dyslipidaemia and hypertension, collectively 
termed as “metabolic syndrome”. All these traditional risk factors, along with the 
independent risk factor of diabetes, can act both independently and cumulatively over 
time to significantly elevate the risk for CVD. The culmination of dysglycemia, IR, 
dyslipidaemia, hypertension, and chronic inflammation can damage the vascular 
endothelium, leading to macrovasculopathy and CVD in people with T2DM (307) 
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Figure 14: Potential mechanisms for diabetes-associated vascular 
abnormalities. NO=nitric oxide, tPA-1=tissue plasminogen activator-1, PAI-
1=plasminogen activator inhibitor-1 (300) 
2.2.3.3. Cellular and Molecular Mechanisms of Cardiovascular Diseases in patients 
with Type II Diabetes Mellitus. 
2.2.3.3.1. Inflammation 
Inflammatory response to tissue injury or pathogen exposure is a normal process of 
body's ability to heal itself or to fight off infection. The inflammatory response, 
encompassing the activation of leukocytes (white blood cells) is mediated, at least in 
part, by a family of cytokines and chemokines. Although initially beneficial, if 
chronically activated, inflammatory response can result in unfavourable 
consequences. Inflammation has long been recognized as a key pathophysiological 
process in both atherosclerosis and T2DM (286). Furthermore, there are evidences to 
suggest that immune activation may precede IR in prediabetic and diabetic states and 
eventually may increase the risk of CV diseases (311). Available evidences from 
studies suggest a cross-talk between the cellular pathways involved in both 
inflammation and insulin signalling, which may provide insights into the strong 
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relationship between insulin-resistant states, inflammation, and CVD (312). 
Furthermore, studies have observed diminished levels of the potent vasodilator NO 
and elevated levels of growth factor endothelin-1, a vasoconstrictor in subjects with 
the metabolic syndrome, and these irregularities not only trigger vasoconstriction, but 
are also associated with the release of pro-inflammatory cytokines (313). 
Proinflammatory cytokines can cause or exacerbate tissue injury by a range of 
mechanisms including enhanced vascular permeability, programmed cell death 
(apoptosis), recruitment of invasive leukocytes, and the promotion of reactive oxygen 
species (ROS) production (314). This inflammatory hypothesis was further 
corroborated by evidences gathered from several observational epidemiological 
studies. Ridker et al (1997 & 2000) have shown that biomarkers of inflammation such 
as high-sensitivity C-reactive protein and interleukin-6 are associated with an 
increased risk of CV events, independent of the cholesterol level (315,316). These 
findings support the notion that low grade systemic inflammation precedes incident 
CV events and, per se, also imply that inflammation might trigger vascular diseases, 
leading to major CVD events. However, the Mendelian randomisation data have 
provided some controversial findings in the context of inflammatory hypothesis of 
CVD. Mendelian randomisation endeavours to substantially attenuate or, in some 
cases, to eliminate the confounding influence and reverse causality seen in 
observational studies and can be viewed as analogues to a RCT by conferring a 
stronger evidence of causality than classical epidemiology (317). Evidence from such 
data indicates that CRP concentration itself is unlikely to cause CVD. Wensley et al 
(2011) in a meta-analysis (N= 194,418; 47 epidemiological studies from 15 countries) 
reported that the relative risk for CHD was 1.00(0.90 – 1.13) per 1 SD higher 
genetically raised CRP concentrations (318). Conversely, it is yet unclear on whether 
these polymorphisms might explain intricacies in the biology of atherosclerosis, such 
as the accumulation of monomeric CRP in plaques (319). In contrast, another 
Mendelian randomisation analysis (40 studies, N= 133,449) have reported that IL 6R 
signalling to have a causal role in development of CHD (320). This finding was further 
corroborated by another collaborative meta-analysis of 82 studies by Sarwar et al 
(2012) (321). However, the inflammatory hypothesis of CVD had not been tested in 
an RCT until recently. There are currently two major RCTS, powered for reduction in 
composite CVD endpoints to test the inflammatory hypothesis in a secondary 
prevention testing: The Cardiovascular Inflammation Reduction Trial (CIRT Trial: 
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using methotrexate-based intervention) and the Canakinumab Anti-inflammatory 
Thrombosis Outcomes Study (CANTOS study; uses a monoclonal antibody against 
IL-β). The results from the CANTOS study have shown that regressing inflammation 
led to significantly lower rate of recurrent CV events than placebo (322). This is the 
only double-blind placebo controlled RCT, to date, that remains the most relevant 
finding supporting the inflammatory hypothesis. However, the results of CIRT trial 
indicate that low-dose methotrexate did not reduce levels of inflammatory biomarkers 
such as IL-1β, IL-6, hs CRP, or CV events (323). It is noteworthy that unlike the 
CANTOS study, this trial did not mandate high residual inflammation among enrolled 
patients.  
The anticipated primary completion date of CIRT trial is presently the end of 2018.                                  
2.2.3.3.2. Oxidative Stress 
As disused in the above section, pro-inflammatory cytokines can trigger the over 
production of ROS by the immune system. ROS production by the immune system is 
body’s natural process to destroy pathogens but leads to oxidative stress when the 
cellular production of ROS exceeds the capacity of anti-oxidant defenses within cells. 
Several lines of evidences, from both pre-clinical and clinical data suggest that chronic 
oxidative stress is purportedly linked to the metabolism of surplus substrates (glucose 
and fatty acids) present in the hyperglycemic state (324) as well as to the 
mitochondrial dysfunction associated with IR (325). Studies have shown that plasma 
levels of hydroperoxides are elevated in T2DM patients compared to nondiabetic 
subjects, and these levels are inversely correlated with the magnitude of metabolic 
control (324). The over production of reactive oxygen species (ROS) plays a pivotal 
role in the activation of other pathogenic pathways involved in diabetic complications, 
including increased polyol pathway activity, nonenzymatic glycation, and protein 
kinase C levels (PKC) which in turn lead to the development of macro and 
microvascular complications (326). Furthermore, this over production of ROS can 
inactivate two critical anti-atherosclerotic enzymes, endothelial nitric oxide synthase 
and prostacyclin synthase (327). The major source of ROS is the mitochondria, and 
at subcellular level the defects in mitochondria are deeply connected with the 
aetiologies of IR and hyperglycemia, as well as their complications (328). 
Hyperglycemia stimulates the over production of ROS, which interacts with both 
deoxyribonucleic acid (DNA) and proteins, resulting in cellular damage, particularly 
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targeting mitochondrial DNA. Studies have demonstrated that very early mitochondrial 
DNA damage with hyperglycemia, induced overproduction of ROS in human retinal 
endothelial cells (329). To further corroborate this, many experimental studies have 
demonstrated that the excessive production of mitochondrial superoxide is the major 
culprit in the development of metabolic abnormalities in diabetics (330). Additionally, 
IR can also induce mitochondrial ROS production from free fatty acids and impedes 
anti-atherosclerotic enzymes resulting in atherosclerosis and cardiomyopathy in 
T2DM patients. In non-diabetic subjects with impaired glucose tolerance, those in the 
highest quintile of IR had a 2 fold elevated risk for CVD compared to those in the 
lowest quintile after adjusting several known CV confounders, including LDL, 
triglycerides, high-density lipoprotein, systolic BP, and smoking (331). All these 
evidences support the notion that oxidative stress is a crucially important concept in 
the pathophysiology of CV complications in diabetes and plays a pivotal role in the 
development of diabetes complications; both microvascular and CV. Regressing 
oxidative stress may have beneficial effect on CV outcome in patients with 
hyperglycemia or IR.  
2.2.3.3.3. Activated Leukocytes 
Leukocytes are major inflammatory mediators and as discussed earlier, in IR and 
hyperglycemia, inflammatory response is over-activated. Activated leukocytes can 
also contribute to over activation of ROS along with mitochondria, and thus 
contributing to diabetes associated oxidative stress. In diabetic hearts, Hokama et al 
(2000) demonstrated that the expression of adhesion proteins on the surface of 
neutrophils, resulting in over-activation of leucocytes and significantly elevated ROS 
production (332). The study demonstrated that during ischemia, leukocyte 
accumulation during reperfusion was increased in the diabetic coronary 
microcirculation, suggesting an enhanced ability of leukocyte-generated ROS to 
aggravate tissue injury after experimental myocardial infarction (MI). Freedman and 
Hatchell (1992) found that stimulated neutrophils from diabetic cats generated 
superoxide radicals (a type of ROS) at considerably higher rates compared to normal 
cats (333). All these observations from experimental studies suggest that the excess 
chronic oxidative stress produced during hyperglycemic state (by both mitochondria 
and accumulated leukocytes) may largely explain the mechanism of increased 
oxidative injury associated with ischemic heart disease in diabetes. This elucidation, 
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consequently, supports our understanding of the higher morbidity and mortality rates 
in diabetic patients post MI as compared to patients without diabetes. 
2.2.3.3.4. Hypercoagulability 
Besides affecting the leukocytes in the blood stream, diabetes is also associated to a 
hypercoagulable condition. The coagulability of the blood is pivotal in ischemic CV 
events as the majority of MI and stroke events are results of atherosclerotic plaque 
rupture and the consequent occlusion of a major artery by a blood clot (thrombus). 
Thrombotic death is very common in diabetic patients (up to 80%), with majority due 
to MI (up to 75%) and the reminder, due to cerebrovascular events and complications 
related to PVD (334). Vascular endothelium has been described as body’s first 
defence mechanism against a thrombotic event. As described in earlier sections of 
this thesis, endothelial dysfunction is a common phenomenon in diabetes and is highly 
prevalent in diabetic patients. The endothelium serves an integral role in the 
hemostatic system and depending on specific tissue requirements and local injury, 
endothelial cells are capable of evoking either antithrombotic or prothrombotic events. 
Healthy endothelial cells release antiplatelet and anticoagulant agents that inhibit 
platelet aggregation and fibrin formation, respectively. However during endothelial 
dysfunction, endothelial cells initiate fibrin formation, as well as platelet adhesion and 
aggregation (335). The intricately linked endothelium and the components of the blood 
initiate clotting signals in the endothelial cell consequently, activating platelets and 
other blood components, and vice versa (336). Diabetic patients have hyper activation 
of platelets and clotting factors in the blood due to circulating platelet aggregates, 
increased platelet aggregation in response to platelet agonists, and the presence of 
higher plasma levels of platelet coagulation products, such as beta-thromboglobulin, 
platelet factor 4, and thromboxane B2, demonstrate. In diabetic patients, coagulation 
activation markers, such as prothrombin activation fragment 1+2 and thrombin–anti-
thrombin complexes, are also elevated. Additionally, diabetic patients also have 
elevated levels of many clotting factors including fibrinogen, factor VII, factor VIII, 
factor XI, factor XII, kallikrein, and von Willebrand factor. Conversely, anticoagulant 
mechanisms are reduced in diabetes. The fibrinolytic system, the primary means of 
removing clots, is relatively repressed in diabetes due to abnormal clot structures that 
are more resistant to degradation, and also because of an elevation in PAI-1 (337).  
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To summarise, the increase in CV morbidity and mortality in patients with 
hyperglycemia is complex and multifactorial and is typically interrelated to a 
combination of both macrovascular and microvascular dysfunction.  
2.2.4. Insulin Resistance and Left Ventricular Hypertrophy. 
2.2.4.1. IR and Development of LVH 
The association between hypertension and IR has been studied extensively as part of 
the metabolic syndrome (338) as has the association between LVH and hypertension, 
with hypertension being one of the strongest independent predictors of LVH (339-341). 
However, studies have reported that LVH persist in normotensive patients (176) and 
even among hypertensive subjects (342,343). Nunez et al (1996) reported no change 
in LVM in 25-30% of subjects with high BP (344). Therefore, all these evidences 
support the notion that there may be other metabolic and genetic factors associated 
with LVH. 
As discussed in the earlier sections of this thesis, LVH and IR are strong predictors for 
CV diseases and adverse clinical outcome. Although, answers to whether IR plays 
any pathogenic role in LVH has been variable, majority of the studies have reported a 
significant positive relationship between IR and LVH. The large studies were mostly 
positive including the Framingham study, the Whitehall study and the Women’s Health 
Initiative study, while the HyperGEN is the one large negative study (47,91-94). Other 
clinical studies have also shown that IR and hyperinsulinemia were related to thick LV 
walls and concentric remodelling (345). In the recent past, there has been 
considerable interest around IR, insulin levels and LVH (Table 4) (346). Results from 
studies investigating the relationship between left ventricular geometric correlates and 
IR are somewhat contradictory, since some studies have found IR or its components 
as powerful independent determinants of LV mass and geometry (347-349), whereas 
another study reported only a trivial association of components of IR with LV geometry, 
but a significant impact on myocardial wall thickness (350). Likewise, few other studies 
have reported a significant positive relationship between IR and LV wall thickness, 
LVH or LVM (indexed or without indexation for body size using different indexation 
criteria such as BSA, height etc.) and suggested IR may be an important modulator of 
LV growth between (351,352). All these evidences support the notion that optimal 
prevention of LVH may require improved insulin sensitivity, irrespective of their BP.  
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There are few pathophysiological and signalling processes that has been implicated 
by preclinical studies to support the hypothesis that IR may promote myocardial 
hypertrophy, including the Akt transforming growth factor, and peroxisome proliferator-
activated receptor (290,353,354). Hyperinsulinemia is associated with alterations of 
myocardial metabolism leading to increased myocardial free fatty acids oxidation 
resulting in lipotoxicity and predisposition to cardiac hypertrophy and dysfunction (355-
357). Hyperinsulinemia can also cause renal sodium retention, increasing cardiac 
preload to cause LVH (358).  It also activates the renin–angiotensin system, 
sympathetic nervous system, promotes oxidative stress, stimulates cardiac 
fibroblasts, and increases heart rate and cardiac overload (234). Hyperinsulinemia is 
associated with elevated plasma glucose which can promote the formation of AGEs 
and, through protein kinase C activation, lead to reactive oxygen species production 
(359).  AGEs make irreversible and stable links with collagen polymers, leading to 
fibrosis (360).  
Another potential mechanism to explain why IR can contribute to LVH is the fact that 
angiotensin II receptor blockers improve both IR and LVH (361).  Angiotensin II type 
1 receptors activity and numbers are up-regulated by the presence of IR (362).  
The mitogenic effect of angiotensin II on the angiotensin II type 1 receptors on smooth 
muscle cell of blood vessels can induce LVH and eventually leading to hypertrophy of 
arterial wall and increased vascular resistance (363). The myocytes of the heart may 
also directly promote LVH due to the effect of angiotensin II via angiotensin II type 1 
receptors on the myocytes(364). This stimulus for the development of LVH may, at 
least in part, explain the elevated oxidative stress of the myocardium caused by 
angiotensin II (365). Figure 15 depicts the potential mechanisms associated with 
metabolic dysfunction in the development of LVH 
Therefore, it is likely that IR contributes to the changes in cardiac tissue seen in LVH 
and is a powerful determinant of LVH
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Table 4: Previous studies of relationship between left ventricular geometric properties and insulin resistance (346) 
Study Study Population IR Method LVM indexation Study Findings 
Uusitupa,1987 229 (111 ♂), 107 DM type-2 OGTT /BSA in ♀: LVMI ➸ f-Ins, OGTT-Ins in ♂: LVMI ✗ 
f-Ins, OGTT-Ins 
Sharp, 1992 102 (51 ♂), 51 HT, 2 LVH f-Ins /height in HT: LVMI ➸ f-Ins, f-Glu in NT: LVMI ✗ f-
Ins, f-Glu 
Sasson, 1993 40 (18 ♂) healthy obese NT IVGTT /height LVMI ➸ IVGTT-f-Ins, -90min-Ins, -AUC-Ins 
and kvalue 
Marcus, 1994 851 (439 ♂) healthy general 
population, age 18-42 
f-Ins /BSA LVMI ➸ f-Glu, TG, stress-NE and -E in 
men: LVH ➸ f-Ins➹, TG➹ 
Costa, 1995 29 (14 ♂) healthy lean HT OGTT /BSA LVMI ✗ OGTT-peak-Ins, IRI 
Ohya, 1996 390 ♂, 180 HT, work-site 
population 
OGTT /BSA  & 
height2.7 
LVMI ✗ f-Ins, OGTT-Ins, f-Glu, OGTT-Glu 
RWT ➸ OGTT-Ins, f-Glu, OGTT-Glu ✗ f-
Ins 
Kamide, 1996 40 (17 ♂) healthy lean HT clamp, OGTT /BSA LVMI (-)➸ WBGD 
Paolisso, 1997 26 ♂ healthy HT clamp, IC /height LVMI (-)➸WBGD, NOGM LVWT ➸ f-Ins, (-
)➸WBGD, NOGM RWT ✗ f-Ins, WBGD, 
NOGM 
Vetta, 1998 49 ♂ healthy NT, 29 obese, 
mean age 69 
OGTT /height2.7 LVMI ➸ f-Ins, OGTT-AUC-Ins, (-)➸Glu/Ins-
ratio 
Verdecchia, 
1999 
101 (58 ♂) healthy HT OGTT - LVM ➸ f-Ins, OGTT-2h-Ins, HOMA-IR, IGF-
I RWT ➸ IGF-I 
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Watanabe, 
1999 
83 (47 ♂) healthy, 65 HT IST, OGTT /BSA LVMI ➸ f-Ins, SSPG, HbA1c 
Rheeder, 1999 1655 (749 ♂) general 
population, mean age 65 
OGTT /BSA LVMI ➸ OGTT-2h-Ins 
Galvan, 2000 50 (32 ♂) healthy, 21 HT clamp, OGTT /height2.7 LVMI, PW, IVS ✗ f-Ins, OGTT-Ins, AUC-
Ins, WBGD 
 
♂ = male; ♀ = female;  HT = hypertensive; ➸ = relation; Ins = insulin; Glu = glucose; NT = normotensive; ✗ = no relation; IVGTT = 
intravenous glucose tolerance test; AUC = area under curve; BSA = body surface area; TG = triglycerides; ➹ = increased; clamp = 
hyperinsulinemic euglycemic clamp; LVWT = sum of left ventricular wall thicknesses; (-)➸ = inverse relation; WBGD = clamp whole-
body glucose disposal; OGTT = oral glucose tolerance test; NOGM = non-oxidative glucose metabolism; IC = indirect calorimetry; ➷ 
= decreased; RWT = relative wall thickness; IGF-I, IGF-II = insulin-like growth factor-I and –II; GH = growth hormone; HOMAIR = f-
Ins * f-Glu / 22.5; PW = left ventricular posterior wall thickness; IVS = intraventricular septum thickening.  
 
 
 
 
 
84 
 
 
Figure 15: Potential Mechanisms by which Metabolic Dysregulation can cause development of LVH ( Adapted  from Rutter 
et al) (47) 
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2.2.5. Treatment strategies in Improving Insulin Resistance in CVD 
As discussed in the earlier sections of this thesis, IR is associated with adverse CV 
events and sufficient evidence is now available to suggest that reducing IR may be 
beneficial, independent of glucose-lowering effects. Several therapeutic options are 
available to treat patients with T2DM, but only a few have been studied in the setting 
of IR (Figure 16). Additionally, there are presently no clinical guidelines or consensus 
statements describing how best to treat patients with IR. The Diabetes Prevention 
Programme (DPP) study has demonstrated that lifestyle interventions are beneficial 
in reversing IR in subjects with IGT(366). Antidiabetic drugs lower blood glucose 
through different mechanisms and their effect on CV system may differ. Several 
potential CV effects of different antidiabetic drugs have been posted over the years to 
explain how they may influence CV risk and outcome among patients with 
hyperglycaemia.  
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Figure 16: Pharmacological Treatment Options in the Setting of Insulin 
Resistance (367). 
 
*Additional A1C lowering in previously treated patients; ↓ = 0.5–1%, ↓↓ = 1–1.5%, ↓↓↓ 
=1.5–2%. †Relative cost per 30-day supply; $ = $750 based on average wholesale 
price 
 
Although, numerous mechanism-based antidiabetic drugs, such as dipeptidyl 
peptidase 4 (DPP-4) inhibitors, glucagon-Like Peptide 1 (GLP-1) receptor agonists 
and sodium/glucose cotransporter 2 (SGLT2) inhibitors, have been in the market for 
over the last 10 years with potential cardioprotective effects as evidenced by large 
clinical trials, none of them specifically target IR except for insulin sensitizers such as 
thiazolidinediones (TZDs) and biguanides. The GLP-1 receptor agonists stimulate the 
GLP-1 receptors in the pancreas and thereby increase insulin release and inhibit 
glucagon secretion, but only in the presence of elevated blood glucose (368). There 
are some evidences to suggest that GLP-1 agonists (liraglutide) could improve all 
components of IR syndrome, when given as monotherapy (369) 
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SGLT2 inhibitors increase the excretion of urinary glucose, thereby diminishing 
plasma glucose concentrations independent of the presence of insulin (370). DPP-4 
inhibitors extend the activity of endogenous GLP-1 and glucose insulinotropic 
polypeptide by inhibiting their breakdown and potentiating their actions (371). 
However, none of these class of drugs have been studied in patients with IR. Insulin 
sensitizers, which exert beneficial effects on both insulin target tissues and the 
pancreas, can possibly reverse IR and prevent the progression to diabetic 
complications. Hence, insulin sensitizers would undoubtedly be preferable for T2DM 
patients as well as non-diabetic patients with IR, if their side effects could be 
minimised. In this section, we will discuss about the main pharmacological 
interventions such as biguanides and thiazolidinedione, which have insulin-sensitizing 
and antihyperglcaemic effects. 
2.2.5.1. Thiazolidinedione (TZDs) 
TZDs are insulin-sensitizing drugs that enhance the disposal of glucose in peripheral 
tissues and act by activating a specific nuclear receptor, the peroxisome proliferator-
activated receptor gamma (PPAR-gamma). Thiazolidinediones have a major effect in 
the stimulation of glucose uptake, skeletal muscle, and adipose tissue. They lower 
plasma insulin levels and are used to treat type 2 diabetes associated with 
IR. Thiazolidinediones include rosiglitazone and pioglitazone (372). TZDs have not 
been evaluated precisely in the setting of IR, but a few studies have investigated their 
use in combination with insulin (373). However, evidences from few studies have 
shown that use of TZDs have been associated with adverse CV outcomes, particularly 
in CHF hospitalisations.  
However, there have been reports of adverse CV outcomes associated with the use 
of TZDs, most notably with CHF hospitalizations. Lago and colleagues (2007) in a 
meta-analysis of randomised clinical trials of TZDs reported that patients on TZDs had 
increased risk for development of congestive heart failure across a wide background 
of cardiac risk (relative risk [RR] 1.72, 95% CI 1.21-2.42, p=0.002) (374). The Food 
and Drug Administration (FDA) have contraindicated TZD use in patients with NYHA 
functional class III/IV CHF, and have introduced a ‘black box’ warning regarding the 
increased risk of CHF. Furthermore, a meta-analysis reported higher risk of MI and 
CHF among patients with IGT or T2DM in patients who use rosiglitazone (375). This 
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has prompted the FDA to place a ‘black box warning on rosiglitazone until additional 
safety data is available.  
2.2.5.2. Metformin 
Metformin and the related drug Phenformin (the latter withdrawn due to side effects of 
lactic acidosis) are derived from galegine, a natural product from the plant Galega 
officinalis, used since medieval times for treatment purposes by French monks to 
control what was described as “intense urination” (376). The active ingredient in the 
French lilac that had therapeutic benefit in reducing blood glucose was identified to be 
guanidine. While guanidine itself and certain derivatives were proven to be too toxic 
in the treatment of diabetes mellitus, the biguanides (two linked guanidine rings) have 
demonstrated useful, and three biguanides became available for diabetes treatment 
in the 1950s.-Phenformin and buformin, the former was withdrawn from the market in 
the early 1970s due to the lethal side effect of lactic acidosis and increased cardiac 
mortality (376). Metformin, a less lipophilic biguanide, proved safer and, after 20 years 
of use in Europe, was approved for use in the USA in 1995 (376). Since then, 
metformin has been the mainstay of therapy in the treatment of T2DM. The recently 
terminated study, the Diabetes Prevention Program (DPP) has reported that 
metformin is an effective drug to decrease the risk of development of the disease 
(376). Furthermore, the widespread use of metformin has largely been underpinned 
by UKPDS study that reported lower CV mortality and morbidity in patients treated 
with metformin in comparison with alternative glucose-lowering drugs, despite similar 
glycaemic control. However, Griffin and colleagues (2017) in a recent meta-analysis 
(13 trials, N=2079 T2DM subjects) reported that CV benefits of metformin could be 
smaller than that reported by UKPDS however, this should be interpreted with caution 
because there has only been a small number of RCTs (377). Whilst patients who have 
CVD with T2DM are the group that are likely to benefit most from metformin, interest 
around potential cardioprotective effects over other anti-diabetic treatments has 
compelled attention in repurposing metformin to treat CVD, irrespective of diabetes 
status. In this context, the results from RCT’s of metformin in non-diabetic subjects 
have so far been mixed (Table 5) (378). 
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Table 5: Summary of Cardiovascular Disease Outcomes in Selected Repurposing Trials for Metformin(378). 
 
Trial  Publication 
Date 
Patient Group No. of Enrolled 
Patients & Dose of 
Metformin 
Selected Outcome Measures 
Jadhav et al 2006 Cardiac syndrome X 33; up to 500 mg BID for 
8 wk 
Improved endothelium-dependent microvascular 
responses 
Stress Test: maximal ST-segment depression, Duke 
score and chest pain incidence 
TAYSIDE 
(NCT00473876) 
2012 Chronic heart failure with 
insulin resistance 
62; 1000 mg BID for 4 
months  
No effect on primary end point of peak Vo2; improved 
predetermined secondary endpoint of Ve/Vco2, as well 
as improvements in fasting insulin resistance index and 
body weight 
CAMERA 
(NCT00723307) 
2014 Coronary artery disease with 
central obesity already 
taking 
statins 
173; 850 mg BID for18 
months 
No effect on primary end point of mean distal carotid 
intimal media thickness 
GIPS III 
(NCT01217307) 
2014 STEMI without diabetes 
mellitus 
380; 500 mg BID for 4 
months 
No effect on the primary end point of left ventricular 
ejection fraction 
REMOVAL 
(NCT01483560) 
2017 Type 1 diabetes mellitus 428; 1000 mg BID for 3 
y 
No effect on the primary end point of mean far-wall 
carotid intimal media thickness; improvement in the 
secondary/tertiary end points of glycohemoglobin; low-
density lipoprotein cholesterol; estimated glomerular 
filtration rate and maximal carotid intimal media 
thickness 
VA IMPACT 
(NCT02915198) 
2024 
(expected) 
Prediabetes and established 
atherosclerotic 
cardiovascular 
disease 
7868; up to 2 g daily for 
4.5 y 
Primary: Time to nonfatal myocardial infarction; stroke; 
hospitalization for unstable angina; or symptom-driven 
coronary revascularization Secondary: 
Cumulative/recurrent incidence of primary end points 
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In non-diabetic subjects with cardiac syndrome X and normal coronary arteries, but 
with 2 consecutive positive exercise tolerance tests, an 8-week metformin therapy 
improved maximal ST-segment depression, Duke score, and chest pain incidence in 
comparison with placebo(379). In the TAYSIDE study, metformin improved the 
VE/VCO2 slope (secondary endpoint), a prognostic indicator of exercise capacity in 
non-diabetic heart failure subjects who are insulin resistant (248).  Conversely, in the 
CAMERA trial (Carotid Atherosclerosis: Metformin for Insulin Resistance Study), 
metformin showed no effect on carotid artery intima-media thickness (cMIT) in non-
diabetic CAD patients who were insulin resistant. It is noteworthy that all the 
participants in the CAMERA study were taking statins, which might have limited the 
ability of metformin to show a reduction in cIMT(380). Furthermore, in the GIPS-III trial 
(Metformin to Reduce Heart Failure After Myocardial Infarction), among patients 
without diabetes presenting with STEMI and undergoing primary PCI, the use of 
metformin compared with placebo did not result in improved LVEF after 4 months. 
This lack of efficacy of metformin in GIPS-III study may be due to the dose of metformin 
administered (500mg BD) and the duration of therapy (4 months)(381). In our study, 
we used a high dose metformin (2000mg/day) and a longer duration (12 months).  The 
recent REMOVAL trial (Reducing with Metformin Vascular Adverse Lesions of Type 1 
Diabetes) reported no beneficial effect on cMIT in subjects with Type 1 DM, despite 
no sustained effect on glycaemia, possibly consistent with a CV effect of the drug that 
is not attributable to changes in glycaemia (382).  
Results of the EMPA-REG OUTCOME trial in patients with T2DM showed that the 
SGLT 2 inhibitor, empagliflozin, another T2DM drug, reduced CVD mortality in patients 
with T2DM with prevalent atherosclerotic CVD. However, this may largely be 
independent of effects on glycaemia, analogous to the multifactorial picture emerging 
with metformin. Such large CV endpoint trials are required in metformin to address the 
current clinical equipoise for metformin in CVD without T2DM.  
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CHAPTER 3: Literature Review 2 - Repurposing Metformin for 
Cardiovascular Diseases 
As discussed in Chapter 2, IR is associated with the development of LVH and LVH 
regression, based on non BP targets, such as IR, are urgently required. Metformin due 
to its mode of action including the insulin sensitizing properties, may be a potential 
drug that may regress LVH. The purpose of this chapter is to critically examine 
metformin’s cardioprotective potential by outlining relevant mechanisms of action, the 
most recent epidemiologic evidence, and recently completed and on-going clinical 
trials. 
3.1. METFORMIN 
3.1.1. Structure & Action of Metformin 
As discussed earlier, three biguanides have been developed for diabetes therapy: 
metformin, phenformin and buformin; only metformin remains part of today’s 
worldwide pharmacopoeia due to its superior safety profile and it is well-tolerated. The 
two other biguanides, phenformin and buformin, were withdrawn in the early 1970’s 
due to the risk of lactic acidosis and cardiac mortality. The incidence of lactic acidosis 
with metformin at therapeutic doses is rare (less than three cases per 100.000 patient-
years) and not greater than with non-metformin therapies (383). Metformin is of 
smaller molecular weight, more chemically stable (Figure 17), freely soluble in water 
and does not undergo substantial metabolism in vivo (384). Metformin has been 
established as a safe and effective diabetic therapy with minimal side effects, even 
before detailed mechanistic studies became possible. Despite its clinical use for 60 
years, its molecular mechanisms of action remain much debated. Nevertheless, there 
is no consensus on its primary site of action, although it is generally agreed to have 
pleiotropic effects. 
Metformin is a complex drug with several evidences to support the notion of multiple 
sites of action and multiple molecular mechanisms. Metformin is traditionally thought 
to act by countering IR, which is thought to occur in liver and muscles (385). Although, 
metformin reduces hepatic glucose production, not all of its effects can be explained 
by this mechanism. Currently, there are mounting evidences to demonstrate the key 
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role of gut as metformin’s site of action (386). Additionally, evidences from preclinical 
studies have shown that the findings at cellular and molecular levels, vary greatly 
depending on the dosage of metformin used and duration of treatment, with clear 
differences between acute and chronic administration(386).  
Metformin has been shown to act via both AMP-activated protein kinase (AMPK)-
dependent and AMPK-independent mechanisms; by inhibition of mitochondrial 
respiration but also perhaps by inhibition of mitochondrial glycerophosphate 
dehydrogenase, and a mechanism involving the lysosome (386). Over the last 
decade, the action of metformin has been evolved from a simple drug that improves 
glycemia by acting on the liver via AMPK activation, to a much more complex depiction 
reflecting it’s multiple modes of action. The focus of this thesis is around AMPK 
activation, and will be discussed in further detail later.  
 
Figure 17. Chemical Structure of Metformin reference?? 
 
3.1.2. Efficacy of Metformin 
As discussed in the earlier sections of this thesis, metformin has been the first line of 
treatment for patients with T2DM since 1957 in Europe and 1995 in US. It is also the 
most widely used antidiabetic medication, globally. This section outlines the 
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therapeutic profile of metformin and its effects on blood glucose, body weight, BP lipid 
profile and mainly the cardioprotective effects, which is the main focus of this thesis.  
3.1.2.1. Improving Glycaemia 
The UKPDS study have reported a greater improvement in glycemic index for 
metformin treatment group compared to patients on diet alone (387). Garber et al 
(1997), in a double-blind RCT have shown that the hypoglycemic properties of 
metformin are dose dependent with the largest study of 451 patients concluding that 
2000 mg of metformin was the optimal daily dose with a mean change in HbA1C from 
baseline -0.7% after 14 weeks (388). The maximum recommended dose of metformin 
is 3000mg per day in Europe and the median daily dosage used in UKDPS study was 
2550mg (387). Studies have previously shown the beneficial role of metformin in 
improving glycemic index, which has been associated with an improvement in CV 
outcomes (389,390). But, there is only limited data available on metformin’s 
effectiveness in glycemic control. Estimates based on trials suggest a modest 
reduction of HbA1c (1-2%) (391). However, a recent systematic review reported this 
as an overestimate of effect (392). It is noteworthy that, this meta-analysis only 
included seven trials of metformin, but did not separately study metformin use as a 
monotherapy or in combination with other antihyperglycemic medications. Conversely, 
another recent meta-analysis by Hirst et al (2012), which included 35 trials have 
reported that metformin monotherapy lowered HbA1c by 1.12% (95% CI 0.92–1.32; 
I2 = 80%) versus placebo, metformin added to oral therapy lowered HbA1c by 0.95% 
(0.77–1.13; I2 = 77%) versus placebo added to oral therapy, and metformin added to 
insulin therapy lowered HbA1c by 0.60% (0.30–0.91; I2 = 79.8%) versus insulin only. 
Furthermore, in a pooled analysis of data from dose-comparison studies (N= 7 trials), 
the authors reported a significantly greater reduction in HbA1c using higher doses of 
metformin compared with lower doses of metformin with no significant increase in side 
effects (391).  
Metformin’s glucose lowering effect is mainly via reversing IR, unlike sulphonylureas, 
by increasing insulin secretion. The precise mechanism by which metformin improves 
insulin action is not completely understood, even after 60 years of clinical use. Some 
of the key mechanisms by which metformin exerts its antihyperglycemic effects are 
via reducing hepatic glucose production by its direct or indirect action, enhancing 
peripheral insulin action, increasing intestinal glucose uptake and reducing lipolysis in 
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adipocytes (386). Furthermore, there is now increasing evidence suggesting 
metformin’s action on the gut to increase glucose utilization, increase GLP-1 and alter 
microbiome (386). At the molecular level, metformin impedes the mitochondrial 
respiratory chain in the liver, resulting in the activation of AMPK, improving insulin 
sensitivity (via effects on fat metabolism) and reducing cAMP, thus diminishing the 
expression of gluconeogenic enzymes. Metformin also has AMPK-independent effects 
on the liver that may include inhibition of fructose-1,6-bisphosphatase by AMP (386) 
 
3.1.2.2. Body Weight 
Majority of T2DM patients are either obese or overweight (393). In contrast to other 
antidiabetic therapies, metformin seems to be weight neutral or can even reduce body 
weight (394,395). However, this weight-loss effect of metformin is not a consistent 
finding in meta-analysis. In a meta-analysis of published controlled, randomised, 
prospective trials of metformin compared to sulphonylurea therapy between 1957 and 
1994, metformin was associated with weight reduction (396). Another two meta-
analysis reported no difference in metformin group, placebo or diet on body weight or 
BMI in patients with T2DM (397,398). In another meta-analysis of RCTs that explored 
body weight changes upon metformin treatment in participants with T2DM, older than 
60 years reported a raw difference of -2.23 kg (95% CI: -2.84 –-1.62 kg, P<0.001) 
body weight change in the metformin-treated groups as compared with that of the 
placebo groups (399). However, the available data on effect of metformin on body 
weight in nondiabetic patients with CVD is promising. The CAMERA study reported a 
significant reduction of all measures of adiposity (body weight, body fat, BMI, waist, 
circumference) in nondiabetic patients with CAD, with a mean weight loss of 3.2kgs in 
metformin group (380). In the TAYSIDE trial, metformin use resulted in a mean weight 
loss of 1.9kg in non-diabetic insulin resistant CHF patients (248).  
 
3.1.2.3. Lipid Profile 
Studies have demonstrated a modest benefit in the lipid profile with metformin, usually 
in reductions in total cholesterol, LDL-cholesterol and predominantly triglycerides, but 
not with HDL-cholesterol (400). Although these beneficial effects on lipid profile would 
tend to reduce the CV risk, the overall benefits on a 10-year risk of macrovascular 
end-points are modest when entered into the UKPDS risk engine (400). 
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3.1.2.4. Blood Pressure 
Evidences from animal models have demonstrated a vasodilatory action of metformin. 
Metformin has been reported to reduce BP in spontaneously hypertensive rats, 
possibly mediated via modulation of adrenergic action (401). Additionally, reductions 
in diastolic BP have been reported in metformin treated normotensive patients with 
uncomplicated non-insulin dependent diabetes mellitus(402). These findings were 
corroborated by another meta-analysis which reported a beneficial effect of metformin 
on DBP in humans (398). However, an overwhelming body of evidence from a recent 
(2017) pooled meta-analysis of randomized controlled trials of metformin on BP in 
patients without T2DM reported that metformin can significantly lower SBP, 
particularly in patients with impaired glucose tolerance or obesity (BMI≥30 kg/m^2), 
with a mean reduction of 5 mmHg and 3mmHg, respectively (403).  
3.1.2.5. Cardiovascular Benefits 
The UKPDS study, initiated in 1977 and reported in 1998, was the first ever 
randomised controlled trial to demonstrate improved outcome with metformin 
treatment. The CV benefits of metformin was largely underpinned by the UKPDS that 
reported lower CV mortality and morbidity in patients treated with metformin (387). In 
the UKPDS, metformin treatment was associated with greater relative risk reductions 
in diabetes-related death (-42%), MI (-39%), stroke (-42%) any diabetes related end-
point (-32%) and all-cause mortality (-36%) when compared with diet. This is in stark 
contrast to the relative risk reductions with sulphonylurea or insulin in diabetes-related 
death (-20%), MI (-21%), stroke (+14%) any diabetes related end-point (-7%) and all-
cause mortality (-8%) when compared with diet. The cardioprotective effects observed 
are independent of glycemia and could not be explained by differences in glycemia. 
Mean HbA1c after follow up in the diet group and metformin group were 8% and 7.4% 
respectively, with no clear difference in the glucose lowering effect between 
metformin, sulphonylurea and insulin. Given that the glucose lowering effects of 
metformin, sulphonylurea and insulin were similar, it has been proposed that 
metformin must confer additional pleotropic effects beyond glycemia (387). However, 
a recent meta-analysis by Griffin and colleagues (2017) reported CV benefits of 
metformin could be smaller than reported by UKPDS and concluded that there still 
remains ambiguity about whether metformin have CVD and mortality benefits among 
patients with type 2 diabetes, for whom it is the recommended first-line drug (377). 
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However, the authors report this uncertainty of metformin’s beneficial effects due to 
lack of evidence. In this meta-analysis, they only included 13 trials (N=2079 T2DM 
subjects allocated to metformin and similar number to comparison group).  It is 
important to note that out of these 13 trials, only four trials compared metformin with 
placebo and collected data on CV outcome. Therefore, this clinical equipoise around 
metformin can only be addressed by conducting large CV outcome trials (377).  
3.1.2.6. Endothelial Function 
Metformin’s effect on endothelial function is somewhat mixed. There are some 
evidences to show that metformin improves endothelial function. Mather et al (2001) 
in an placebo controlled study of diet-treated T2DM patients (N=44) reported that 
metformin treatment improved endothelial function assessed by forearm 
plethysmography during an infusion of acetylcholine (404). Additionally, the 
Hyperinsulinemia the Outcome of its Metabolic Effects (HOME) trial also reported an 
improvement in endothelial function in metformin treated T2DM patients compared to 
placebo (405). Furthermore, there is extensive pre-clinical and clinical literature that 
have demonstrated beneficial effects of metformin on vascular function (406).  
There is also however, conflicting evidence demonstrating no effect on endothelial 
function with metformin. A double blind RCT of T2DM patients, reported no effect of 
metformin on endothelial function (407). Similarly, in another randomised study in 
patients with T2DM, metformin didn’t improve endothelial function (408).  
3.2. Metformin- Mode of Action 
As discussed earlier in this thesis, the effects of metformin may go beyond improving 
glycemia and may include cardioprotective effects independent of glycaemic control.  
Perhaps the most exciting advancement in elucidating the cellular action of metformin 
was the proposed involvement of 5' AMP-activated protein kinase (AMPK) and its 
downstream pathways which are the key modulators of metformin in conferring the 
metabolic and cardioprotective effects, directly or indirectly (409). AMPK is a critical 
cellular energy sensor and regulator of energy homeostasis and is activated by energy 
stresses that increase cellular ADP: ATP and/or AMP: ATP ratios, either by 
diminishing the catabolic production of ATP (e.g. via nutrient deprivation and exposure 
to mitochondrial toxins) or by promoting ATP consumption (e.g. by muscle 
contraction). Additionally, AMPK might be an important molecular effector, as (1) 
metformin can reduce cellular ATP:ADP ratios in hepatocytes; and (2) downstream 
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effects of AMPK activation (e.g. promotion of glucose uptake and fatty acid oxidation 
in muscle, inhibition of lipid synthesis in the liver simulate the therapeutic effects of 
metformin) (409). Animal studies have shown that metformin induced AMPK is 
associated with inhibition of glucose production in rat primary hepatocytes and 
reduces levels of sterol regulatory element-binding protein-1 (SREBP-1), a key 
lipogenic transcription factor, at both the mRNA and protein level in hepatocytes and 
liver tissue (409). Furthermore, clinical studies have also reported that metformin 
enhances fatty acid oxidation in hepatocytes, albeit, oral ingestion of metformin 
resulted in suppression of whole body lipid oxidation as well as inhibition of hepatic 
glucose production in humans (410). 
The exact mechanism of how metformin activates is still not completely elucidated. As 
discussed earlier in this section, the effects of metformin are thought to be mediated, 
mainly, by the activation of AMPK, which is highly expressed not only in the liver but 
also in other tissues including the intestine, adipose, and skeletal muscle, and in the 
myocardium. However, more recently, AMPK independent mechanisms have also 
been suggested, which will be discussed in the next section. 
3.2.1. AMPK-dependant Mechanism of Action 
Metformin can activate AMPK, both in vitro and in vivo, with either direct or indirect 
pathways (411). The metabolic effect of metformin, both after acute and chronic 
treatment, occurs without an increase in intracellular total AMPK levels therefore, 
being independent upon the increase in the phosphorylated-to-unphosphorylated 
AMPK ratio (412). It directly binds to AMPK subunits, resulting in an elevated, more 
accessible, upstream kinases, which are enzymatically active, heterotrimeric 
complexes. Furthermore, metformin can indirectly activate AMPK, by altering 
AMP/ADP-to-ATP ratio in at least two ways: (i) by blocking AMP-deaminase, and (ii), 
by inhibiting mitochondrial complex 1, a transmembrane protein involved in the 
respiratory chain. 
Consequently there will be an increase in AMP/ADP-to-ATP ratio, resulting in AMPK 
activation. In this regard, metformin mimics a condition of imbalance between energy 
supply and use similar to the conditions of fasting and exercise. This elevated AMPK  
catalytic  activity  affects various metabolic pathways responsible for modulating some 
key enzymes in energy-consuming biosynthetic pathways, such as  
hydroxymethylglutaryl-CoA  reductase,  acetyl-CoA carboxylase 1 and 2 (ACC1 and 
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ACC2), and glycogen synthase . AMPK modulates glucose uptake through effects on 
the RabGAP TBC1D1 protein, thus influencing GLUT4-mediated glucose uptake, in 
muscle and fat tissues (413). Furthermore, via transcriptional changes, AMPK is also 
involved in an adaptive reprogramming of metabolism, resulting in a switch from ATP-
consuming anabolic pathways to ATP-generating catabolic pathways, particularly 
inhibiting the synthesis of triglycerides and proteins, and stimulating fatty acid 
oxidation, promoting glucose transport, and accelerating glycolysis, thereby reducing 
intracellular lipid stores. Pathological build-up of lipids in the liver damages insulin 
signalling through the diacylglycerols mediated activation of protein kinase C ε (PKC-
ε) (412). In an animal study, Fullerton et al (2013) have shown that metformin’s 
hypoglycaemic effect depends on its ability to lower cellular fatty acid levels through 
the AMPK-dependent phosphorylation of ACC1 and ACC2. This observations 
underpins the central role of intracellular lipids (414). Furthermore, Wang et al (2008) 
have shown that upper intestinal lipids activate an intestine-brain-liver neural axis to 
inhibit glucose production, and thereby reveal a previously unappreciated pathway 
that regulates glucose homeostasis (415). There, metformin may seem to improve 
glucose homeostasis indirectly via this “gut-brain-liver axis” (412). Additionally, 
metformin has been shown to activate a previously unappreciated pathway, the 
duodenal AMPK-dependent pathway to lower hepatic glucose production in rat models 
of both obesity and diabetes, by activating duodenal enterocyte AMPK and PKA-
dependent GLP-1 secretion (416) 
3.2.2. AMPK-independent mechanism of action.  
Foretz et al (2010) have demonstrated in rodent models that metformin inhibits hepatic 
gluconeogenesis in an LKB1- and AMPK-independent manner (417) by decreasing 
hepatic energy state (418). This is via the inhibition of mitochondrial glycerol-3-
phosphate dehydrogenase, which alters the cytosolic redox state (as reflected by a 
higher lactate-to-pyruvate ratio) and increases the mitochondrial redox state   (as   
reflected   by   beta-hydroxybutyrrate-to-acetoacetate ratio) (419). By inhibiting this 
enzyme, metformin moderates the NAD+ available for converting lactate into pyruvate, 
resulting in reduction of gluconeogenesis and subduing fasting hepatic glucose 
production. Additionally, metformin’s insulin sensitizing effect have also been linked to 
modification in microbiota composition (412). In high-fat diet-fed mouse models, 
metformin treatment attenuates endotoxemia, enhances insulin signalling and reduces 
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postprandial serum gut microbiota- derived lipopolysaccharide (LPS) (420), which 
plays a key role in the development of IR, obesity and endothelial dysfunction (421).  
3.3. Cardioprotective Effects of Metformin 
Numerous pre-clinical studies have demonstrated some direct effects of metformin 
both on isolated cardiomyocytes and on the beating heart (Figure 18). However, 
clinical studies are scarce. There are several lines of evidence suggesting that 
metformin can play, potentially several roles in different cardiomyocyte activities, such 
as electrical activity, energy metabolism, ischemia-reperfusion injury, cardiac 
remodelling, as well as systolic and diastolic functions. 
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Figure 18: Effects of metformin on the heart: Metformin has been suggested to exert its beneficial effects on electric activity, 
cardiomyocyte metabolism, ischemia, remodelling as well as on myocardial systolic and diastolic functions.
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3.3.1. Electric Potential and Conduction 
Only limited data is available regarding the effect of metformin on cardiomyocytes 
electrical activity. In male Wistar diabetic rats, high doses of metformin provided 
greater dispersion of the QT interval, possibly due to the increased ventricular 
repolarization inhomogeneity, whereas low metformin doses decreased QT intervals 
(422). In rat models of acute MI, metformin treatment prevented pathologic alterations 
in the ECG, suggesting protective effects on cell membrane function (423). On the 
contrary, there is only one study that has been conducted to investigate the effect of 
metformin on ECG markers. In a study of patients with T2DM, metformin treatment 
was associated with a 12msec reduction in corrected QT interval (QTc) and a neutral 
effect in QTc dispersion. Therefore, in conclusion, there is no clear evidence of a 
direct, significant influence of metformin treatment on cardiomyocyte electric activity 
in a clinical study. 
3.3.2. Energy Metabolism of Normal Heart. 
Depending on the concentration and duration of exposure of metformin, studies have 
shown that metformin can activate glucose uptake and glycolysis, both by AMPK-
dependant and AMPK independent mechanisms (p38-MAPK and PKC) in isolated 
cardiomyocytes, whilst the increase in fatty acid oxidation is evident only if AMPK is 
activated (412). Studies have shown that metformin enhances glucose transport and 
glycolysis and initiates fatty acid oxidation, inhibiting synthesis of triglycerides in intact 
myocardium. Importantly, in a normal intact heart, the effect of metformin on fatty acid 
utilization appears to predominate and occur independently of AMPK activation (412). 
However, chronic treatment of metformin was not associated with (16 mg/kg/day) a 
different pattern of myocardial substrates utilization in diabetic animal models (412).  
On the contrary, the available clinical data is somewhat conflicting. In a study of T2DM 
patients, Hallsten et al (2004) observed no significant effect of metformin on 
myocardial or whole body glucose uptake in a positron emission tomography (PET) 
study (424). However another PET study in T2DM, with slightly more sample size 
reported a small reduction in myocardial glucose uptake and FFA utilization (425). 
Interestingly, in another study by Lyons et al (2013) showed that, although there was 
no metformin treatment effects on myocardial substrate metabolism in the whole 
cohort, a gender based sub-group analysis showed that metformin treatment 
decreased fatty acid clearance which was linked to increased plasma FA levels, 
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myocardial FA utilization and oxidation, and lower myocardial glucose utilization, in 
men, suggesting that gender should be taken into consideration when designing a 
treatment (426).  
Taking into consideration these limited data, deriving conclusive evidence on 
metformin’s beneficial effects on myocardial metabolism is elusive. More clinical 
studies are required to assess this effect of metformin. It is noteworthy that in resting 
and fasting conditions, the energy metabolism of the heart relies mainly on the 
availability of circulating FFA, whose serum concentration is extremely sensitive to 
factors such as the duration of fasting, stress, fat mass, insulin, and glucagon relative 
serum concentrations. As such, it cannot be excluded that some of these confounding 
factors might be responsible for the variability observed in the results in vivo. However, 
a properly designed clinical trial is warranted to investigate this.  
 
 
3.3.3. Ischemia – Reperfusion Injury 
In an animal study, metformin acutely improved cardiac function after a mild ischemic 
dysfunction in non-diabetic isolated heart models (427). This beneficial effect of 
metformin has been replicated by some studies in vivo, where acute metformin therapy 
significantly reduced post ischemic myocardial damage. Numerous studies performed 
in both isolated hearts and intact animals, have shown that metformin treatment has 
direct beneficial effects on the heart; reduce infarct size - compared to the control 
group and metformin administration before or during ischemia-reperfusion injury was 
associated with an infarct size reduction between 22% and 65% (412). It is noteworthy 
that the metformin’s infarct size-limiting effect was predominantly shown in animal 
models after either a single intraperitoneal injection or a single intra-ventricular 
administration during reperfusion. Importantly, the cardio beneficial effect of metformin 
has been demonstrated, both in diabetic and non-diabetic animal models (412).  The 
cardioprotective effect of metformin on ischemia-reperfusion injury may be secondary 
to either a more efficient shift from fatty acid aerobic oxidation to glucose anaerobic 
utilization or to an improvement in cardiomyocyte insulin signalling (428).  
However, data from clinical studies are somewhat conflicting. Although, most of the 
observational studies were consistent with the protective role for metformin in acute 
CAD, data from RCTs were not consistent with these observations. In a post-hoc 
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analysis of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial 
Infarction (DIGAMI) 2 study, metformin treatment, when compared to other 
hypoglycaemic agents, was associated with improved survival after ST-elevation MI 
(STEMI) in patients with T2DM (429). This finding has been consistent in other studies 
in patients with T2DM and history of CAD, where metformin treatment was associated 
with a lower mortality rate compared with sulfonylureas (412). In another retrospective 
study of 154 diabetic patients, chronic pre-treatment with metformin was associated 
with the reduction of the no-reflow phenomenon in patients with DM after primary 
angioplasty for acute MI (430). Furthermore, in a bigger retrospective cohort study of 
diabetic patients presenting with STEMI, chronic metformin treatment was associated 
with reduced MI size compared to non-metformin users and lower peak values of 
cardiac cell death markers, such as creatinine kinase (CK), mbCK, and troponins, 
were observed in metformin users (431). On the contrary, another observational study 
did not confirm this finding (432). Importantly, data from RCTs are not very 
encouraging, albeit with inherent limitations such as treatment exposure time, dosage 
used etc. In the Glycometabolic Intervention as Adjunct to Primary Percutaneous 
Coronary Intervention in ST-Segment Elevation Myocardial Infarction (GIPS-III) trial, 
metformin treatment had no significant benefit on LVEF and NT-proBNP levels at 4 
months in non-diabetic patients’ presented with STEMI (381). However, in patients 
with metabolic syndrome, metformin treatment (250 mg, 3 times daily) started 7 days 
prior to elective percutaneous coronary intervention resulted in both a smaller (50%) 
cardiac biomarker release (creatinine kinase-MB) and troponin I levels) after 
intervention and an improved 1-year clinical outcome (8% vs. 29% major clinical 
events) (433). 
3.3.4. Cardiac Remodelling  
Several animal studies have shown the efficacy of metformin in regressing cardiac 
hypertrophy. Zhang et al (2011), in rat models have shown that long term treatment 
with metformin could regress ventricular hypertrophy induced by pressure overload, 
via activation of AMPK and a downstream signalling pathway involving AMPK-
endothelial nitric oxide synthase pathway (434). Further, in another study performed 
in mouse models, metformin inhibited cardiac fibrosis induced by pressure overload 
in vivo and inhibited collagen synthesis in cardiac fibroblasts perhaps via inhibition of 
the transforming growth factor (TGF)-beta (1)- Smad3 signalling pathway and also 
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improved diastolic function (435). Metformin has also been shown to have an inhibitory 
effect on cardiac hypertrophy in vivo in isoprenaline-induced cardiac hypertrophy and 
in pressure-overload induced cardiac hypertrophy (436). In a canine model of 
tachycardia induced HF, metformin treatment regressed oxidative stress-induced 
cardiomyocyte apoptosis via reduced TGFβ1 mRNA and prevented progression of 
HF, along with activation of AMPK (437). Furthermore, in mouse models exposed to 
transverse aortic constriction-induced hypertrophy, metformin treatment was effective 
in attenuating transverse aortic constriction-induced LV remodelling in both wild-type 
and AMPKα2 knockout mice, as evidenced by reduced LV and lung weights, a 
preserved LV ejection fraction, and reduced phosphorylation of mammalian target of 
rapamycin (p-mTOR(Ser2448)) and its downstream target p-p70S6K(Thr389) (438), 
indicating  that metformin can exert cardioprotective effects through an AMPK-
independent molecular pathway. In rodent models of ischemic HF, both short term (4 
weeks) and long term treatment (12 weeks) of metformin post MI resulted in 
attenuated cardiac remodelling and prevented the progression of ischemic 
cardiomyopathy and HF. Importantly, rat models treated with metformin demonstrated 
a reduced infarct size, improved echocardiographically assessed LV geometry, and a 
smaller increase in molecular correlates of LV remodelling, such as ANP and collagen 
production.  
However, there is only limited clinical data available on metformin’s effect on cardiac 
hypertrophy. A small (n=40), open-labelled, echocardiographic study reported that 6 
months treatment with metformin reduced LVM and relative wall thickness in non-
diabetic subjects with metabolic syndrome (439). Furthermore, in an 
echocardiographic sub-study of the GIPS III trial, four months metformin treatment 
was associated with a non-significant, marginal reduction of LVMI in non-diabetic 
subjects presented with STEMI (440). Conversely, a recent network meta-analysis 
reported minimal beneficial effects of metformin on LVM in subjects with T2DM (441). 
The latter meta-analysis was based on small number of metformin trials (N=3), with 
notable limitations, among an unrepresentative subset of patients. Therefore, we 
would like to highlight the importance of a prospective placebo controlled randomized 
trial that utilizes MRI for accurate and reproducible LVM measurements and sufficient 
follow-up for the interpretation of effect of metformin on LVH regression.  
In conclusion, while data from clinical studies are currently lacking, the results from 
animal studies are very promising. Therefore, the results from the present study, which 
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is a prospective placebo controlled randomized trial, accurately powered to detect 
changes in hypertrophy and that utilizes MRI for accurate LVM measurements will 
clarify the effect of metformin on cardiac remodelling in humans.  
3.3.5. Systolic and Diastolic Functions 
Numerous animal studies have demonstrated the beneficial effects of metformin on 
systolic and diastolic functions. In animal models of post ischemic HF, metformin 
treatment significantly improved LVEF and survival by 47% (vs vehicle) at 4 weeks 
post permanent left coronary artery occlusion. Additionally, in an in vivo study on rat 
models of post MI cardiac remodelling, long term treatment of metformin was shown 
to be associated with preserved cardiac function (412). However, this was not a 
consistent finding in a non-ischemic HF setting. In a rodent model of volume-overload 
HF, metformin treatment did not result in any improvement in systolic or diastolic 
function (412). But long term metformin treatment improved the myocardial 
performance to an increase in preload in isolated streptozotocin-treated diabetic rat 
hearts (442). The cardioprotective effect of metformin in workload-dependant HF has 
been demonstrated to be dependent on the AMPK pathway. The protective effect of 
metformin in workload-dependent HF has been shown to be dependent on the AMPK 
pathway. In a series of experiments by Taegtmeyer and colleagues showed that 
glucose metabolic changes precede and regulate functional (and possibly also 
structural) remodelling of the heart and implicated a pivotal role for G6P in load-
induced mTOR activation and ER stress (443). Furthermore, in canine diabetic model, 
metformin treatment prevented the progression of LV diastolic chamber stiffness and 
diastolic dysfunction (444).  
In this regard, data from clinical studies are not so promising. An interesting 
observation of metformin treatment associated with subclinical LV dysfunction was 
reported from an observational study of subjects with T2DM (N=219) (445). It is 
noteworthy that, the baseline BMI was higher in the metformin treated group; as a 
consequence, the weak, negative effect of metformin on diastolic function might be 
due to this confounding influence. Increased BMI is associated with worse LV diastolic 
function (446).  In a very recent study it was shown that overweight and obesity was 
associated with impaired LVEF and global longitudinal strain in both patients with 
T2DM and non-diabetic subjects (447).  
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This observation was further corroborated from another observational study which 
reported that metformin treatment was associated with a greater risk of LV dysfunction 
(448), where the subjects in the metformin treatment group had higher waist 
circumference, confirming that in this setting metformin therapy might rather represent 
a marker of visceral adiposity. Nevertheless, the data from clinical trials are also not 
consistent with observations from animal studies. In an RCT of metformin, 6 months 
metformin treatment (2g/day) had no significant effect on diastolic function as 
assessed by echocardiography in patients with normal left ventricular function and 
negative dobutamine stress test (425). In the GIPS-III trial, metformin treatment did 
not improve LVEF in non-diabetic subjects presented with STEMI (381). However, in 
this study, a lower dose of metformin was used (1 g daily) and for a shorter treatment 
duration (4 months). It may be plausible that the dosage and the treatment duration 
may not be enough to have a beneficial impact on LVEF. However, in a recent study 
of T2DM patients, metformin treatment was associated with improvements in glycemic 
control over a 12-month period, leading to improvements in LV systolic and diastolic 
function (449). 
3.4. Metformin and Major Cardiac Clinical Outcomes 
Till date, there are three RCTs that have reported similar conclusions regarding the 
possible beneficial cardioprotective effects of metformin: (a) The UKPDS, (b) HOME 
Trial and (c) SPREAD-DIMCAD trial. However, the CV benefits of metformin has 
largely been underpinned by the UKPDS that reported lower CV mortality and 
morbidity in patients treated with metformin. The UKPDS study demonstrated that in 
obese subjects with T2DM, metformin compared to comparator therapies, albeit 
similar glycemic control, was associated with a reduction in 10-year overall mortality 
and diabetes-related death by 36% and 42%, respectively, and lowered the risk of MI 
by 39% (387). Importantly, the beneficial effects of metformin were sustained for 10-
year of post-trial follow-up (389).  
In the HOME trial, which compared metformin to placebo as add on basal insulin, a 
similar reduction (40%) of macrovascular events, a heterogeneous composite 
secondary endpoint (hazard ratio, 0.61 (95% CI, 0.40-0.94; P = .02) was reported 
(450). These findings were further corroborated by another multicentre, RCT of 
subjects with T2DM and CAD, the SPREAD-DIMCAD study. In this study, treatment 
with metformin for 3 years substantially reduced major CV events in a median follow-
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up of 5.0 years compared with glipizide (451). On the contrary, another trial, the 
BARI2D trial, performed in T2DM subjects with IHD, was largely neutral (452).  
However, this study compared two therapeutic strategies, insulin sensitizing 
(metformin and/or thiazolidinediones) versus insulin providing (SUDs and/or insulin) 
drugs therefore, it does not provide direct information on the effect of metformin per 
se. 
Additionally, meta-analyses of observational studies have reported cardioprotective 
benefits for metformin compared to sulfonylureas (SUs). Metformin treatment was 
associated with reduced risk of MI (453). In another met-analysis of 35 RCTs, 
metformin was not associated with significant harm or benefit on CV events (Mantel 
Haenszel-Odds Ratio 0.94[0.82-1.07], p = 0.34). A significant benefit was observed in 
trials versus placebo/no therapy (MH-OR 0.79[0.64-0.98], p = 0.031), but not in active-
comparator trials (MH-OR 1.03[0.72-1.77], p = 0.89) (454). Furthermore, another 
meta-analysis of RCTs also suggest that the CV effects of metformin could be smaller 
than that reported by UKPDS; however, this should be interpreted with caution as 
there has only been a small number of randomized controlled trials (377). 
While CVD patients with T2DM comorbidity are likely to benefit most from metformin, 
indications of CV benefit over other diabetes treatments has driven interest in 
repurposing metformin to treat CVD, irrespective of diabetes status (378).   
Therefore, the accumulating evidences, though limited are pointing towards the 
direction of a potential beneficial effect of metformin. This is somewhat in line with the 
cardioprotective effects of metformin observed in pre-clinical studies, which also 
suggest that the effects are proportional to the load of metabolic and/or hemodynamic 
stress.  
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CHAPTER 4. Overview of Thesis 
This thesis comprises of an RCT that investigated the efficacy of metformin in 
regressing LVH in CAD patients with IR AND/OR prediabetes.  LVH is an independent 
predictor of mortality and is highly prevalent in patients with CAD, even in the absence 
of hypertension (31,455). LVH is a common finding in approximately one third of patients 
with CAD (32). Importantly, LVH is one of the most powerful prognostic factors in CAD, 
after age and coronary disease severity with a prognostic importance equivalent to 
that of left ventricular ejection fraction (32,33).  Regression of LVH can reduce the 
incidence of major CV events irrespective of BP changes (161,183). However 
controlling BP is only partially effective as LVH persists in 20% of hypertensive patients 
who attain target BP (176). Therefore, additional strategies are required. 
 
Other than BP, IR and central obesity are implicated in the development of LVH. 
Dysglycemia is very common in patients with CAD and is linked to IR (436). Large 
studies have reported a significant positive relationship between components of 
dysglycemia such as IR and LVH (47,92,93). Specifically, central obesity has been 
associated with IR, hypertension and LVH (456). Metformin - an anti-diabetic drug, 
has been shown to improve insulin sensitivity and reduce IR (457). In a meta-analysis 
of randomised controlled trials (RCT’s), Salpeter et.al reported a reduction of weight 
and calculated IR in metformin users (458). As discussed in the earlier sections of this 
thesis, metformin has multiple mode of actions involving both AMP-activated protein 
kinase (AMPK)-dependent and AMPK-independent mechanisms that may be 
implicated in cardiac hypertrophy (386). In this respect, metformin has been shown to 
reduce cardiac hypertrophy in different animal models of hypertrophy (412). 
Observational studies have also reported CV benefits especially in patients with T2DM 
and heart failure (459) For these reasons, there is now much interest in the 
repurposing of metformin for CV diseases (378).  All these evidences supported the 
notion that metformin may cause regression of LVH.  
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Hypothesis 
For this PhD, I hypothesized that metformin may regress left ventricular hypertrophy 
in patients who have CAD with IR and/or pre-diabetes. 
Aims of Study 
The MET-REMODEL trial was designed to test the above hypothesis. The main aim 
of the MET-REMODEL trial was to assess the ability of metformin XL (2000mg/day) 
to regress LVMI in normotensive patients with LVH and CAD. The secondary aims of 
this study were to assess the effects of metformin on; (a) endothelial function; (b) IR; 
(c) abdominal obesity; (d) blood biomarkers of interest; (e) other cardiac parameters 
(LVM, LVEF, LVSV, LVDV), as measured by cardiac MRI in patients with LVH and 
IHD.  
Objectives 
The overall objectives of this study are; 
Primary Objective   
To study the efficacy of metformin to cause regression in LVH in participants with CAD 
who are insulin resistant/pre-diabetes.   
Secondary Objectives   
• To study whether metformin improves IR in patients with confirmed IHD.    
• To assess whether metformin will reduce central and abdominal obesity in this 
patient group.     
• To examine any differences following treatment with metformin in blood 
markers such as NT proBNP, TBARs, Soluble ST2 and IL-6.   
• To assess whether metformin will improve endothelial function as measured 
by, flow mediated dilatation.  
• To assess if metformin has effects on other cardiac volumetric parameters 
LVEF, LVSV, LVDV as measured by cardiac MRI.    
The research evidence and theoretical underpinnings in relation to this study were 
discussed in the introduction and literature reviews. The introduction section discusses 
general concept around CV diseases, particularly CAD and LVH and also 
dysglycemia, which are main therapeutic focus points of this study. The literature 
review comprises of two parts: the literature review part 1 critically analyses literature 
relating to LVH, abnormal glucose metabolism (both diabetic and prediabetic) and the 
rationale for targeting dysglycemic states such as IR and prediabetes in regressing 
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LVH. The literature part 2 critically analyses literature around repurposing metformin 
in CVD.  This will then be followed by the results of this study. Thereafter, the 
discussion section provides a consideration of result in the context of current available 
evidences. The final sections of this thesis discuss the overall conclusions and 
recommendations for future research in this area. As the incidence of CVD and 
diabetes is globally rising, the findings from this thesis are likely to be of great 
importance for researchers and clinical decision makers. 
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CHAPTER 5 – Randomized Controlled Trial: Effect of Metformin 
on Left Ventricular Hypertrophy in Nondiabetic Patients with 
Coronary Artery Disease – The MET-REMODEL Trial 
5.1. Methods 
5.1.1. Study Aims 
The main aim of this study was to assess the ability of metformin XL (2000mg/day) to 
regress LVMI in normotensive patients with LVH and CAD. The secondary aims of this 
study was to assess the effects of metformin on; (a) endothelial function; (b) IR; (c) 
abdominal obesity; (d) blood biomarkers of interest; (e) other cardiac parameters 
(LVM, LVEF, LVSV, LVDV), as measured by cardiac MRI in patients with LVH and 
IHD.  
5.1.2. Study Hypothesis 
Metformin has been shown to regress LVM in animal models of LVH. We hypothesize 
that 12 months’ metformin treatment may regress LVH in non-diabetic and 
normotensive CAD patients with IR and/or pre-diabetes, when compared to placebo 
therapy. 
5.1.3. Study Overview 
This study was conducted between April 2015 and September 2016 at a single centre, 
Ninewells hospital, Dundee, Scotland. It was funded by British Heart Foundation 
(Grant Ref: PG/14/4/30539) approved by the Tayside Research Ethics Committee 
(Ref: 14/ES/1061 IRAS) and was done in accordance with the Declaration of Helsinki. 
Approval was also obtained from the Medicines and Healthcare Products Regulatory 
Agency (Ref: 41692/0009/001-0001). All participants provided written informed 
consent after receiving a patient information sheet at least 24 hours before. This study 
was registered with clinical trials.gov (Identifier: NCT02226510) and European Clinical 
Trials Database (EudraCT number: 2014‐003189‐26).  
5.1.4. Study Design, Randomization and Masking 
The MET-REMODEL study was a single centre, double blind, placebo-controlled trial 
designed to evaluate the efficacy of a 12-month Metformin XL (prolonged release) 
1000 mg twice daily treatment on LVH in non-diabetic, participants identified to have 
CAD, LVH and IR and/or pre-diabetes. Figure 19 shows the MET-REMODEL trial 
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consort type flow diagram with number of participants throughout the trial and 
supplementary material, Figure 20 shows the study design. Randomization was 
carried out by Tayside Pharmaceuticals using a validated block randomization method 
(www.randomization.com). The IMP supply was sequentially numbered and the 
randomization key held in sealed envelopes by Tayside Pharmaceuticals, Ninewells 
Pharmacy. The investigating team did not have access to the key until after analysis 
had taken place. If the study drug was stopped, patients remained in the study in order 
to perform a “modified intention-to-treat” (mITT) analysis.  Participants were allowed 
to continue all their usual medication throughout the course of the trial. The 
participants and the research team directly involved in the study did not have access 
to this allocation sequence. 
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                                                                                Figure 19: Trial Consort Diagram. 
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Figure 20: Study Design 
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5.1.5. Trial Management Group 
The trial was managed by the trial management group (TMG), consisting of the grant 
holders, including the chief Investigator (CI), the principal investigator (PI) and a senior 
trial manager from Tayside Clinical Trials Unit. As a member of the TMG, the clinical 
trial protocol, patient information sheet, brief patient information leaflets, case report 
form was designed and developed by the author of this thesis in discussion with other 
TMG members. The PI (author) was responsible for the day-to-day activities (such as 
screening, recruitment and conducting follow-up visits of study participants) and was 
supervised by the CI.  
5.1.6. Study Endpoints 
The primary end point was to determine whether metformin induces regression of 
LVMI assessed by CMRI. The secondary endpoints were changes in LV ejection 
fraction, mass and volumes; changes in abdominal obesity assessed by MRI; changes 
to glycaemic parameters, changes in endothelial function and changes in blood 
biomarkers.  
5.2. Study Population 
The study population included 68 CAD patients recruited between April 2015 and 
September 2016 from Tayside, Scotland, using research databases, hospital records 
and local general practices.  
5.2.1. Participant Inclusion Criteria 
1. Participant is willing and able to give informed consent for participation in the 
study. 
2. Aged 18 years or over. 
3. Documented CAD (previous myocardial infarction/unstable angina and/or 
previous revascularisation by either percutaneous coronary intervention or 
coronary artery bypass graft surgery).  
4. Have screening echocardiography based diagnosis of LVH based on published 
sex specific normal values of LV mass allometrically scaled to height (LV mass/ 
height1.7 > 95th percentile) as ascertained by screening echocardiography 
(males >81 g/h1.7, females >60 g/h1.7) 
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5. IR [defined using fasting insulin resistance index (FIRI ≥2.7)] AND/OR 
American Diabetes Association defined pre-diabetes: glycated haemoglobin 
(HbA1c) ≥ 39 mmol/mol and <48 mmol/mol.  
6. Clinic blood pressure ≤ 140/85 mm Hg (mean value of three measurements 
performed at 5 min interval on same arm) or 24 h BP ≤ 135/85 daytime average, 
if clinic BP above the cut-off value of 140/85 mmHg. 
7. Able (in the Investigators opinion) and willing to comply with all study 
requirements. 
5.2.2. Participant Exclusion Criteria 
1. Unable to give written informed consent. 
2. Diagnosis of Type 1 or 2 diabetes mellitus 
3. Left ventricular ejection fraction <45% on screening echocardiography or a 
diagnosis of heart failure.  
4. Contraindications to MRI (pacemakers, claustrophobia, metal implants, history 
of penetrative eye injury or exposure to metal fragments in eye requiring 
medical attention) 
5. Current malignancies (receiving active treatment) or other life-threatening 
diseases 
6. Renal disease; eGFR  45 
7. Pregnancy and lactating women 
8. Participants who have participated in any other clinical trial within the previous 
30 days. 
5.2.3. Screening for Eligibility 
Participating patients were aged 18-85 years with documented CAD (previous 
myocardial infarction/unstable angina and/or previous revascularisation by either 
percutaneous coronary intervention or coronary artery bypass graft surgery) and 
without diabetes (ascertained by clinical history extracted from medical notes and 
screening HbA1c measurement of ≥ 48 mmol/mol). Patients were also required to 
have IR [IR defined using fasting insulin resistance index (FIRI ≥2.7) measured by an 
empirical FIRI, consisting of the product of plasma insulin and glucose: FIRI = fasting 
glucose x fasting insulin / 25] AND/OR American Diabetes Association defined pre-
diabetes: glycated haemoglobin (HbA1c) ≥ 39 mmol/mol and <48 mmol/mol (206,460). 
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They were also required to have a clinic BP ≤140/85 mm Hg (mean value of three 
measurements performed at 5 min intervals on same arm). Presence of LVH was 
based on published sex specific normal values of LV mass allometrically scaled to 
height (LV mass/ height1.7 > 95th percentile) as ascertained by screening 
echocardiography (males >81 g/h1.7, females >60 g/h1.7) (88). Given the high 
prevalence of obesity (BMI ≥ 30 kg/m2) in these study patients we determined LVMI 
by LVM/height1.7, which has been shown to be a sensitive method to assess LVMI 
(88).  
5.3. Study Visits and Investigations 
Table 6 shows the total number of study visits and study assessments conducted at 
each study visits. 
Study Visit Study Assessments 
Visit 1 (Screening Visit) Participant consent, screening 
echocardiography, blood tests (LFTs, 
U&E’s, FBG, FPI & HbA1c), record vital 
signs, office BP (24hr ambulatory BP if 
office based BP criteria out of range 
/home based BP monitoring if ABPM 
not tolerated, record vital signs (physical 
examination, anthropometric 
measurements), medical & family 
history and concomitant medications. 
 
Visit 2 (Randomisation Visit) 
(up to 4 weeks post screening visit) 
Vital signs, safety bloods (LFTs & 
U&E’s), research bloods (IL-6, 
NTproBNP, TBARs & Soluble ST2), 
FMD, MRI (cardiac & abdominal), 
record changes to current medication 
and dispense study medication (starting 
dose 500mg metformin XL / matching 
placebo – twice daily 
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Visit 3 (Dose-up titration visit) 
(2 weeks post randomisation) 
Vital signs, safety bloods (LFTs & 
U&E’s), record changes to current 
medication, dispense study medication 
(up-titrated dose 1000mg metformin XL 
/ matching placebo – twice daily), 
recording of adverse events and drug 
compliance.  
Visit 4, 6 & 8 (Months 1,4 & 8) 
(Study follow-up visits) 
Vital signs, safety bloods (LFTs & 
U&E’s), record changes to current 
medication, dispense study medication 
(1000mg metformin XL / matching 
placebo – twice daily), recording of 
adverse events and drug compliance. 
Visit 5, 7 & 9(Months 2,6 & 10) 
(Telephone Interviews) 
Assess any adverse events, record any 
change in concomitant medications, 
checking drug compliance.  
Visit 10 (Month 12) 
(Final Visit) 
Vital signs, safety bloods (LFTs & 
U&E’s), research bloods (IL-6, 
NTproBNP, TBARs & Soluble ST2), 
FMD, MRI (cardiac & abdominal), 
record changes to current medication 
and checking drug compliance 
 
Table 6: Total number of study visits and study assessments conducted at each study 
visits. 
5.3.1. Screening Visit 
Pre-screening check on participant’s medical notes were carried out to ascertain that 
the participant has documented CAD and are not diabetic prior to approaching the 
participant about the study. At screening visit, as detailed in the above section (section: 
3.2.3), screening assessments, such as screening echocardiography to ascertain 
presence of LVH, clinic BP, safety bloods (full blood count, liver function and renal 
function test), glycaemic assessments (Fasting blood glucose, fasting insulin and 
HbA1c to assess IR and prediabetes), anthropometric assessments (height, weight 
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and BMI), baseline demographics, concomitant medications and past medical history 
were collected. Blood samples were collected in vacutainer and was sent to NHS 
Tayside blood sciences laboratory at Ninewells hospital for measuring full blood count, 
renal function, liver function and glycaemic indices such as fasting blood glucose, 
fasting plasma insulin and HbA1c. The samples were analysed using an automated 
Siemens’ high-volume hematology analyzer, the ADVIA® 2120i System (peroxidase 
method). Clinic BP as measured using Omron 705IT machine for all the patient at 
screening visit and all subsequent study follow-up visits (2- randomisation visit, 3, 4, 
6, 8, 10). At screening visit, echo participant will undergo a transthoracic echo to 
ascertain diagnosis of LVH based on study criteria as described in section 3.2.3.) and 
to exclude impaired LVH function or any significant valvular abnormality. Screening 
echo was performed by an experienced sonographer or a clinicians listed in the 
delegation log. With the subject lying on the left decubitus position at a 45o angle, in 
the parasternal long axis view an M-mode measurement of LVM was obtained by 
aligning the beam perpendicular to the septum and just below the tips of the mitral 
valve leaflets. Measurements were made in end-diastole and at the onset of QRS 
complex as according to the American Society of Echocardiography (ASE) 
recommendation. Measurements of the IVS, LV internal dimensions and posterior wall 
thickness were made using the leading edge to leading edge convention and an 
average of 3 readings were taken. LVM was calculated using the Devereux modified 
cubed formula: LV mass = 0.8 [1.04 [(LVIDd + LVPW + IVSd)3- (LVIDd)3]] + 0.6g. 
LVMI was calculated by indexing LVM by height1.7. Presence of LVH was defined 
based on published sex specific normal values of LV mass allometrically scaled to 
height (males >81 g/h1.7, females >60 g/h1.7)(88) . 
5.3.2. Randomization & Final Visit 
During randomization visit, participants who met the eligibility criteria were randomly 
assigned to either metformin XL 500mg twice daily or matching placebo in a double 
blind fashion (randomization protocol described in Section 3.1.4) for two weeks. If this 
was tolerated, the dosage was increased to 1000mg twice daily for a further 11 
months. If the higher dose could not be tolerated, it was reduced to 1000mg/day, or 
stopped altogether if this lower dosage was not tolerated. However, participants were 
allowed to continue all their usual medication throughout the course of study. Patients 
also had flow-mediated dilatation (FMD) and MRI (cardiac and abdominal) and bloods 
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(safety & research bloods as detailed in Table 9) performed as part of study 
investigations at the randomisation visit (study protocol will be detailed, later in this 
thesis) and final visit (visit 10 – month 12).   
5.3.3. Follow-up visits 
The next visit after two weeks, post randomisation (visit 3) is the dose-up titration visit. 
During this visit, the dose of study drug was up-titrated to 1000mg, twice daily, 
following safety blood checks and clinical review of adverse events. If the initial dose 
(500mg, twice daily) is not tolerated or the participant wishes to stop, the study drug 
was withdrawn, however the participants will remain in the study in order to perform a 
“modified Intention-to-treat (mITT) analysis.  Vital signs, safety bloods (LFTs & U&E’s), 
changes to current medication, dispense study medication (up-titrated dose 1000mg 
metformin XL / matching placebo – twice daily), recording of adverse events and 
checking drug compliance were performed at all follow-up visits (visit 4,6 & 8), except 
for telephone interviews (visit 5,7 & 9). During the telephone interviews, the study staff 
assessed any adverse events, recorded any change in concomitant medications and 
checked drug compliance. 
5.3.4. Laboratory Investigation 
5.3.4.1. Biochemistry and Haematology 
Safety blood tests (full blood count, renal function and liver function) were taken at 
each study visit. Blood samples were collected in vacutainer and was sent to 
centralized NHS laboratory in Ninewells Hospital, Dundee, for analysis. Glycaemic 
indexes such as fasting blood glucose, fasting plasma insulin and HbA1c were 
performed at screening visit (visit 1) and final visit (visit 10). The samples were 
analysed using an automated Siemens’ high-volume hematology analyzer, the 
ADVIA® 2120i System (peroxidase method). IR was assessed using fasting insulin 
resistance index (FIRI) measured by an empirical FIRI, consisting of the product of 
plasma insulin and glucose: FIRI = fasting glucose x fasting insulin / 25] AND/OR 
American Diabetes Association defined pre-diabetes: glycated haemoglobin (HbA1c) 
≥ 39 mmol/mol and <48 mmol/mol, as detailed in section 3.2.3. Estimated glomerular 
filtration rate (eGFR) was calculated using Modification of Diet in Renal Disease 
equation (461) 
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5.3.4.2. Biomarkers 
Biomarkers such as interleukin-6 (IL-6 - inflammation), N-terminal pro-brain natriuretic 
peptide (NTproBNP - wall stress), Soluble ST2 (wall stress & fibrosis) and 
thiobarbituric acid reactive substances (TBARs - oxidative stress) were measured at 
randomisation visit (visit 2) and final visit (visit 10).  As blood-borne biomarkers can 
offer objective and biologically relevant and mechanistic insights that complements 
the findings of study specific end points, we propose to include these 4 biomarkers of 
distinct mechanisms that contribute to the pathophysiology of left ventricular 
hypertrophy. Biomarkers were analysed from stored (-80oC) frozen plasma samples. 
IL-6 and NTproBNP were analysed using a MULTI- ARRAY assay system (Meso 
Scale Discovery). High sensitivity enzyme linked immunosorbent assays (ELISA) were 
used to measure Soluble ST2 (R&D Systems, UK) and TBARs (Cayman Chemicals, 
UK). The intra-assay coefficient of variation was 6.22% for IL-6, 14.6% for NTproBNP, 
13.68% for TBARs and 1.62% for soluble ST2. The inter-assay coefficient of variation 
was 4.2% for IL-6, 10.5% for NTproBNP, 7.5% for TBRAs and 7.33% for soluble ST2.  
5.3.5. Flow Mediated Dilatation (FMD) 
All the eligible study participants underwent FMD of the brachial artery at 
randomisation visit (visit 2) and final visit (visit 10) using a Sequoia 512 (Siemens, 
Camberley, UK) ultrasound machine with a 8MHz linear array probe and was 
performed as per the International Brachial Artery Reactivity Task Force guidelines 
(462). All the participants were asked to fast (at least 8 hours), and not to consume 
caffeine, not to smoke and high fat food or vitamin C for 4 hours prior to test. 
Furthermore, they were advised to hold nitrate tablets off the morning test, if they were 
on, until the test is finished. The study was performed in a quiet, temperature controlled 
room (22-24oC) with the participant lying supine position with their right arm 
outstretched on a table. The images of the brachial artery were acquired using ECG 
gating at the peak of R wave. A baseline image of the brachial artery was acquired. 
Then the cuff was inflated distal to the elbow to 200mmHg for five minutes. On 
deflation of the cuff, the brachial arterial diameter was recorded for two minutes. After 
a 10-minute rest period, endothelial independent dilatation was assessed by the 
response of brachial artery size to 400 micrograms of sublingual glyceryl trinitrate 
(GTN) spray. FMD was the percentage change in maximum diameter achieved after 
cuff deflation relative to the baseline mean artery diameter (Figure 21).  The FMD was 
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analysed using Vascular Research Tools software (Medical Imaging Applications LLC, 
Coralville, IA, USA). The analysis of the FMD images were performed by blinded 
technician (MSH).   
 
Figure 21. Brachial Artery FMD (462) 
 
5.3.6. Magnetic Resonance Imaging (MRI) 
Cardiac MRI (CMRI) and Abdominal MRI (AMRI) was performed at randomisation visit 
(visit 2) and final visit (visit 10). MRI was performed at the Clinical Research Centre 
by qualified technicians. A detailed MRI study protocol is detailed below. 
5.3.6.1. Cardiac MRI 
A stacked acquisition of 2D ECG retrospectively gated segmented breath-hold CINE 
TrueFISP images were acquired in the short axis orientation from the atrio-ventricular 
ring to the apex of the left ventricle.  Other key imaging parameters were, repetition 
time (TR) = 3.34 ms; echo time (TE) = 1.46 ms; flip angle (FA) = 50°; field of view 350-
450 mm; slice thickness 6mm; inter-slice gap 4mm; resolution 256x256 pixels; and 
bandwidth of 977 Hz/pixel.  Analysis of images was performed offline (Argus 
Ventricular Function Software, Siemens) by a single observer (S.A.T.) who was 
blinded to randomized therapy and sequence, for the assessment of ejection fraction, 
ventricular volumes (EDV, end-systolic volume, stroke volume) and LVM. For each set 
of images, the observer placed endo-cardial and epi-cardial border contours at end-
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diastole and end-systole, thus delineating all areas where LV myocardial structure 
could be observed.  Papillary muscle and trabecular structures were included within 
the blood volume unless indistinguishable from the myocardial wall, in which case they 
were attributed to the myocardial mass.  Each measurement was conducted at least 
twice for each imaging time-point.  The final LVM were indexed to height1.7 for each 
patient (LVMI).  
For Reproducibility and Variability of CMR: Two measurements of LVM were obtained 
for every study participant at baseline time-point by a single observer. We elected to 
use a single observer to undertake all of the segmentation work in order to optimise 
the reproducibility since it is widely known that inter-observer variation tends to 
introduce the greatest variability in these measurements. For all of the LVM values we 
examined every ‘segmentation pair’ closely.  By recording the mean LVM in each case, 
this process lead to improved confidence that the actual LVM values (and changes) 
were correct and representative of genuine change - i.e. not just measurement error.  
From these paired baseline measurements of LVM we calculated the intra-class 
correlation coefficient (ICC) to be 0.98 and we obtained an intra-observer test-retest 
root-mean-square coefficient of variation (RMS CoV) of 3.77%. 
5.3.6.2. Abdominal MRI 
Subjects were positioned supine inside the magnet and the abdomen was imaged 
using a 3D ‘DIXON’ volume interpolated breath-hold examination (VIBE) sequence, 
acquired in a single breath-hold (typically 12 seconds) - providing a series of 64 image 
slices centred on the L4 vertebra.  The imaging parameters were TR = 3.97 ms, TE = 
1.26 and 2.49 ms, section thickness 2mm, in-plane pixel resolution 165x320, 
bandwidth 1040 Hz/pixel, parallel imaging ‘iPAT’ factor 4, and a field-of-view up to 480 
mm.  The DIXON VIBE sequence was used to obtain ‘fat only’ and ‘water only’ images, 
as well as images with fat and water signals in/out of phase. 
The ‘fat only’ images were analysed using post-processing software ‘Analyze’ (Version 
12.0, Mayo Clinic, Rochester, MN, USA).  A global signal intensity threshold value was 
applied to the images in order to separate adipose tissue signals from the background 
and other tissues present. Manual segmentation methods were then used to remove 
other signals (e.g. bone marrow) that did not correspond to either visceral or 
subcutaneous adipose tissue.  Images were analysed on a slice-by-slice basis in this 
manner in order to derive two fat compartments – the sub-cutaneous adipose tissue 
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(SCAT) and visceral adipose tissue (VAT).  All volumes were analysed by a single 
observer (A.M) who was blinded to randomized therapy and sequence to minimise 
variation. 
For Reproducibility and Variability of Abdominal MRI: For Abdominal MRI: For 
abdominal adiposity, repeatability data were not derived specifically for this study 
cohort.  However, the methods used were identical to those reported by Marzetti et al 
(463) where the top of the L3 intervertebral disc and base of the L5 intervertebral disc 
were used as anatomical boundaries to determine MRI slice limits for the localised 
volume assessments of visceral adipose tissue (VAT) and subcutaneous adipose 
tissue (SCAT).  In the above work, the intra-observer test retest RMS coefficient of 
variation (CoV) was measured to be 3.47% for VAT and 1.17% for SCAT, and we are 
confident that similar figures would apply to the cohort studied in this work - since we 
used the same software and analysis methods 
5.3.7. Sample Size Calculations 
The study has been powered for an absolute change in LVM based on a previously 
published study. In this study of LVH regression using allopurinol in patients with IHD, 
it was found that allopurinol significantly reduced LVM by -5.2  5.8 grams compared 
to placebo -1.3  4.5 grams (P<0.007) (185). Based on power calculation from this 
LVH regression study, 29 participants were needed per group to detect a 5g change 
in LVM using CMRI, assuming a significance level of 5% (two-tailed, α=0.05) and a 
statistical power of 80%. We enrolled 34 patients per group to allow a 15% drop out 
rate.  
5.3.8. Statistical Analysis 
The primary analysis will be based on a between-group, modified intention-to-treat 
(mITT) principle, i.e. all participants who had baseline measurements and took at least 
one dose of study drug and will be analysed as part of the group to which they were 
randomized, using the outcome data collected at baseline and 12-13 months’ follow-
up. However, to provide a true estimate of the efficacy of intervention, a per-protocol 
analysis was also performed. Descriptive statistics in the form of means and standard 
deviations for continuous variables and percentages and denominators for categorical 
variables will be tabulated at baseline and for each visit.  
The comparison between intervention and placebo groups was compared using 
independent samples t tests for continuous variables and chi-square test for 
125 
 
 125 
dichotomous variables. Continuous variables with normal distribution are presented 
as mean (SD). Non-normally distributed data were presented as medians alongside 
their interquartile ranges (IQR). They subsequently underwent log transformation to 
achieve normality. Additionally, we performed a sensitivity analysis using analysis of 
covariance (ANCOVA) model in the per-protocol population to evaluate the robustness 
of treatment with change in LVMI, LVM and treatment as fixed effects, and age, sex 
and baseline values for LVMI/LMI, body weight, systolic blood pressure (SBP) as 
covariates. A p value <0.05 was considered significant. Data was analysed using 
SPSS 22.0 (IBM Corp, Armonk, NY, USA). Regarding missing data:  The extent of 
missing data will be examined and the reason for drop-out ascertained. Missing post-
baseline values will be imputed using the baseline observation carried forward (BCOF) 
approach. Given the relatively small sample size of this study, we regard the results 
of the between group inferential analyses as exploratory and hypothesis generating. 
All analyses will be conducted by the trial statistician blinded to group allocation, using 
R Software (version 3.3.2, R core development team) or SPSS 22.0 (IBM Corp, 
Armonk, NY, USA). 
5.3.9. Safety Checks 
All the study participants were informed of potential side effects at screening visit, 
before obtaining informed consent and this is also clearly stated in the patient 
information sheet. Participants were also asked for side effects or adverse events at 
all follow-up visits as well as during the telephone interviews and was documented in 
the participant’s case report form. The sponsor was informed of any serious adverse 
events. Safety blood tests (U&E’s & LFT’s) were performed at all study visits to 
regularly monitor liver function and renal function.  
5.3. Results 
5.3.1. Screened Participants 
A total of 187 participants were screened (Figure 12- study consort diagram) of which 
119 participants were excluded due to the following reasons: 
• 89 participants did not meet the echo criteria for LVH 
• 22 participants did not meet criteria for IR/Prediabetes 
• 05 participants did not meet criteria for BP 
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• 03 participants were excluded for other reasons (MRI contraindications (N=01), 
LV impairment (N=02) etc.  
5.3.2. Randomized Participants 
Of the 187 participants who were screened, 68 subjects (Figure 1) fulfilled all the study 
criteria and were randomly allocated to receive either metformin (N=34) or placebo 
(N=34).  5 patients were excluded from all study analysis prior to unblinding: no 
baseline MRI measurements due to claustrophobia (N=1); comorbidity - incidental 
finding of abdominal aortic aneurysm on MRI that required immediate medical 
attention prior to starting on study drug (N=1), withdrawn consent (N=1) and protocol 
breach (N=2; co-enrolment). Seven patients discontinued study medications:  
premature treatment discontinuation due to adverse events (N=5); lost to follow-up 
(N=1) and pre-existing co-morbidity (N=1) however, they were included in our mITT 
analysis. 63 patients in total completed the study (N=31 in metformin group; N=32 in 
placebo group) as per the study protocol and were included for analysis in the modified 
intention-to-treat arm of the study and 56 patients (N=27 in metformin group; N=29 in 
placebo group) in the per-protocol population.   
5.3.3. Baseline Characteristics of Study Population 
Baseline characteristics of study population are described in Table 7. The average 
age of participants was 65 years. The study population was predominantly male (75%) 
with slightly higher percentage of males in the metformin group (84% vs 66% in 
placebo, p=0.096). Both treatment arms were well balanced at baseline in regards to 
BMI, smoking status, BP, heart rate, FMD, pre-existing comorbidities, laboratory 
measurements and data on medication use. However, when compared to the placebo 
group, patients in the metformin group had somewhat higher fasting insulin resistance 
index, absolute LV mass measurements, weighed more, had more frequent positive 
exercise tolerance testing and use of calcium channel blockers, although these 
differences were not statistically significant.  As seen in Table 7, all the participants 
were on optimum medical therapy for CAD. 98% were on antiplatelet therapy (aspirin 
or clopidogrel), 91% on statins, 81% on beta-blockers whilst 88% were on ACE 
inhibitor/ARBs.  
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Table 7: Baseline characteristics of study population 
 
Variable All 
patients 
(n=63) 
Metformin 
(n=31) 
Placebo 
(n=32) 
P value 
Demographics  
Age, in years 64.6 ± 8.4 64.5 ± 8.9 64.6 ± 8.0 0.971 
Sex (% of males) 47(75) 26(84) 21(66) 0.096 
Ex-smokers, (%) 3 (5) 16(52) 17(53)  
0.993 Current smokers, (%) 8 (13) 4(13) 4(13) 
Alcohol consumption, 
(%) 
41(65) 19(61) 22(69) 0.430 
Weight,  Kgs 90.3 ± 
12.9 
93.3 ± 12.9 87.3 ± 12.3 0.074 
Body Mass Index, kg/m2  32.0 ± 3.5 32.2 ± 3.4 31.9 ± 3.6 0.419 
Systolic Blood Pressure, 
mmHg  
130.6 ± 
10.9 
130.8 ± 10.7 130.5 ± 11.2 0.903 
Diastolic Blood 
Pressure, mmHg  
75.8 ± 7.9 75.3 ± 8.0 76.4 ± 7.9 0.591 
Prediabetes, % 50 (79) 23(74) 27(84) 0.326 
Insulin Resistant, % 44(70) 25(81) 19(59) 0.096 
Prediabetes + Insulin 
Resistance, % 
32(51) 17(55) 15(47) 0.535 
Heart Rate, beats per 
minute  
57.7± 9.1 57.6 ± 9.9 57.8 ± 8.4 0.953 
 
MRI Study Assessments 
Absolute LVM, g 114.8 ± 
24.8 
120.7 ± 20.3 109.1 ± 27.6 0.064 
LVMI (height1.7 ) 47.3 ± 8.1 48.7 ± 6.5 46.0 ± 9.3 0.197 
Subcutaneous Adipose 
Tissue, cm3 
3332.7 ± 
1044.1 
3371.6 ± 
1037.0 
3301.6 ± 
1090.3 
0.897 
Visceral Adipose Tissue, 
cm3  
2422.6 ± 
878.5 
2407.1 ± 
881.7 
2441.8 ± 
892.2 
0.713 
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Flow Mediated Dilatation 
Response to 
Hyperaemia (%) 
5.3 ± 2.3 5.4 ± 2.4 5.1 ± 2.1 0.690 
Response to GTN (%) 14.8 ± 5.4 15.2 ± 4.8 14.3 ± 6 0.540 
Past Medical History 
Myocardial infarction, 
(%) 
32(51) 15 (48) 17(53) 0.803 
Elective PCI, (%) 15 (24) 5(16) 10(31) 0.237 
Positive ETT in those 
without 
angiogram/previous MI, 
(%) 
11 (18) 7(23) 4(13) 0.337 
CABG, (%) 8(13) 5(16) 3(9) 0.421 
Hypertension, (%) 31 (49) 15(48) 16(50) 0.898 
Dyslipidaemia, (%) 58(92) 28 (90) 30 (94) 0.615 
 
Medication 
ACE inhibitors, (%) 44 (70) 24(77) 20 (63) 0.197 
ARB, (%) 11 (18) 4(13) 7(22) 0.348 
Beta-blockers, (%) 51 (81) 24 (77) 27 (84) 0.482 
Calcium-channel 
blocker, (%) 
14(22) 9(29) 5(16) 0.508 
Statins, (%) 57 (91) 30(97) 27(84) 0.094 
Anti-platelet drugs, (%) 62 (98) 30 (97) 32 (100) 0.306 
Laboratory measurements 
Creatinine, μmol/L 76.2 ±14.0 78.3 ± 12.1 73.4 ± 15.1 0.504 
Urea, mmol/L 5.9 ± 1.2 5.9 ± 0.9 5.7 ± 1.2 0.743 
eGFR,mL/min, MDRD  91.7 ± 
17.6 
92.0 ± 14.8 91.0 ± 20.3 0.580 
Fasting Insulin, mU/L 17.8 ±10.0 19.5 ± 9.6 15.2 ± 10.0 0.220 
Fasting glucose, mmol/L  5.5 ± 0.6 5.5 ± 0.5 5.4 ± 0.5 0.856 
FIRI 3.8 ± 2.1 4.2 ± 2.0 3.3 ± 2.2 0.263 
HbA1c, mmol/mol  40.2 ± 2.5 39.9 ± 2.6 40.5 ± 2.5 0.279 
129 
 
 129 
NTproBNP, 
pg/ml(median IQR) 
877.2 
(1166.4) 
957.8(1029.1) 796.5(1247.0) 0.490 
IL-6 pg/ml, (median IQR) 0.6 (0.39) 0.6(0.4) 0.6 (0.4) 0.980 
Soluble ST2, 
ng/ml(median IQR) 
18.1 (11.3) 17.2(11.5) 18.9(11.9) 0.440 
TBARs,uM  3.0 ±1.2 2.9 ±1.5 3.1 ±1.2 0.520 
 
Values are mean ± SD, n (%), or median (interquartile range). 
Abbreviations:  ACE inhibitor = Angiotensin-converting enzyme inhibitor; ARB = 
Angiotensin II receptor blockers; CABG = coronary artery bypass grafting;  ETT =  
Exercise tolerance test;  eGFR =  Estimated glomerular filtration rate;  FIRI = fasting 
insulin resistance index;  GTN = Glyceryl trinitrate; HbA1c = Glycated haemoglobin ; 
IL-6 = Interleukin 6;  LVM = Left ventricular mass;  LVMI =  Left ventricular mass index;  
MI = Myocardial Infarction;  MDRD =  Modification of Diet in Renal Disease ;  
NTproBNP=   N-terminal prohormone of brain natriuretic peptide;  PCI = Percutaneous  
coronary intervention;  TBAR’s = Thiobarbituric acid reactive substance
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5.3.4. Study Primary End Points 
5.3.4.1. Effect of Metformin on LVMI assessed by CMR 
In the mITT analysis, metformin treatment significantly reduced LVMI (change in LVMI: 
Metformin group -2.71 ± 2.31 g/m1.7 vs. placebo group -1.34 ± 2.65 g/m1.7; p=0.033), 
leading to an absolute mean difference of -1.37 (95% confidence interval: - 2.63 to        
-0.12).  The reduction on LVMI was even greater in the per-protocol population 
(change in LVMI: metformin group -3.12 ± 1.95 g/m1.7 vs. placebo group -1.29 ± 2.67 
g/m1.7; p=0.005) (Table 8; Figure 22). Additional sensitivity analysis for the mITT and 
per-protocol population conducted using a one-way ANCOVA to compare the 
effectiveness of treatment, adjusting for relevant confounders showed that the change 
in LVMI observed in metformin group was higher compared to placebo: (a) for mITT 
arm - estimated marginal means: metformin group -2.8 g/m1.7 [95% confidence 
interval, - 3.8, - 1.9] vs placebo group -1.2 g/m1.7 [95% confidence interval, -2.1, -0.3] 
and (b) per-protocol population - estimated marginal means: metformin group -3.3 
g/m1.7 [95% confidence interval, - 4.2, - 2.3] vs placebo group -1.2 g/m1.7 [95% 
confidence interval, -2.1, -0.23] and remained statistically significant   ( P=0.019 for 
mITT and P= 0.004 for per-protocol analysis), suggesting that this finding was robust 
and not driven by potential relevant baseline characteristics. 
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Table 8. CMR changes Seen after 12 months Metformin Treatment 
Outcomes Modified Intention – to – Treat Analysis Per-Protocol Analysis 
Metformin Placebo Difference* 
(95% CI) 
P Value Metformin Placebo Difference* 
(95% CI) 
P Value 
Primary Outcome 
LVMI, g/m1.7 - 2.71 ± 2.31 -1.34 ± 2.66 -1.37(-2.63 to - 0.12) 0.033 - 3.12 ± 1.95 -1.29 ± 2.67 -1.83 ( - 3.1 to - 0.57) 0.005 
Key Secondary Outcomes 
LVM, g - 6.53 ± 5.59 - 3.23 ± 6.32 - 3.3(-6.32 to - 0.29) 0.032 -7.53 ± 4.66 -3.13 ± 6.36 -4.4 (-7.4 to -1.4) 0.005 
SCAT,% - 6.74 ± 11.19 - 0.27 ± 7.21 - 6.47(-12.06 to - 0.89) 0.024 - 8.84 ± 10.0 - 0.28 ±7.39 -8.56 (-13.95 to -3.16) 0.003 
Body 
Weight, Kgs 
- 3.61 ± 4.88 -0.01 ± 3.63 - 3.6 (- 5.77 to -1.44) 0.001 - 4.22 ± 4.9 - 0.04 ±3.81 - 4.18(-6.52 to - 1.83) 0.001 
TBARs, uM - 0.26 ± 1.04 0.33 ± 1.14 -0.59 (-1.16 to -0.03) 0.040 -0.32 ±1.1 0.36 ± 1.15 - 0.68 (-1.29 to -0.07) 0.030 
Other Outcomes 
SBP, mmHg - 4.81 ± 15.57 4.31 ± 15.26 -9.12 (-16.89 to -1.35) 0.022 -4.56 ± 15.82 4.28 ± 15.9 -8.83 (-17.34 to -0.33) 0.042 
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P-values in bold indicate P<0.05; * Absolute mean Difference between groups. All values expressed in mean ± SD unless stated.  
Abbreviations:  LVMI, Left Ventricular Mass Index; LVM, Left Ventricular Mass; SBP: Systolic Blood Pressure; SCAT, Sub-
cutaneous Adipose Tissue; TBARs, Thiobarbituric acid reactive substances. 
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 Graph (a) illustrates the effect of 12 months of metformin or placebo treatment on the 
LVMI. Metformin significantly reduced LVMI after 12 months of therapy compared with 
placebo (p = 0.033 for mITT and p=0.005 for per-protocol analysis). And graph (b) 
illustrates the effect of 12 months of metformin or placebo treatment on the LVM. 
Metformin significantly reduced LVM after 12 months of therapy compared with 
placebo (p = 0.032 for mITT and p=0.005 for per-protocol analysis. 
 
Figure 22: Effect of Metformin on LVMI & LVM 
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5.3.5. Study Secondary End Points 
5.3.5.1. Effect of Metformin on LV Mass and Volumes assessed by CMR 
Metformin treatment significantly reduced LVM (change in LVM: metformin group - 
6.53 ± 5.59g vs. placebo group -3.23 ± 6.32g; p = 0.032) in the mITT analysis, leading 
to an absolute mean difference of -3.3 (95% confidence interval: -6.32 to -0.29) (Table 
8, Figure 22).  The treatment effect on LVM was greater when analysed using the per-
protocol population with a highly significant reduction in LVM (change in LVM: 
Metformin group -7.53 ± 4.66g vs. placebo group -3.13 ± 6.36g; p=0.005). 
There were no significant differences between treatment groups at 12 months for other 
cardiac secondary endpoints such as Left Ventricular Ejection Fraction (LVEF), Left 
Ventricular End Diastolic Volume (LVEDV), Left Ventricular End Systolic Volume 
(LVESV) and Left Ventricular Stroke Volume (LVSV) (Table 9).   
 
5.3.5.2. Effect of Metformin on Abdominal Obesity assessed by MRI 
Abdominal MRI images were obtained from 61 patients but 13 patients were excluded 
from this analysis due to inadequate image quality (anatomical mismatch – anatomical 
area not fully consistent between baseline and follow-up scan). Hence, 48 and 44 
patients were included in the mITT arm and per-protocol population analysis, 
respectively. Subcutaneous adipose tissue (SCAT) and visceral abdominal tissue 
(VAT) areas were quantified and there was no statistically significant difference 
between treatment groups at baseline. Treatment with metformin significantly reduced 
SCAT (mITT: % change in SCAT: Metformin group -6.74 ± 11.19 vs. placebo group -
0.27 ± 7.21; p=0.024; per-protocol: Metformin group -8.83 ± 10 vs. placebo group -
0.284 ± 7.39; p=0.003) (Table 8) whereas metformin treatment did not have a 
significant effect on VAT (Table 9). 
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Table 9: Changes after 12 months of metformin treatment on other secondary outcomes 
 
Outcomes Modified Intention – to – Treat Analysis Per-Protocol Analysis 
Metformin Placebo Difference* 
(95% CI) 
P Value Metformin Placebo Difference* 
(95% CI) 
P Value 
Other Secondary Outcomes 
LVEF,% - 3.58  ± 7.98 - 3.53 ± 6.58 -0.05 (-3.73 to 3.63) 0.980 - 4.11 ± 8.39 - 3.90 ± 
6.81 
- 0.21 (- 4.30 to 3.88) 0.918 
LVEDV, mls 2.18 ± 16.91 7.05 ± 10.53 - 4.87 (-11.95 to 2.20) 0.174 0.77 ± 16.24 6.68 ± 9.86 - 5.91 (-13.1 to 1.23) 0.103 
LVESV, mls 6.53 ± 13.66 7.34 ± 9.44 - 0.81 (-6.71 to 5.10) 0.784 6.97 ± 14.31 7.67 ± 9.68 -0.70 (-7.21 to  5.80) 0.829 
LVSV, mls - 4.33 ± 15.49 - 0.29 ± 12.50 - 4.04 (-11.12 to 3.05) 0.259 -6.17 ± 15.14 - 0.99 ±12.6 - 5.20 (-12.63 to 2.27) 0.172 
VAT,% 0.48 ± 15.92 -1.38 ± 15.37 1.86 (-7.28 to 11.0) 0.684 -1.07 ± 16.24 -0.51±15.18 - 0.56(-10.16 to  9.03) 0.907 
FMD 
response to 
hyperemia, 
% 
0.96 ± 1.10 1.11 ± 1.15 -0.15 (-0.74 to 0.45) 0.618 0.87 ± 1.15 1.27 ± 1.17 - 0.39 (-1.10 to 0.30) 0.257 
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FMD 
response to 
GTN, % 
0.004 ± 4.24 1.30 ± 2.51 -1.30 (-3.28 to 0.69) 0.195 -0.46 ± 4.06 1.3 ± 2.56 -1.77 ( -3.78 to 0.25) 0.085 
IL-6, pg/ml, 
(median 
IQR) 
0.44 ± 1.86 0.43 ±  1.46 0.02(- 0.85 to 0.88) 0.973 0.49 ± 2 0.43 ±  1.48 0.06(- 0.88 to  1.01) 0.895 
Soluble 
ST2, ng/ml, 
0.97 ± 4.65 - 0.18 ± 3.74 1.15 (-1.04 to 3.33) 0.297 1.2 ± 4.93 -0.19 ± 3.8 1.39 (-0.98 to  3.76) 0.244 
NTproBNP, 
pg/ml, 
(median 
IQR) 
308.71 ± 
1389.84 
98.10 ± 
474.55 
210.62 ( -326.11 to 
747.34) 
0.435 375.9 ± 
1478.62 
70.43 ± 
457.67 
305.43 (- 273.46 to  
884.31) 
0.295 
HbA1c, 
mmol/mol 
-1.48 ± 2.29 - 0.63 ± 2.13 - 0.86 (-1.98 to  0.26) 0.129 -1.52 ± 2.46 - 0.69 ±2.23 - 0.83 (- 2.09 to  0.43) 0.192 
FIRI - 0.74 ± 2.26 0.40 ± 3.33 -1.14 (-2.59 to 0.31) 0.120 -0.87 ± 2.37 0.43 ± 3.45 -1.31 (- 2.91 to  0.29) 0.106 
Fasting 
Insulin, 
mU/L 
-3.03 ± 10.51 0.67 ± 12.45 -3.70 (- 9.6 to  2.2) 0.214 -3.59 ± 11.07 0.72 ± 12.9 - 4.31(-10.83 to  2.21) 0.189 
137 
 
 137 
FBG, 
mmol/L 
- 0.20 ± 0.54 0.08 ± 0.72 -0.28 (- 0.6 to  0.04) 0.087 - 0.25 ± 0.56 0.17± 0.61 -0.43 (- 0.74 to - 0.11) 0.009 
 
 
Other Outcomes 
DBP, mmHg -2.58 ± 7.72 - 0.69 ± 8.95 -1.89 (-6.11 to  2.33) 0.373 -2.92 ± 7.7 - 0.86 ± 
9.39 
- 2.06 (- 6.69 to  2.56) 0.375 
P-values in bold indicate P<0.05; * Absolute mean Difference between groups. All values expressed in mean ± SD unless stated.  
Abbreviations:  DBP, Diastolic Blood Pressure; FBG, fasting blood glucose ; FIRI, fasting insulin resistance index; FMD, Flow 
Mediated Dilatation; GTN, glyceryl trinitrate; HbA1c, glycated haemoglobin A1c; IL-6, interleukin 6; LVEF, Left Ventricular Ejection 
Fraction; LVEDV, Left Ventricular End Diastolic Volume; LVESV, Left Ventricular End Systolic Volume; LVSV, Left Ventricular 
Stroke Volume; NT-proBNP, N-terminal pro B-type natriuretic peptide; SBP: Systolic Blood Pressure ; SCAT, Sub-cutaneous 
Adipose Tissue; TBARs, Thiobarbituric acid reactive substances ; VAT, Visceral Adipose Tissue.
138 
 
 138 
5.3.5.3. Effect of Metformin on Blood Biomarkers 
At baseline, there were no significant differences in the concentration of biomarkers 
such as IL-6, Soluble ST2, NTproBNP and TBARs. No significant differences were 
identified in changes in concentration of NTproBNP, soluble ST2 and IL-6 after 12 
months of metformin treatment (Table 9), however, metformin treatment significantly 
reduced the concentration of TBARs; a by-product of lipid peroxidation and a marker 
of oxidative stress (change in TBARs: metformin group -0.3 ± 1 uM vs. placebo group 
0.3 ± 1.1 uM; p=0.04) in the mITT analysis (Table 8). 
 
5.3.5.4. Effect of Metformin on Glycaemic Index 
At baseline, patients in the metformin group had a slightly higher level of FIRI and 
fasting insulin. There were no significant metformin treatment induced changes in 
glycaemic parameters such as fasting plasma glucose, fasting insulin, HbA1c or FIRI 
but there was a statistically significant reduction in fasting glucose (p=0.009) when 
analysed in the per-protocol population (Table 9). 
 
5.3.5.5. Effect of Metformin on Endothelial Function assessed by FMD 
We did not observe any effect of metformin treatment on FMD in both mITT and per-
protocol analysis (mITT: % change in FMD response to hyperaemia: metformin group 
0.964 ± 1.1 vs placebo group 1.11 ± 1.15, P= 0.618; % change in FMD response to 
GTN: metformin group 0.003 ± 4.24 vs placebo group 1.3 ± 2.51, p = 0.195 ; per-
protocol analysis: % change in FMD response to hyperemia: metformin group 0.86 ± 
1.14 vs placebo group 1.27 ± 1.17, P= 0.257; % change in FMD response to GTN: 
metformin group -0.46 ± 4.06. vs placebo group 1.3 ± 2.56, p = 0.085) (Table 9)
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5.3.6. Effect of Metformin on BP and Weight 
At baseline, SBP and DBP were well balanced between the two arms of the study. But 
the participants in the metformin arm weighed more compared to placebo, but this was 
non-significant (0.07). Compared with placebo, metformin treatment resulted in a 
significant reduction of body weight and SBP in the modified intention-to-treat and per-
protocol analysis arm of the study (Figure 23 & Table 8), but no changes in the DBP. 
These findings on office SBP and weight reduction were corroborated by a subgroup 
analysis, which showed that reduction of office SBP, and body weight was progressive 
over the entire duration of study (Figure 24).
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Graph (a) illustrates the effect of 12 months of metformin or placebo treatment on body 
weight. Metformin significantly reduced body weight after 12 months of therapy 
compared with placebo (p = 0.001 for mITT and p=0.001 for per-protocol analysis). 
Graph (b) illustrates the effect of 12 months of metformin or placebo treatment on 
systolic blood pressure. Metformin significantly reduced systolic blood pressure after 
12 months of therapy compared with placebo (p = 0.022 for mITT and p=0.042 for per-
protocol analysis. 
Figure 23: Effect of Metformin on Body Weight and Systolic Blood Pressure 
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This graph illustrates the effect of 12 months of metformin or placebo treatment on 
reduction of office SBP and body weight was progressive over the entire duration of 
study.  
Figure 24: Effect of Metformin on Body Weight and Systolic Blood Pressure over 
the Entire Duration of the Study 
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5.3.7. Safety & Tolerability of Metformin 
5.3.7.1. Adverse Events 
Study medication was generally well tolerated with no reported cases of lactic acidosis 
or renal impairment during follow-up. There were 34 AEs and 11 SAEs recorded for 
the study cohort; 19 AEs and 6 SAEs in the metformin group (N=31) and 15 AEs and 
4 SAEs in the placebo group (N=32). Majority of patients in the metformin group 
experienced gastrointestinal disorders (diarrhoea = 47%; flatulence =26%; abdominal 
discomfort = 5%) compared to placebo group. Although majority of these AE’s were 
transient and were mild to moderate in severity, study medication was prematurely 
terminated for five patients (Metformin group= 4, due to severe diarrhoea or abdominal 
discomfort; placebo group = 1, developed T2DM). Dose was reduced to 1g daily for 4 
patients in the metformin group who could not tolerate the higher dose of study 
medication due to diarrhoea or abdominal discomfort. The mean tolerable dose of 
metformin was 1610 mg per day in this study.  
 
5.3.8. Important Medications Changes During Study Period 
During the study period, a small number of participants (metformin group n=01, 
placebo group, n=01) had changes made to their medication due to clinical reasons. 
One participant in the metformin group was commenced on an anticoagulant 
(following a cerebral infarction) whilst a participant in the placebo group had a dose 
up-titration for anti-hypertensives.  
 
 
 
 
 
 
 
 
 
143 
 
 143 
CHAPTER 6: Discussion 
In this study, we present findings from a double-blind, placebo controlled RCT on 
metformin’s effect on LVH in patients with CAD and without T2DM. To the best of our 
knowledge, this is the first randomized controlled trial investigating the effect of 
metformin on LVH in non-diabetic CAD patients, who are normotensive identified to 
have IR and/or pre-diabetes. The main finding of our study is that a modified-release 
2000 mg daily dose of metformin treatment significantly reduced LVMI & LVM in 
patients without T2DM who have CAD, LVH and IR and/or pre-diabetes who were 
optimally treated with evidence-based therapy. We also found that metformin reduced 
measures of obesity, reduced SBP and oxidative stress compared to placebo. All 
these findings were consistent in both mITT and per-protocol analysis, suggesting a 
robust beneficial cardio-protective effect of metformin in this group of patients.  In this 
section, I will discuss the findings of this study in detail in the context of previous clinical 
and scientific evidences, explore plausible mechanisms to explain and corroborate the 
study findings, highlight the limitations of this study and conclude by suggesting the 
need for future studies to address the current clinical equipoise for metformin in the 
context of CVD.  
6.1. Effect of Metformin on LVMI and LVM 
The primary finding of our study is that a 2000 mg daily dose of metformin treatment 
significantly reduced LVMI & LVM in patients without T2DM who have CAD, LVH and 
IR and/or pre-diabetes who were optimally treated with evidence-based therapy. Our 
findings are consistent with experimental animal studies and human studies showing 
that metformin can regress LVH. Metformin stimulates AMPK and transgenic mice 
lacking a functional subunit of AMPK are well known to develop LVH and ECG 
abnormalities (464).  Zhang et al found that AMPK –alpha2 deficiency exacerbated 
pressure-overload-induced left ventricular hypertrophy in mice(465).   Importantly, in 
different animal models of hypertrophy, metformin has been shown to reduce cardiac 
hypertrophy.  Metformin has been shown to inhibit in-vitro cardiac myocyte 
hypertrophy induced by phenylephrine (466).    Metformin has also been shown to 
have an inhibitory effect on cardiac hypertrophy in vivo in both isoprenaline-induced 
cardiac hypertrophy (467) and in pressure over-load induced cardiac hypertrophy 
(468,469).  
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There is only limited clinical data on effect of metformin on LVH regression and the 
available data is somewhat mixed. In a subgroup analysis of the Lindavista II study 
(echocardiographic study), Velazquez et .al (2016) showed that metformin reduced 
LVM and relative wall thickness in patients with metabolic syndrome (470). 
Conversely, in a recent network meta-analysis (2018) of RCT’s on effects of oral 
antidiabetic drugs on LVM in patients with T2DM, the authors reported minimal 
beneficial effects of metformin on LVM (surface under the cumulative ranking curve = 
45.2, Rank 4) (441). However, the results from this meta-analysis should be 
interpreted with caution when generalizing the findings. Firstly, there was no RCT’s 
that compared the effect of metformin with a placebo, all of the comparisons were with 
other oral diabetic drugs. Secondly, the total number of trials that investigated the 
effect of metformin on LVM was very small (N=3) (Figure 25), with a shorter treatment 
duration (< 6 months).Thirdly, among the total RCTs studied (N=11) in this network 
meta-analysis, a greater discrepancy was noted between each study in terms of LVM 
evaluation method (echocardiography and MRI) and importantly, none of the 
randomised subjects had a prior CVD in the metformin arm of the study. Finally, the 
authors report that the quality of RCTs included in this network meta-analysis is low, 
hence a properly designed double-blind RCTs are warranted to provide a conclusive 
evidence of effect of diabetic drugs on LVM. Furthermore, in an echocardiographic 
sub-study of the GIPS III trial have reported no statistically different changes in LVM 
or LVMI after 4 months 1g/day metformin treatment (440). However, there was a trend 
towards LVMI and LVM reduction in the metformin arm of the study after 4 months 
treatment (change between randomisation and final visit: LVMI = 2.7g/m2 (-16.0, 6.9) 
and LVM = -0.9 g (-31.1, 13.7), although this was not statistically significant (P=0.41 
for LVMI and P=0.46 for LVM). It’s noteworthy that the dosage used in this study and 
the duration of treatment was much less than our study. Additionally, majority of these 
studies used echocardiography derived data and have inherent limitations. In our 
study, we used the gold standard “MRI” to assess cardiac parameters (mass & 
volumes) and to quantify abdominal obesity.  
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Figure 25: Network map of clinical trials on oral antidiabetic drugs or placebo in 
patients with type 2 diabetes (441) . Lines connect the interventions that have been 
studied in head-to-head comparisons in eligible RCTs. The width of the lines 
represents the total number of RCTs for each pairwise comparison. The size of every 
node is proportional to the number of randomized participants 
 
6.2. Effect of Metformin on Other LV Volumes 
In this study, there were no significant differences between treatment groups at 12 
months for other cardiac secondary endpoints such as LVEF, LVEDV, LVESV and 
LVSV. Our results did not confirm with the effects reported in experimental animal 
studies.  In animal studies, metformin was associated with improved LV function. 
Metformin has been shown to reduce infarct size of 22% and a relative improvement 
of LVEF of 52% as compared with placebo, in non-diabetic rat models (471). However, 
data from clinical studies are not consistent with the animal studies. In the GIPS III 
trial, metformin use didn’t improve LVEF in patients without diabetes presenting with 
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STEMI and undergoing PCI (381). However the data reported of the protective effects 
of metformin on LV function in animal models are derived from animals undergoing 
occlusion of the left main or the proximal left anterior descending coronary artery, 
resulting in a larger area of risk (381). This may have influenced our findings from this 
study. The cardioprotective effects of metformin on LV function and myocardial infarct 
size are proven when metformin was administered prior to or during ischemia-
reperfusion in experimental animal studies (472). Our findings on other cardiac 
parameters such as LVEDV and LVESV are also consistent with the anciliary analyses 
from the GIPS III sub-study aimed at investigating the effects of metformin on 
lipoprotein subtractions, which reported no beneficial effect of metformin on LVEDV 
and LVESV (473). However, in a very recent (2018) systematic review and meta-
analysis of no-diabetic patients with STEMI, the authors reported that compared to 
control intervention, metformin treatment significantly reduced LVEF, and improved 
LVEDV as well as LVESV (474). However, the results from this meta-analysis should 
be interpreted with caution. Their analysis was only based on 4 RCTs, hence more 
RCTs with large sample size is required to explore this research question.  
 
6.3. Effect of Metformin on Endothelial Function Assessed by FMD 
We did not find any changes to vascular function (FMD) in this group of patients. It is 
noteworthy that the effect of metformin on endothelial function as assessed by FMD 
has not been consistent. Metformin’s effect on endothelial function is somewhat 
mixed. There are some evidences to show that metformin improves endothelial 
function. Mather et al (2001) in an placebo controlled study of diet-treated T2DM 
patients (N=44) reported that metformin treated improved endothelial function 
assessed by forearm plethysmography during an infusion of acetylcholine (404). 
Additionally, the Hyperinsulinemia the Outcome of its Metabolic Effects (HOME) trial 
also reported an improvement in endothelial function in metformin treated T2DM 
patients compared to placebo (405). Furthermore, there is extensive pre-clinical and 
clinical literature that have demonstrated a beneficial effects of metformin on vascular 
function (406). There is also, however, conflicting evidence demonstrating no effect 
on endothelial function with metformin. A double blind RCT of T2DM patients, reported 
no effect of metformin on endothelial function (407). In another randomised study in 
patients with T2DM, metformin didn’t improve endothelial function (408). In our study, 
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most of the patients were on statins (91%) and was well balanced between two 
treatment arms. Previous studies have shown the ability of statins to improve anti-
inflammatory, anti-thrombotic and endothelial functions along with their lipid-
decreasing effects (475). All the subjects in our study were taking statins, which might 
have limited the ability of metformin to show a beneficial effect on endothelial function.   
Therefore, larger studies addressing the existing limitations are required to investigate 
the beneficial effects of metformin on vascular function.  
 
6.4. Effect of Metformin on Glycaemic Indexes 
In this study, metformin treatment reduced fasting plasma glucose (in the per protocol 
analysis) but only resulted in non-significant marginal reductions in FIRI and HbA1c. 
Previous studies on metformin in non-diabetic individuals also reported no or modest 
effects on HbA1c (380,381). The significant reduction of fasting plasma glucose in our 
study is consistent with the findings that metformin suppresses endogenous glucose 
production, the main determinant of fasting plasma glucose concentrations (476). 
Additionally, in the Diabetes Prevention Program, the effect of metformin on HbA1c in 
prediabetic subjects were modest comparing to lifestyle intervention (477). To further 
corroborate these findings, a recent study have demonstrated that the beneficial 
effects on metformin on glycemic control was predominantly seen in T2DM patients 
who have HbA1c values above 6.7% (478). In our study, the mean HbA1c 
concentrations was 5.8% (40 mmol/mol) for all patients and was well balanced 
between two treatment arms.  
 
6.5. Effect of Metformin on Body Weight & Abdominal Obesity. 
In our study, metformin therapy reduced body weight by approximately 4 kgs and 
reduced MRI measured sub-cutaneous adipose tissue (SCAT) by 8.8%. Our results 
are in keeping with the findings of different studies that demonstrated metformin’s 
beneficial effects on weight in T2DM subjects and the CAMERA study involving non-
diabetic individuals, where metformin significantly reduced all measures of adiposity 
(body weight, body fat, BMI, waist, circumference) in non-diabetic patients with CAD, 
with a mean weight loss of 3.2 kgs in metformin group (380,398,477). In our study, we 
only observed a significant effect of metformin on SCAT and not on visceral adipose 
tissue (VAT). Our findings on the effect of metformin on SCAT is consistent with the 
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findings from another clinical study which showed beneficial effect on metformin on 
SCAT in a 6-month crossover study compared the effects of metformin 2000 mg/day 
and placebo in 28 obese, insulin-resistant young adolescents (479). The effect of 
metformin on VAT in non-diabetic individuals has not been well studied before. In 
T2DM patients, metformin has been reported to reduce VAT although this is not a 
consistent finding (394,480). Hence, more studies are needed to investigate the 
impact of metformin therapy on abdominal obesity, especially on endogenous fat 
depots.   
 
6.6. Effect of Metformin on Oxidative Stress 
Several lines of evidences have shown that oxidative stress mediates cardiac 
hypertrophy (83,481,482). Additionally, experimental and human studies have shown 
the efficacy of metformin to reduce oxidative stress (483,484). In this study, metformin 
reduced oxidative stress as observed by the reduction of TBARs, a biomarker of 
oxidative stress (485). The ways by which metformin could reduce oxidative stress are 
manifold. Firstly, metformin could engage with ROS directly in vitro. Metformin could 
directly scavenge ROS or indirectly by modulating the intracellular production of 
superoxide anion, although the effect was rather weak even at peak concentrations 
(486). Secondly, metformin is also capable in reducing the intracellular ROS 
production by either by reducing NAD(P)H, or to a lesser extent by 
decreasing respiratory chain reactions in mitochondria (487). Thirdly, metformin could 
exert its protective effects in part via modulating serum insulin concentrations. In an 
observational study of subjects with T2DM, subjects taking insulin at elevated doses 
had higher levels of oxidative stress compared with those taking both oral agents and 
insulin; indicating hyperinsulinemia might exaggerate oxidative stress (488). In concert 
with their findings, we also observed marginal reduction in serum insulin concentration 
in our cohort, although this was not statistically significant. However, this study was 
not powered to assess for changes in glycemic indices including serum insulin 
concentrations.  Finally, due to the guanidine structure of metformin, metformin is able 
to react with α-dicarbonyls. In a clinical study of T2DM patients metformin treatment 
reduced methylglyoxal ( an essential AGE with α-dicarbonyl structure) in a dose-
dependent manner (489) 
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6.7. Effect of Metformin on BP 
In this study, metformin treatment significantly reduced SBP by 4.6 mmHg. Our 
findings are consistent with animal and few human studies. In spontaneously 
hypertensive rat models, metformin treatment resulted in dose-dependent reversible 
reduction in mean arterial pressure, heart rate and efferent renal sympathetic activity 
(490). However, effect of metformin on BP is not consistent in human studies. In 
hypertensive, obese, non-diabetic subjects, metformin treatment resulted in a slight 
BP lowering effect (491,492). It is noteworthy that these findings were not consistent 
in more recent studies, in both diabetic and non-diabetic population (412). In a  recent 
pooled meta-analysis of randomized controlled trials of metformin on BP in patients 
without T2DM reported that metformin can significantly lower SBP, especially in 
patients with impaired glucose tolerance or obesity (BMI≥30 kg/m^2), with a mean 
reduction of 5 mmHg and 3mmHg, respectively (403). The magnitude of BP reduction 
was similar in our study with a reduction of SBP (4.6mmHg) in metformin group. 
Therefore, the overall balance of evidence suggest that metformin seem to have a 
beneficial effect on SBP, more relevant to patients with obesity and/or nondiabetic 
hyperglycemia, perhaps secondary to the metformin-related body weight reduction.  
 
6.8. Plausible Mechanisms Why Metformin Reduced LVM 
There are plausible mechanisms for why metformin produce LVH regression in our 
study (Figure 26). Firstly, metformin could mediate this through its insulin sensitizing 
properties (458). IR is thought to contribute to changes in cardiac tissue seen in LVH 
(493). In this study, metformin treatment reduced fasting blood glucose but only 
resulted in non-significant marginal reductions in FIRI and HbA1c. A second plausible 
mechanism for the LVH regression may be the metformin induced reduction in body 
weight. In our study, metformin therapy reduced body weight by approximately 4 kgs 
and reduced MRI measured SCAT by 8.8%. Our results are in keeping with the 
findings of the other metformin that showed a significantly reduction in measures of 
obesity with metformin treatment (380,398,477). A third consideration is metformin’s 
ability in reducing BP that could cause LVH regression. In our study, we observed a 
significant reduction of SBP in the metformin treatment arm and this finding is 
consistent with a  meta-analysis that reported metformin can significantly lower SBP, 
especially in patients with impaired glucose tolerance or obesity (BMI≥30 kg/m^2), with 
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a mean reduction of 5 mmHg and 3mmHg, respectively (403). The magnitude of BP 
reduction was similar in our study with a reduction of SBP (4.6mmHg) in metformin 
group. Fourthly, oxidative stress has been pathophysiologically linked to LVH and in 
our study metformin reduced oxidative stress as observed by the reduction of TBARs, 
a biomarker of oxidative stress (404,482,485). Our findings are in keeping with the 
study by Esteghamati et.al that reported that metformin is more effective in reducing 
oxidative stress compared with lifestyle modification alone (484). Finally, as suggested 
by previous studies with animal models of LVH (16-19), it is plausible that activation 
of AMPK by metformin (15) could have played a role in the regression of LVH. 
However, this remains purely speculative and cannot be directly inferred from this 
clinical study. 
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Figure 26 - Plausible mechanisms by which metformin regressed LVM
152 
 
 152 
6.9. Clinical Perspective 
6.9.1. What is known? 
• Observational studies have repeatedly shown a benefit of metformin in 
reducing incidence of cardiovascular events in patients with type 2 diabetes 
mellitus. However, the exact mechanism by which metformin exerts its 
cardioprotective effect is unclear. 
• Preclinical studies have shown that metformin has a beneficial effect on left 
ventricular function, cardiac remodelling and infarct size in nondiabetic animal 
models of MI. 
• However, the effect of metformin on surrogate markers for cardiovascular 
prognosis in non-diabetic people is unknown. 
 
6.9.2. What is new? 
• This is the first double blind, randomized, placebo-controlled trial evaluating the 
effect of metformin on left ventricular hypertrophy (LVH), a strong surrogate 
marker of cardiovascular outcomes, in non-diabetic patients with CAD who are 
insulin resistant and/or have prediabetes. 
• 2g daily dose of metformin treatment for 12 months regressed LVH assessed 
by magnetic resonance imaging; reduced SBP, body weight and oxidative 
stress in insulin resistant and/or prediabetic patients with CAD. 
 
6.10. Study Strengths and Limitations  
Firstly, this is a single centre study with relatively small number of patients. However, 
this trial is the largest prospective, adequately powered RCT conducted to date, 
investigating the efficacy of metformin to regress LVH. Secondly, the study was 
statistically powered only for a single outcome and not statistically powered to detect 
changes in other study secondary end points. Therefore, inferential between group 
comparisons for these secondary endpoints are likely to be exploratory rather than 
definitive. Thirdly, our study was limited to those with CAD and does not address LVH 
in those without CAD. Fourthly, in this study we only used one biomarker to measure 
oxidative stress. We recognise the importance to use more than one criterion to 
evaluate oxidative stress, as  there may be methodological bias associated with 
different biomarkers for oxidative stress (494). Nevertheless, TBARs has been shown 
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as a promising biomarker with prognostic implications, particularly in patients with 
CAD (485). Fifthly, our patient cohort with dysglycemia have either IR or prediabetes 
or both. We recognise that IR and pre-diabetes may represent different sub-set of 
populations of patients. Importantly, there was no difference in the proportion of these 
dysglycaemic states between the two groups.  
In this study, only 25% of the recruited study participants were female. Sex and gender 
differences in CVD pathophysiology, clinical presentation, and outcomes have been 
described in literature, as have differences in drug safety and efficacy (495). Although 
women participation in clinical trials have improved over the past several decades,  a 
recent study by Scott et al (2018) reported that the participation to prevalence ratio of 
women fell below very minimal  for trials in CHF and CAD (495). Importantly, this 
under- representation of women in clinical trials have clinical implications. Adequate 
participation of women in CV trials is vital in examination of possible gender 
differences in treatment response. Additionally, majority of CV evidences are 
extrapolated from studies with predominantly male participants.  Furthermore, there 
are gender differences in the presentation and progression of CV disease due to the 
differences in biological, hormonal and psychosocial factors (496).  Research is 
needed to better define barriers that limit participation of women in CV trials. As we 
moving into the era of precision medicine, it is important that clinical trial participants 
represent the full spectrum of patients for whom the drug will be prescribed.  
Few experimental studies have reported a possible direct anti-ischemic effect of 
metformin in both T1DM and T2DM (497). In this study metformin regressed LVMI and 
LVM. But it is unclear as to whether regression is, at least in part due to the anti-
ischemic effects of metformin, which can only be addressed by doing a CMR perfusion 
study. The deleterious effect of hypertrophy is due to the presence of myocyte 
degeneration and myocardia fibrosis. In our study, we didn’t use gadolinium based 
contrast agents in CMR, which can detect fibrosis and scar. Hence, it remains 
speculative as to whether metformin has any potential beneficial effects on myocardial 
fibrosis. Finally, because of the relatively small sample size, we cannot exclude the 
possibility that some subtle baseline and demographic differences between the two 
groups, although not statistically different, might have collectively contributed to our 
results.  
However, this study had several strengths; including its randomized placebo-
controlled double-blind design; inclusion of high CV risk patients, all patients on current 
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optimal medical therapy; use of state-of-the-art MRI technology to quantify cardiac and 
abdominal obesity end points. Although the baseline body weight and LV mass were 
higher in the metformin group, we have sought to minimize these as far as practicable 
by doing sensitivity analysis; by using analysis of covariance (ANCOVA) model to 
evaluate the robustness of treatment by adjusting for relevant baseline covariates.  
 
6.11. Final Conclusion 
In this proof of concept RCT, among CAD patients with LVH and non-diabetic 
hyperglycaemia, metformin significantly reduced LVMI and LVM compared to placebo.  
It also improved SBP, reduced oxidative stress and reduced measures of obesity such 
as body weight and SCAT. This study has shown, for the first time in a randomized 
controlled trial, a potential mechanism by which metformin might exerts its cardio-
protective effects. Although LVH is a good surrogate marker of cardiovascular 
outcome, definitive evidence for the cardio-protective role of metformin in non-diabetic 
cardiovascular disease will have to be provided by large randomized cardiovascular 
outcome clinical trials. The results of on-going cardiovascular outcome trials such as 
the VA IMPACT trial (VA IMPACT NCT02915198) and Glucose Lowering in Non-
diabetic hyperglycaemia Trial (GLINT; ISRCTN34875079), will be informative.   
6.12. Future Studies 
There is presently a clinical equipoise for metformin in CVD without T2DM. This can 
only be addressed by large cardiovascular outcome trials with longer follow up. 
Several lines of evidence suggest that metformin has the potential as a treatment for 
CVD irrespective of diabetes status, however the evidences so far from prospective 
randomized trials in subjects without T2DM have so far been largely neutral on CV 
outcomes. This warrants for future CV outcome trials incorporating better hard end 
points. Such study can provide a conclusive evidence as on whether metformin can 
be used over other emerging CVD treatments.  
Another consideration is the utility of metformin in targeting other CV diseases such 
as heart failure, particularly in heart failure with preserved ejection fraction (HFpEF). 
Drugs or devices which are recommended in current HF treatment guidelines to 
improve outcomes in heart failure with reduced ejection fraction (HFrEF) have not 
been shown to have similar benefit in HFpEF patients, and to date, phase III 
randomised controlled trials have not consistently yielded evidence-based therapy for 
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HFpEF. The lack of treatment options in HFpEF patients represents a significant 
unmet need that urgently demand new therapeutic strategies that arguably target 
mechanisms specific for HFpEF. In this context, metformin may have substantial 
beneficial effects on HFpEF (Figure 27).  
             
 
 
Figure 27: Plausible benefit of Metformin in heart failure with preserved ejection 
fraction. Reproduced from CS Lam et al. European Heart Journal 
 
A key feature of HFpEF patients is the presence of several comorbidities, including 
obesity, diabetes and hypertension. Additionally, the new paradigm of HFpEF 
hypothesises that the high prevalence of comorbidities in HFpEF synergistically 
induces a systemic pro-inflammatory state that can lead to coronary microvascular 
and generalized endothelial inflammation, which in turn results in abnormalities in 
ventricular and vascular function ultimately leading to increased LVH, diastolic LV 
stiffness and HFpEF development. Indeed, patients with HFpEF have evidence of 
inflammation not only in the myocardium but also in lungs, skeletal muscles, and 
kidneys that contributes to pulmonary hypertension, exercise intolerance, and renal 
impairment in HFpEF. Metformin has been shown to have anti-inflammatory effects. 
In a translational study, metformin inhibited tumor necrosis factor-α–dependent IκB 
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degradation and the expression of pro-inflammatory mediators’ interleukin-6, 
interleukin-1β, and CXCL1/2 in primary hepatocytes of healthy animals (286). This in-
vitro findings were validated in large treatment naïve T2DM patients in a population 
cohort study (498) and in a subset of non-diabetic HF patients from a double blind 
randomized controlled trial (248), and showed that metformin treatment suppressed 
inflammatory cytokines including the aging-associated cytokine CCL11 (286). 
Secondly, metformin has the potential to regress the adverse ventricular remodelling 
in HFpEF as observed in this study and in animal models of hypertrophy.  Thirdly, 
metformin’s ability to reduce weight is a consideration for its potential benefits in 
HFpEF. In the study, metformin reduced weight (by 4 kg) that is a consistent finding 
with metformin use. This reduction in weight could also be beneficial in HFpEF. 
Fourthly, in this study, metformin reduced blood pressure that could also potentially 
benefit HFpEF. Finally, metformin has also been shown to improve pulmonary 
hypertension related to HFpEF, at least in animal models (499-501). It is noteworthy 
that all the above evidence has only been in animal models and if in man, it did not 
involve HFpEF patients since this study only involved patients with CAD. However, in 
another study of patients with HFrEF and IR, improved the VE/VCO2 slope in patients 
with HFrEF and insulin resistance (248). In that study, there was a non-statistical 
marginal reduction of NTproBNP in metformin arm. Therefore, taking into account, the 
effects of metformin observed from this study (such as regression of LVH, oxidative 
stress, SBP and obesity) and the anti-inflammatory effects reported by earlier studies, 
metformin may have potential therapeutic benefits for patients with HFpEF.  Future 
studies exploring the beneficial effects of metformin in HFpEF patients is warranted. 
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Appendix A: Informed Consent Form 
Study Number: (EudraCT) 2014 -003189-26 
Participant Identification Number for this trial:…………………… 
 
Title of Study: MetfoRmin and its Effects on Myocardial Dimension and Left ventricular hypertrophy 
in normotensive patients with Coronary Artery Disease (The MET-REMODEL Trial)  
Name of Researcher: 
Chief Investigator: Professor Chim C Lang  
               Please initial box 
1. I confirm that I have read and understand the information sheet 
dated___________ (version ___) for the above study.  I have had the 
opportunity to consider the information, to ask questions, and have had 
them answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
3. I give permission to store my anonymised data for future research and if I 
withdraw from the study any data collected up to the point of withdrawal 
may be analysed by the research team.  
4. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by the research team or from the 
regulatory authorities, NHS Tayside, or the University of Dundee (or their 
appointed third party), where it is relevant to my taking part in this study.  I 
give permission for these individuals to have access to my records. 
5. I agree to my GP being informed of my participation in this study. YES/NO 
(please circle) 
6. I understand and agree that the data I provide will be gifted by myself, and 
analysed by members of the study team (or stored anonymously) for up to 
15 years and may be used for future, as yet unspecified, medical research 
into health, illness and medical treatment.  
OPTIONAL 
7. I agree to donate an additional 10ml of blood for genetic research purposes 
and understand that this may be stored indefinitely for future research use.  
  YES/NO (please circle) 
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OPTIONAL 
 
8. I agree any spare blood left over from the 30ml blood sample taken for 
research purposes at the start and end of the study may be stored 
indefinitely for future research use.  YES/NO (please circle) 
 
9.  Women of child bearing potential 
I agree to provide a urine pregnancy test at the screening visit, and all 
subsequent study visits, while I remain on study medication.  
YES/Not applicable (please circle) 
 
10. I agree to take part in the above study. 
 
    
 
________________________________ 
Name of participant 
____________ 
Date 
______________________ 
Signature 
 
 
________________________________ 
Name of person taking consent 
 
 
____________ 
Date 
 
 
______________________ 
Signature 
 
Original to be kept with TMF, 1 copy for participant; 1 copy for hospital notes  
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Appendix B: Patient Information Sheet 
 
PARTICIPANT INFORMATION SHEET 
 
Title of Study 
METfoRmin and its Effects on MyOcardial DimEnsion and Left Ventricular Hypertrophy in 
Normotensive patients with Coronary Artery Disease: The MET REMODEL Study 
 
Name of Researchers 
Chief Investigator: Professor Chim Lang     
Researchers: Mr Pradeep Mohan, Ms Fatima Baig 
 
Details of Study 
You are being invited to participate in a clinical trial being sponsored by the University of Dundee and 
NHS Tayside. This study will form part of a PhD for Mr Mohan and some of the data collected will be 
analysed to form part of a master’s degree for Ms Baig.  Before you decide whether or not to take part 
it is important for you to understand why the research is being carried out and what it involves.  Please 
take time to read the following information carefully and discuss it with others if you wish.  Please ask 
if there is anything that is unclear or if you would like more information.  Take your time to decide 
whether or not you would like to take part. 
 
Background 
Patients who have had a heart attack or evidence of blocked blood vessels in the heart are at increased 
risk of another heart attack or stroke. Current treatments are aimed at reducing the risk of a future 
event. One risk factor which increases the risk of a future event is the presence of Left Ventricular 
Hypertrophy (LVH). This is the thickening of the heart muscle (left ventricle) and its presence can often 
go undetected as there are no symptoms and it can only be diagnosed effectively through an 
ultrasound scan of the heart.  
Patients with LVH are 2-5 times more likely to have a heart attack or stroke. LVH can often be caused 
by high blood pressure, however obesity and insulin resistance may also contribute to its presence in 
patients with normal blood pressure. Insulin resistance is a condition in which the body produces 
insulin but is unable to use it effectively.  
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Metformin, a medicine used to treat diabetes; can reduce insulin resistance and cause weight loss and 
may therefore, reduce the thickening of the heart muscle and reduce the risk of a heart attack or 
stroke. If Metformin can help reduce the thickening of the heart muscle, this might be a new way to 
reduce the risk of heart attack or stroke in these patients. 
This study will investigate the ability of metformin to reduce the thickening of the heart muscle in 
patients with heart disease. We aim to recruit 64 patients who do not have diabetes but have insulin 
resistance with well controlled blood pressure. 
The thickness of the heart muscle will be measured at the start of the study by an ultrasound scan and 
then more accurately with a Magnetic Resonance Imaging (MRI) scan. Non-invasive tests to measure 
the function of blood vessels will also be carried out. These tests will all be repeated at the end of the 
study.  
As this is a clinical trial, participants will be randomly allocated to either metformin or a dummy 
medication (placebo) and will receive one year of treatment so that we can compare if there is a 
difference between normal treatment and addition of metformin. All participants will continue to take 
all currently prescribed medication, as well as the study drug. 
 
Do I have to take part? 
Participation in this study is entirely voluntary and you are free to refuse to take part or withdraw 
from the study at any time (without having to give a reason) and without, in any way, affecting your 
future medical care or your relationship with medical staff looking after you.  Some insurance 
companies consider that participation in medical research such as this is a “material fact” which should 
be mentioned in any proposal for health-related insurance or which could influence their judgement 
in consideration of claims under existing policies.  You should check that participation in this research 
does not affect any policy you might be thinking about taking out or any existing policy. 
 
What is involved in the study? 
This study takes between 12 to 13 months. Visits will be scheduled to take place at your convenience. 
This study is a randomised, double blinded, placebo controlled single centre study to be conducted at 
Ninewells Hospital & Medical School, Dundee. You will be given a tablet which contains the medication 
we are testing (called metformin) or an inactive tablet (called a placebo). Before you start on any study 
medication a doctor will check you’re eligibility for the study. A summary of all tests performed is 
detailed at the end of this information sheet.  
Visit 1 Screening  
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The purpose of this screening visit is to confirm you are eligible for the study.  
 
The screening period may take between 1 and 4 weeks whilst the doctor assesses your suitability for 
the trial. Typically this may involve a maximum of two visits. 
For the first (and final study) visit you are required to fast overnight, (except for sips of water for your 
medications) from midnight the night before. We also ask you not to take any caffeine, alcohol, or 
smoke cigarettes for 12 hours before these visits. You will be given refreshments after the study tests 
are completed.  
At the screening visit, the doctor will check your medical history and perform an ultrasound scan of 
your heart (unless you have had an ultrasound of your heart within the last 6 months) to check if you 
have evidence of LVH.  This is a painless procedure where the doctor will apply gel to your chest and 
use an ultrasound scanner to take a picture of your heart. If you do not have LVH, this study is not 
suitable for you and do not need to participate further. 
Should you have LVH, your blood pressure and pulse readings will be checked. Blood will be taken to 
assess your liver and kidney function and insulin levels to confirm it is safe and appropriate for you to 
participate. The blood tests will also show if you are insulin resistant/pre-diabetic. If you are not 
insulin resistant or pre-diabetic you will be ineligible to participate in this study further. 
The total volume of blood taken at this visit will be approximately 22ml (4 teaspoons full).  
If your blood pressure is high, you may have a 24 hour BP monitor test to assess your BP over a 24 
hour period, when convenient for you or if you are unable to tolerate 24hr BP you will be given a home 
BP monitor and instructions on how to record this information by the doctor If your blood pressure is 
not well controlled we will advise your GP or hospital consultant and will not require you to 
participate further in this study.  
 
Baseline MRI Scan 
For the MRI Scan you will receive an appointment either by telephone call, letter or e-mail and will be 
sent directions to attend the MRI department of the Clinical Research Centre, Ninewells Hospital, 
Dundee.  If you are a woman of child bearing potential you will be asked to provide a urine specimen 
which you can either bring with you (a specimen bottle will be provided) or provide at the clinic visit. 
A pregnancy test will be performed to ensure your safety. A positive result will exclude you from 
having an MRI scan and participating further in this study.  
Before your scan a research physician will check you are eligible for the scan, and written consent will 
be obtained by a member of the research team.  You will then be seen by the radiographer, the person 
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performing your scan, and he/she will help you to complete a checklist about matters that might 
prevent you from having the scan.  
If at Visit 1 you are found to have a history of a penetrative eye injury or exposure to metal fragments 
in your eye(s) that required medical attention, you will be advised that it is unsafe for you to continue 
further in this study as there is a risk that the magnetic field in the MRI scan could move the metal 
fragment which may cause harm to your eye. With your consent, we will write to your GP informing 
them of your MRI safety status, as this information may be of benefit for your future health care needs.  
If at Visit 1 you are found to have NO history of a penetrative eye injury and have had NO exposure to 
metal fragments in your eye(s), or otherwise the radiology staff establishes that it is SAFE to scan, you 
will proceed to have your MRI whereupon you will then be asked to change into a gown for the scan. 
After being prepared for your scan, you will be asked to lie up on the scanning table and then will be 
moved into the center of the scanner (the scanner is shaped like a big doughnut). During the scan, 
which takes around 45 minutes, you will be able to speak to the radiographer. The scan will take 
pictures of your heart and blood vessels. As the scan is noisy you will be wearing hearing protection.  
After you have completed the scan you are free to go home. You can drive if you need to or if you 
prefer, a taxi can be arranged to take you to and from the hospital. A specialist will examine your scan 
at a later date for any signs of abnormality and will measure your left ventricular mass of your heart 
and will also examine images from your abdomen for the amount of fat lining your internal organs and 
under your skin as high levels of abdominal fat have also been associated with insulin resistance.  
This MRI visit should take no longer than one and a half hours.  
Visit 2 Baseline 
This visit will take place following the MRI Scan, anytime up to two weeks after the MRI scan but 
usually on the day of it. It will include the following investigations: 
Vital signs- checks of your BP, pulse, height, weight and waist measurements. 
Blood samples will be taken to assess your liver and kidney function.  Research Bloods will be taken 
and stored, for analysis at the end of the trial. At visits where safety bloods and research bloods are 
drawn, it will be a total of 52mls, where safety bloods only it will be a total of 22mls 
Following completion of the trial we may test for additional markers of interest on any left-over blood 
with your permission. These left over samples will be stored anonymously in the secure Dundee 
University laboratory in the Division of Cardiovascular and Diabetes Medicine. 
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Genetic analysis blood test - You will be asked to provide one 10ml blood sample for storage at this 
visit.  The sample will be fully anonymised and will be subject to approval of a Research Ethics 
Committee prior to future DNA analysis. The results of any future genetic tests would not be linked to 
your records and you will not receive any information about the results. You can opt not to have this 
done, without affecting your participation in the study. This sample will be stored in the secure 
laboratory within the Division of Cardiovascular and Diabetes Medicine at Ninewells Hospital.  
 
Please note that you may decline the following Pulse Wave Analysis (PWA), Flow Mediated Dilatation 
(FMD) or reactive hyperaemia measurements without it affecting your participation in the rest of the 
trial, or stop them if they are too uncomfortable for you.  
  
 
Flow-mediated dilatation - We will look at a blood vessel in your arm (the brachial artery) using an 
ultrasound scanner. The function of this artery will be assessed by measuring its diameter before and 
after stopping blood flow through it with an inflated blood pressure cuff for 5 minutes. Occluding the 
artery can cause some tingling in the fingers (like when you have fallen asleep on your arm), but that 
should be the only discomfort. The diameter of the artery will again be measured before and 5 minutes 
after a spray of Glyceryl Trinitrate (GTN) is given under the tongue. GTN is a medicine that is normally 
used in the treatment of angina and can cause a mild headache. It is being used here to help dilate the 
brachial artery. Throughout these measurements, the electrical activity of your heart will be 
monitored using an ECG machine.  
At the end of this first drug dosing visit you will be randomly assigned to either low dose metformin 
(500mg twice a day) or placebo so that the tablets allocated to you are decided in a random way (a bit 
like tossing a coin) such that neither you nor the research staff will know which tablet you are taking 
at any time until after the study is completed.  This ensures that the study results cannot be influenced 
by knowing whether you are receiving the medication or not. 
You will be given enough study drug to take once daily for two weeks.  
Visits 3 
Visit 3 will occur approximately two weeks after visit 2. At this visit you will have safety bloods, blood 
pressure and pulse checked and the doctor will assess if you have had any problems on the study 
medication. At the end of the visit your dosage will be increased to metformin or placebo (1000mg 
twice daily) for the duration of the study.  
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Visits 4, 6 & 8  
Visits 4, 6 and 8 will occur at approximately one month, four months and eight months respectively 
from the baseline visit. At these visits safety blood tests will be taken and the doctor will assess if you 
have had any problems on the study medication. Study medication will be dispensed to you at these 
visits. If you have tolerated a lower dose of medication but have had difficulty tolerating a higher dose, 
the doctor will discuss with you returning to a lower dose, with your agreement. If the study drug 
needs to be stopped, you will still remain in the study in order to do an “intention to treat” analysis. 
 
Telephone visits; 5, 7, 9.  
Visits 5, 7 and 9 are telephone visits only where a member of the research team will contact you to 
check how you are doing on your study medications. If there is any cause for concern they will arrange 
for you to be reviewed by the doctors. The telephone visits are designed to reduce the number of 
times you need to attend the hospital for this study.  
Final Visit 10 
This is the final study visit. At this visit the final safety and research blood tests will be performed, you 
will have a MRI scan (within 2 weeks of the visit) and all tests performed at the baseline visit will be 
repeated.  
 
Medication being tested 
The medication used in this study is called metformin. It has been prescribed for over 50 years, 
predominantly for use in the treatment of type 2 diabetes.  It is generally well tolerated with an 
excellent safety record. Like most medicines however, metformin may causes side effects.  The most 
common side effects with metformin are weight loss, nausea, vomiting, diarrhoea (usually transient), 
abdominal pain, metallic taste. These side effects are usually self-limiting and tend to resolve 
spontaneously in most cases.  Taking the medication with food and starting at lower dose helps to 
reduce side-effects. The dose will start at 500mg twice a day and your tolerance to the drug will be 
monitored prior to increasing it to 1000mg twice daily.   
A very rare side–effect of taking metformin is lactic acidosis. Lactic acidosis occurs in one out of every 
30,000 patients. The symptoms of lactic acidosis are weakness, breathlessness or deep and rapid 
breathing, vomiting, cardiac arrhythmias, muscle pain, abdominal pain, dizziness and hypothermia 
(body’s temperature falls below than normal). Even though lactic acidosis is very rare in patients taking 
metformin, all precautions will be taken with study participants. Individuals who are at high risk of 
developing lactic acidosis will be excluded from taking part, i.e. those with kidney failure. All 
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participants will be closely monitored for; lactic acid level and blood tests will be carefully examined 
for any concerns.  
The complete range of reported side effects is set out in the Patient Information Leaflet, a copy of 
which will be given to you at your screening visit. This will be further discussed with you before you 
make a final decision about taking part in this study. 
If you experience any symptoms of lactic acidosis you should contact the study team immediately and 
stop study medications.  
Drug Interactions 
The doctor will assess if there are any possible interactions between any medications you might be 
prescribed and the study medication, Metformin, and will advise you of these accordingly and stop 
the study medications.  
Contraceptive Advice 
Anyone who is pregnant cannot take part in this study. If you are a woman of childbearing age we will 
need to do a pregnancy test before the study.   We will do a urine pregnancy test at all clinic visits if 
you are a women of childbearing potential and not practicing one of the types of contraception or 
abstinence noted below. It is also important that you do not become pregnant during the study. Here 
is some advice on contraception. To avoid getting pregnant, not having sex at all is obviously effective. 
If you follow this strictly, no contraception is needed. If not, these are effective types of contraception: 
• Combined Oral Contraceptive Pill 
• EVRA-oestrogen and progestogen: ‘Transdermal Patch’ 
• Progestogen only pill: ‘mini pill’ 
• Depoprovera injection (medroxyprogesterone acetate) 
• Implanon Implant (Etonogestrel) 
• Mirena Coil (Intra-Uterine System) 
• IUD-copper containing intrauterine device 
• Female sterilisation 
Male vasectomy is also a good form of contraception but only if the procedure has been checked 
afterwards by your doctor to make sure it has worked. 
No contraception method is 100% reliable by itself. Even surgical sterilisation in men and women has 
been known to fail very occasionally.  We advise using additional contraception from the start of the 
study. 
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You may normally use ‘barrier methods’ such as the condom, diaphragm or cap. There is no definite 
proof that using a spermicide with a ‘barrier method’ gives extra protection but some condoms are 
manufactured with spermicide on them.  If you require further advice on contraception, please ask. 
 
What are the discomforts, risks and side effects? 
The side effects of Metformin are discussed under the ‘medication’ section above. 
Having blood taken may cause some mild bruising. The flow mediated dilatation and reactive 
hyperaemia may cause temporary numbness in the arm, as noted above.  
MRI scanning: This type of scan is very safe and does not use radiation. Some people, when being 
scanned, may feel a bit closed in but you will be in constant contact with the person performing the 
scan and you can come out at any time. The scanner is a bit noisy but you will be given ear protection 
which also plays music.  
What are the benefits of taking part in the study? 
You will be monitored closely during the study and will be seen by a doctor with a special interest in 
cardiology at your study visits.  Besides having tests that have already been mentioned, your 
medication will be reviewed on a regular basis.  The tests will give us information about the function 
of your heart, kidneys and blood circulation.  If any of these investigations, including information from 
the MRI scan of your heart or abdomen, reveal any new abnormality we will either discuss this with 
your hospital consultant or refer you to a specialist clinic (whichever seems most appropriate).  The 
study will not immediately benefit you, but if the results of the study are positive it may change the 
practice of managing patients with heart disease who may still have LVH, like you and potentially will 
have a great impact on other such patients in the future.  If so, you may gain eventually from our 
discovering a new treatment for your condition. 
 
Complaints, Insurance and indemnity 
Right to raise concerns 
If you have any concerns about your participation in the study you have the right to raise your concern 
with a researcher involved in conducting the study or a doctor involved in your care. 
Right to make a complaint 
If you have a complaint about your participation in the study, you should first talk to a researcher 
involved in the study. However you have the right to raise a formal complaint. You can make a 
complaint to a senior member of the research team or to the Complaints Officer for NHS Tayside. 
Complaints and Claims Manager 
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Complaints and Advice Team 
Level 7, Ninewells Hospital 
Dundee DD1 9SY 
Freephone: 0800 027 5507 
Email: nhstaysidecomplaints@thb.scot.nhs.uk 
 
Right to make a claim 
In the event that you think you have suffered harm as a result of your participation in the study there 
are no automatic financial compensation arrangements.  However, you may have the right to make a 
claim for compensation against the University of Dundee or NHS Tayside. Where you wish to make a 
claim, you should consider seeking independent legal advice but you may have to pay for your legal 
costs.   
 
Insurance 
The University of Dundee maintains a policy of professional negligence clinical trials insurance which 
provides both legal liability cover and no fault compensation in respect of accidental injury. Tayside 
Health Board is a member of the Clinical Negligence and Other Risks Insurance Scheme which provides 
legal liability cover. 
 
Genetic testing 
You should be aware that if you apply for health insurance you may be asked questions about your 
health, including medical history, pre-existing medical conditions and if you have had any genetic test. 
If you have a diagnosed medical condition, even where the condition is diagnosed as part of a clinical 
research study, the insurer may take this in to consideration when deciding whether to offer insurance 
to you.  
Participation in this study DOES NOT constitute a “genetic test” as defined by insurance companies. 
Your data will remain confidential unless we are legally required to disclose information by Court order 
or by statute. 
 
Will the research influence the treatment I receive? 
The research will not immediately alter the regular treatments you currently receive.  
 
Will my taking part in the study be kept confidential? 
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Your personal data will be kept confidential. With your permission, identifiable information about you 
and data collected during the study will be held securely by the University of Dundee and under the 
control of the Chief Investigator.   All data collected in this study will be coded and stored on a 
computer system protected by a password only available to the researchers.  No one outside the 
research team will have access to any identifiable information and all identifiable information and 
data will be kept securely.  Your data will be archived securely for at least five years after the end of 
study as this is a legal requirement for drug studies.  With your permission, we will inform your GP of 
your participation in this study.  It is a requirement of the regulatory authority for clinical trials that 
your records in this study, together with any other relevant medical records, be made available for 
scrutiny by appropriate staff from NHS Tayside, University of Dundee (or their appointed third party) 
and the regulatory authority themselves. Should you withdraw from the study, data collected prior to 
withdrawal will be kept, anonymously, for purposes of future medical research should you agree to 
that. However, if you wish, your data can be removed from our database. You simply need to inform 
the research staff what you prefer to happen in this instance. . 
 
Additionally there will be two sets of information obtained after you have had your MRI scan. One set 
will be the MRI scan images and the other, the research data obtained from those images. The MRI 
images obtained will be stored indefinitely using your name and unique hospital record number within 
the NHS clinical system and can be made available to specialist doctors for your future health care 
needs. Your research data will be stored using a unique study code which is non-identifiable and held 
on password protected University of Dundee secure databases.  Only individuals directly involved with 
the study will have access to this information.   
Will I continue to receive the medication used in this study after it finishes? 
No.  The study is designed to give an indication of possible benefit from the medicine being tested and 
it may be some time before we can be sure about how useful it actually is. 
 
Expenses 
Taxi transport, or reasonable costs to cover your travel costs, will be provided for any extra visits to 
the hospital for the purposes of this study. You will be given refreshments and food on the two days 
you are asked to attend fasted.  
 
Who has reviewed this study? 
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The East of Scotland Research Ethics Services (REC 2) which has the authority to scrutinise proposals 
for medical research on humans, has examined this study and has raised no objections from the point 
of view of medical research.  
It is a requirement that your records in this research, together with any relevant medical records, be 
made available for scrutiny by monitors from The University of Dundee, NHS Tayside and by the 
Regulatory Authorities, whose role it is to check that research is properly conducted and the interests 
of those taking part are adequately protected.   
Contact details for the study Doctor and other researchers involved in this study. 
 
If you are worried at any time about the research or wish to discuss things generally further, please 
do not hesitate to contact: 
 
Prof Chim C Lang 
University of Dundee 
Division of Cardiovascular and Diabetes Medicine 
Medical Research Institute 
Mail Box 2, Ninewells Hospital and Medical School 
Dundee DD1 9SY 
Tel: (01382) 383282 
Email: c.c.lang@dundee.ac.uk 
 
Contact Numbers if unwell during the trial 
If during the study you become unwell or are concerned, you can contact the study team during 
normal working hours on (01382) 383115. If you are unwell and need urgent advice or assistance do 
not delay in seeking further advice or treatment as usual through the NHS services such as NHS24 (Tel: 
111) or by contacting your GP who will have received details of your participation in this study should 
you agree to them being informed.  
 
Thank you for reading this information sheet and considering taking part in this study. If you would 
like more information or want to ask questions about the study please contact the study team on the 
number above. 
 
What will happen to me during the study? 
The following diagram is the programme of visits involved in this study.  
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VISIT Visit 1 
Screening  
Visit 2 
Baseline/ 
Randomisation 
Visit 3 
 
Visit 4 
 
Visit 5 
Tele Call 
Visit 6 
 
Visit 7 
Tele Call 
 
Visit 8 
 
Visit 9 
Tele Call 
Visit 10 
Final Visit 
Early 
discontinuation visit 
 Up to 4 
weeks pre 
visit 2  
Day 0 2 week 
 (+/- 3 days) 
Month 1 
(+/- 3 days) 
Month 2 
(+/- 1 week) 
Month 4 
(+/- 2 weeks) 
Month 6 
(+/- 1 week) 
Month 8 
(+/- 2 week) 
Month 10 
(+/- 1 week) 
Month 12 
(+/- 2 weeks) 
As required 
Daily drug dose if increasing  1000mg/ 
placebo 
2000mg/ 
placebo 
        
Informed Consent √           
 Doctor to check suitability for trial √ √          
Medical & Social History, Family History √           
Echocardiography (unless one done 
within 6 months prior to screening) 
√         √ √ 
Check BP, Pulse Weight, Height √ √ √ √  √  √  √ √ 
24 Hour BP monitoring# if required √           
Safety Blood Tests  √ √ √ √  √  √  √ √ 
Research Bloods   √        √ √ 
Urine Pregnancy Test (If applicable) √ √ √ √  √  √  √ √ 
Genetic blood sample (if consented)  √          
MRI  √        √ √ 
FMD  √        √ √ 
Receive Study medication  √ √ √  √  √    
Doctor to check for any side effects  √ √ √ √ √ √ √ √ √ √ 
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                     Appendix C: Case Report Form                                         
The MET-REMODEL Study 
Case Report Form 
 
 
 
 
 
 
 
                Visit         Date     Time                    Taxi 
      Required?                     Booked? 
      Comment 
Visit 1 
              (Screening) 
     
Visit 2 (a) (Day 0) 
          (Randomisation) 
     
Visit 2 (b) 
                     (MRI) 
     
Visit 3 (2 weeks, +/- 3 days) 
             (Progress visit) 
     
Visit 4 (Month 1, +/- 3 days) 
              (Progress visit) 
     
Visit 5 (Month 2, +/- 1 wks) 
          (Telephone contact) 
     
Visit 6 (Month 4, +/- 2 wks) 
          (Progress visit) 
     
Visit 7 (Month 6, +/- 1 wks) 
        (Telephone contact) 
     
Visit 8 (Month 8, +/- 2 wks) 
           (Progress visit) 
     
Visit 9 (Month 10, +/- 2 wks) 
         (Telephone contact) 
     
Visit 10 (a) (Month 12, +/- 2 wk) 
              (Final visit) 
     
Visit 10 (b) 
              (Final MRI) 
     
 
Participant Initials  Date of Birth  
Screening ID  
Randomisation ID  
CRF Start Date  
METfoRmin and its Effects on MyOcardial DimEnsion and Left Ventricular Hypertrophy 
in Normotensive patients with Coronary Artery Disease 
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Study Visits Overview 
Visit 1– Screening Visit 
 Participant consent  
 Echocardiography to assess for presence of LVH 
 Fasting insulin resistance index (FIRI)/HbA1c 
 Safety bloods 
 Record Vital signs 
 Office based BP monitoring 
 24hr ambulatory BP monitoring  
 Medical and Family history 
 Record list of current medications 
 
          Visit 2 – Baseline Randomisation visit 
 Assess eligibility criteria 
 MRI Scan (+/- 2 weeks of baseline visit) 
 Vital signs assessment, BP and BMI measurements.  
 Safety & research bloods  
 Genetic analysis bloods for storage (if consented) 
 FMD 
 Randomise patient to treatment 
 Dispense study medication: Metformin XL/placebo  
 Record changes to current medications  
 
         
Visit 3 - Progress visit (Dose-up titration) 
                          (2 week; +/- 3 days) 
 Safety bloods. 
 Vital signs assessment 
 Assess any adverse events since previous visit 
 Check drug compliance & record medication   
 (Up titrate metformin XL/placebo 
      Visit 4 - Progress visit  
 Safety bloods. 
 Vital signs assessment 
 Assess any adverse events since previous visit 
 Check drug compliance 
 Record changes to current medications 
 
       Visit 5 & 7, 9- Telephone Contact Visits  
 Assess any adverse events previous clinic visit 
 Record list of current medications 
 Check drug compliance 
 
      Visit 6 & 8- Progress visit  
 Vital signs 
 Safety bloods. 
 Record changes to current medications 
 Assess any adverse events since previous visit 
 Check drug compliance 
 Dispense study medication  
 
       Visit 10- Final visit  
 Safety & research bloods  
 Vital signs assessment,  
 Assess any adverse events from previous visit 
 Check drug compliance 
 Record changes to of current medications 
 FMD 
 MRI Scan  (+/- 2 weeks of final visit) 
 
                                                                                                
MET-REMODEL Case Report Form:  Version 1.3: 12th January 2016  
Participant ID: _______                                                                       
 
 
 
                                                                           
V1A.  Has a consent form been completed & filed in the TMF?                                    YES / NO 
            Date of Consent:  ____/____/______ 
 
Inclusion Criteria: 
                                                 YES                         NO 
Participant aged 18 years or over                                            
Participant diagnosed with Ischemic heart disease (IHD)                                             
Screening echo LVH (males >81g/h1.7, females > 60g/h1.7)                                               
Fasting insulin resistance index (FIRI) ≥ 2.7  AND/OR HbA1c ≥ 5.7% 
(39mmol/mol) at screening visit 
                                            
Clinic Blood pressure < 140/85 mm Hg or 24hr BP <135/85 daytime 
average 
                                            
 
Exclusion Criteria: 
     
Unable to give informed consent                                              
Known diagnosis of Diabetes or HbA1c ≥48mmol/mol                                              
LV Ejection Fraction <45% on screening echocardiogram or a diagnosis of 
CHF 
                                             
Contraindications to cardiac MRI                                             
Malignancy (receiving active treatment) or other life threatening diseases                                              
Severe aortic stenosis                                              
Pregnant or lactating woman                                              
In another clinical trial of an investigational medical product within last 30 
days 
                                             
Any other serious illness or significant abnormalities that may compromise 
their  safety or successful participation in the study 
                                             
Renal disease; CKD class 3B or worse (eGFR <45)                                               
V1B. Is the subject eligible to participate in this study?                                                                        
If ineligible please document reason(s): 
 
VISIT - 1 
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V1C. Past Medical History:                                                                                                            
HTN        COPD                            
Dyslipidaemia     Atrial Fibrillation          
Stroke/TIA     Peripheral Arterial Disease  
V1D. Record concomitant medications at back of CRF (medication log)                            
V1E. Social History: 
Smoking status:  1. Current smoker  2. Never  3. Ex-smoker   
Average weekly alcohol intake: ______units 
         N/A   Yes      No 
V1F. Participant female of child bearing potential?                      
If yes what is the result of a pregnancy test? ______________     
V1G. Family History: 
1st degree relative with MI/CVA: Yes/No 
Relationship: father/mother/brother/sister/son/daughter 
V1H. Demographics: 
Age  ______yrs.                   Height  ______ m   
Sex: Male / Female   Weight ______ kg   
V1I. Physical Examination:  
General 
 
 
Cardiovascular      Respiratory 
 
 
 
Gastrointestinal      Neurological 
 
Signed  Name  Date  
VISIT - 1 
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V1J. Screening Echocardiogram 
                                                     Yes   No 
Diagnosis of LVH ( LVMI males >81g/h1.7, females > 60g/h1.7)                                         
  
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                          Check when completed  
V1K. Venepuncture (Safety / Screening bloods)                                                       
Samples required: 
 2 x EDTA (purple) – FBC & HbA1c 
 2 x clotted (golden) – U&E’s, LFT’s, TFT’s & fasting Insulin 
 1 x glucose (grey) – Fasting glucose. 
          Yes    No 
V1L. Participant Insulin Resistant AND/OR Pre-diabetic         
Fasting Plasma Glucose: ________    Fasting Insulin: ___________ 
Fasting Insulin Resistance Index (FIRI) = ____________ 
LEFT VENTRICLE:                                                                Comments :                                                                                                    
LVIDd (cm)  
PWTd (cm)  
SWTd (cm)  
LV Mass (g)  
LV Mass/height 1.7(g/h1.7 )  
LV Mass/BSA (g/m2 )  
Systolic Function (EF) (%)  
 
AORTIC VALVE: 
 
Nil significant  
MITRAL VALVE: 
 
Nil significant  
TRICUSPID VALVE: 
 
 
Nil significant  
PULMONARY VALVE: 
 
 
Nil significant  
RIGHT VENTRICLE: 
 
 
Nil significant  
ADDITIONAL COMMENTS: 
 
 
VISIT - 1 
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(Fasting plasma x fasting insulin/25) 
 
HbA1c = ____________ 
 
 
                                           Check when completed 
V1M. Blood Pressure (Three measurements will be taken with an average of the three calculated)           
(Same arm should be used throughout trial) 
 
Time Systolic Diastolic HR 
 
 
   
 
 
   
 
 
   
Average  
 
  
 
Office/Clinic based Blood Pressure      :     ______/_______ mmHG          HR____bpm 
24hr Ambulatory BP (Average, ONLY performed if office based BP is > 140/85 mmHG ______/_____ mmHG           
HR____bpm 
Home based Blood Pressure:     ______/_______ mmHG          HR____bpm (Average, ONLY performed if 
participant is intolerant to ABPM) 
V1N. CMRI safety checklist/form completed           
V1O. Visit 2 booked and recorded on front of CRF                      
Remind them of FMD requirements:        
• not eating for four hours before attending 
• no tea/coffee for four hours before attending 
• no cigarettes for four hours before attending 
  
Comments:  
 
 
 
 
VISIT - 1 
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Check when completed 
 
V2A. Inclusion / Exclusion criteria checked                          
V2B. Vital Signs checked                                                                                    
Height (cms)  Weight (Kg)  
V2C. Blood Pressure checked              
Office/Clinic based Blood Pressure      :     ______/_______ mmHG          HR____bpm 
V2D. Venepuncture (Safety / Baseline-Research bloods)                                                       
Samples required (Safety) 
 1 x EDTA (purple) – FBC  
 1 x clotted (golden) – U&E’s, LFT’s & TFT’s  
 
 Samples required (Baseline /Research bloods)  
 5 x EDTA (purple 2 ml)  
 3 x Serum (Yellow 5 ml) 
V2E. Blood samples taken for storage (genetic analysis), if consented                   
V2F. Urine pregnancy testing   Result _____________   N/A                 
V2G. Medication log updated                                      
V2H. FMD  
Completed            
Reported (recorded in FMD log)            
 
V2K. Study Medication Dispensed                                   
Number of tablets supplied: _______________ 
Randomisation number: __________________ 
V2L. Participation letter sent to GP sent                                                                          
          Copy of letter/trial sticker/trial notes placed in case notes                                                    
V2M. MRI Scan  
 Booked             
 Completed            
 
Signed  Name  Date  
VISIT – 2 (Randomisation) 
                                                                                                
MET-REMODEL Case Report Form:  Version 1.3: 12th January 2016  
Participant ID: _______                                                                       
 
V2N. Date of visit 3 booked and recorded on front of CRF                                                 
 
 
 
         
 Check when completed 
V3A. Vital Signs checked                                                                                      
Weight (Kg)  
 
V3B. Blood Pressure checked                    
Office/Clinic based Blood Pressure      :     ______/_______ mmHG          HR____bpm 
V3C. Venepuncture (Safety bloods)                                                                                                        
Samples required (Safety) 
 1 x EDTA (purple) – FBC  
 1 x clotted (golden) – U&E’s, LFT’s & TFT’s  
V3D. Adverse Events log updated                                                                                                        
V3E. Medication Log Updated.                                                                                                                   
V3F. Study Medication Dispensed                                                                                                           
 Number of tablets supplied ________ 
V3G Checked drug compliance                                                                                                                   
         Number of tablets remaining: ___________ 
        Comments:  
Signed  Name  Date  
VISIT – 3 (Dose up-titration) 
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V3H. Date of fourth visit booked and recorded on front of CRF                                                 
 
 
         Check when completed 
V4A. Vital Signs checked                                                                                      
Weight (Kg)  
 
V4B. Blood Pressure checked                    
Office/Clinic based Blood Pressure      :     ______/_______ mmHG          HR____bpm 
V4C. Venepuncture (Safety bloods)                                                                                                        
Samples required (Safety) 
 1 x EDTA (purple) – FBC  
 1 x clotted (golden) – U&E’s, LFT’s & TFT’s  
V4D. Adverse Events log updated                                                                                                        
V4E. Medication Log Updated.                                                                                                                   
V4F. Study Medication Dispensed                                                                                                           
 Number of tablets supplied ________ 
V4G Checked drug compliance                                                                                                                   
         Number of tablets remaining: ___________ 
        Comments:  
Signed  Name  Date  VISIT – 4 (Progress) 
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V4H. Date of fifth & sixth visit booked and recorded on front of CRF                                               
 
 
 
V5A. Adverse Events to report                                    Yes/No      
            Check when completed 
V5B. Adverse Events log updated                                                                                                           
V5C. Medication Log Updated.                                                                                                                     
V5D. Check drug compliance                                                                                            
         Number of tablets remaining: ___________ 
         Comments:  
 
 
V5E. Confirm patient appointment time/date/transport for Visit 6                              
 
 
 
 
 
 
 
 
Signed 
 
 
 
 
 
Name  Date  
VISIT – 5 (Tel) 
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         Check when completed 
V6A. Vital Signs checked                                                                                         
Weight (Kg)  
 
V6B. Blood Pressure checked                   
Office/Clinic based Blood Pressure      :     ______/_______ mmHG          HR____bpm 
V6C. Venepuncture (Safety bloods)                                                                                                         
Samples required (Safety) 
 1 x EDTA (purple) – FBC  
 1 x clotted (golden) – U&E’s, LFT’s & TFT’s  
V6D. Adverse Events log updated                                                                                                         
V6E. Medication Log Updated.                                                                                                                    
V6F. Study Medication Dispensed                                                                                                             
 Number of tablets supplied ________ 
V6G Checked drug compliance                                                                                                                   
         Number of tablets remaining: ___________ 
        Comments:  
V6H. Date of 7th & 8th visit booked and recorded on front of CRF                                                       
Signed 
 
ed 
 
 
 
Name  Date  
VISIT – 6 (Progress) 
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V5A. Adverse Events to report                                        Yes/No      
          Check when completed 
V5B. Adverse Events log updated                                                                                                           
V5C. Medication Log Updated.                                                                                                                     
V5D. Check drug compliance                                                                        
       Number of tablets remaining: ___________ 
         Comments:  
 
 
V5E. Confirm patient appointment time/date/transport for Visit 8                         
 
 
 
 
 
 
 
 
 
Signed  
 
 
Name  Date  
VISIT – 7 (Tel) 
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         Check when completed 
V6A. Vital Signs checked                                                                                      
Weight (Kg)  
 
V6B. Blood Pressure checked                    
Office/Clinic based Blood Pressure      :     ______/_______ mmHG          HR____bpm 
V6C. Venepuncture (Safety bloods)                                                                                                        
Samples required (Safety) 
 1 x EDTA (purple) – FBC  
 1 x clotted (golden) – U&E’s, LFT’s & TFT’s  
V6D. Adverse Events log updated                                                                                                        
V6E. Medication Log Updated.                                                                                                                   
V6F. Study Medication Dispensed                                                                                                           
 Number of tablets supplied ________ 
V6G Checked drug compliance                                                                                                                 
         Number of tablets remaining: ___________ 
         Comments:  
V6H. Date of 9th & 10th visit booked and recorded on front of CRF                                                  
Signed 
 
 
 
 
Name  Date  
VISIT – 8 (Progress) 
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V5A. Adverse Events to report                                Yes/No      
         Check when completed 
V5B. Adverse Events log updated                                                                                                           
V5C. Medication Log Updated.                                                                                                                     
V5D. Check drug compliance                                                                                            
         Number of tablets remaining: ___________ 
         Comments:  
 
V5E. Confirm patient appointment time/date/transport for Visit 10                              
Remind them of FMD requirements:                    
not eating for four hours before attending 
no tea/coffee for four hours before attending 
no cigarettes for four hours before attending 
 
 
 
 
 
 
Signed  
 
 
Name 
 
 Date  
VISIT – 9 (Tel) 
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Check when completed 
V10A. Vital Signs checked                                                                            
Height (cms)  Weight (Kg)  
 
V10B. Blood Pressure checked         
Office/Clinic based Blood Pressure      :     ______/_______ mmHG          HR____bpm 
V10C. Venepuncture (Safety / Baseline-Research bloods)                                             
Samples required (Safety) 
 1 x EDTA (purple) – FBC  
 1 x clotted (golden) – U&E’s, LFT’s & TFT’s  
 
 Samples required (Baseline /Research bloods) - BNP/F2 Isoprostanes/oxi-LDL/TroponinT 
 5 x EDTA (purple 2 ml)  
 3 x Serum (Yellow 5 ml) 
V10D. Medication log updated                                    
V10E. FMD  
 Completed           
 Reported (recorded in FMD log)           
 
V10F. PWA  
 Completed           
 Reported (recorded in FMD log)           
 
V10G. Skin Reactive Hyperemia  
 Completed           
 Reported (recorded in FMD log)           
 
V10H. MRI Scan  
 Booked             
 Completed            
 
V10I. Completion of study form (next page) filled out                                                         
Signed  
 
 
Name  Date  
VISIT – 10 (Final) 
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MET-REMODEL Participant ID: __________   Initials: ________ Date: ____________ 
Completion 
Did the subject complete the study?                                              
Date of completion/withdrawal_____/_____/______ 
If subject did not complete, give reason:___________________________________________ 
__________________________________________________________________________________________
__________________________________________________________ 
 
Follow-up    
Is any follow-up required?                                                                                                       
If so, provide details:__________________________________________________________ 
__________________________________________________________________________________________
__________________________________________________________ 
 
Protocol 
Where there any deviations from the protocol?                                                      
If so provide details:__________________________________________________________ 
__________________________________________________________________________________________
__________________________________________________________                     
 
 
I verify that all the data contained in the CRF is complete and accurate.  
 
Chief Investigator 
 
Signed  
 
 
Name  Date  
Signed  
 
 
Name  
 
Date  
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Medication Log 
Medication Code Dose Frequency End date 
(if stopped) 
1.     
2.     
3.     
4.     
5.     
6.     
7.     
8.     
9.     
10.     
11.     
12.     
13.     
14.     
15.     
16.     
17.     
18.     
     
Medication Coding: 
1. ACEI     5. Statin   9. Other  
2. β Blocker    6.ARB   
3. Ca channel Blocker   7. Aspirin  
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4. α Blocker     8. Clopidogrel    
Allergies:   
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Participant ID: _______                                                                       
 
Baseline/Safety Blood + Pregnancy Log 
MET-REMODEL Participant ID: __________                                                                   Initials: ________                                                                                         Randomisation ID: ____________ 
Lab Measurements Visit 1 
(Screening) 
Visit 2 
(Baseline) 
Visit 3 
(Progress) 
Visit 4 
(Progress) 
Visit 6 
(Progress) 
Visit 8 
(Progress) 
Visit 10 
(Final) 
                    
Hb (g/L)        
WBC (x10ˆ9/L)        
PLT (x10ˆ9/L)        
RBC (x10ˆ12/L)        
HCT        
MCV (fl)        
MCH (pg)        
MCHC (g/L)        
NE (x10ˆ9/L)        
LY (x10ˆ9/L)        
MO (x10ˆ9/L)        
FBC 
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EO(x10ˆ9/L)        
BA (x10ˆ9/L)        
Lab Measurements Visit 1 
(Screening) 
Visit 2 
(Baseline) 
Visit 3 
(Progress) 
Visit 4 
(Progress) 
Visit 6 
(Progress) 
Visit 8 
(Progress) 
Visit 10 
(Final) 
                    
ALT (U/L)        
BILIRUBINS (umol/L)        
ALKALINE PHOSPHATASE (U/L)        
ALBUMIN (g/L)        
ESTIMATED GFR (mL/min)        
CKD STAGE IF eGFR <60        
        
Sodium (mmol/L)        
Potassium (mmol/L)        
Urea (mmol/L)        
Creatinine (umol/L)        
Liver Function Tests 
   Urea & Electrolytes 
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Pregnancy Test (+/-) 
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Lab Measurements Visit 1 
(Screening) 
Visit 2 
(Baseline) 
Visit 3 
(Progress) 
Visit 4 
(Progress) 
Visit 6 
(Progress) 
Visit 8 
(Progress) 
Visit 10 
(Final) 
                    
HbA1c        
Fasting Plasma glucose        
Fasting Insulin        
        
BNP (pg/ml)        
F2 Isoprostanes        
Oxidised LDL (U/l)        
Troponin T (ng/ml)        
 
 
 
Blood Glucose 
   Research Bloods 
       
         Not done on these visits. 
 
                Not done on these visits. 
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MET-REMODEL Participant ID: __________   Initials: ________     Date: ____________ 
Visit 2 (Baseline / Randomisation) 
Flow Mediated Dilatation (FMD) 
FMD PRE - CUFF 
 
POST - CUFF CHANGE % 
 
FMD- DIAMETER (MM) 
   
 
GTN- DIAMETER (MM) 
   
 
VELOCITY (I) (M/S) 
   
 
VELOCITY (M) (M/S) 
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MET-REMODEL Participant ID: __________             Initials: ________                              Date: ____________  
Visit 10 (Final Visit) 
Flow Mediated Dilatation (FMD) 
FMD PRE - CUFF 
 
POST - CUFF CHANGE % 
 
FMD- DIAMETER (MM) 
   
 
GTN- DIAMETER (MM) 
   
 
VELOCITY (I) (M/S) 
   
 
VELOCITY (M) (M/S) 
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Adverse Event Log 
Description of Adverse 
Event (provide additional 
information on notes pages if 
required) 
Date of 
Onset 
Date reported Severity 
1.Mild 
2.Moderate 
3.Severe 
Relationship to 
IMP 
1.Unrelated 
2.Possible 
3.Probable 
4.Definite 
5.Suspected 
6.Unknown 
Action Taken 
1.None 
2.IMP dose reduced/temp 
withheld 
3.IMP stopped 
4.Con.meds commenced 
5.Other 
Date resolved 
(if not solved at end of 
study mark as ongoing) 
Outcome 
1.Recovered 
2.Ongoing 
3.SAE reported* 
4.Unknown 
*If the AE led t the SAE, 
record here, complete an 
SAE form and fax it to the 
sponsor) 
        
        
        
        
        
        
        
        
        
        
        
 
